Boston Scientific (BSX)

Company ID: 121 | CIK: 0000885725
10-Q view:
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-K data
No 10-K data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
Segments are charted by their disclosed metrics (revenue, segment profit, etc.). Each line is a single segment. Reconciliation/corporate items are excluded. Major customers are shown as a percentage of revenue. Operational KPIs are grouped by metric concept; sub-metrics appear as separate lines.

Geographic Segments

No 10-Q data
No 10-Q data
No 10-Q data

Business Unit / Product Segments

Major Customers (% of Revenue)

No major-customer concentration data found.

Operational KPIs

Deferred revenue (backlog)

No 10-K data

Product liability cases (claims_count)

No 10-K data

Common Stockholders (customers)

Customer facilities served (customers_served)

No 10-Q data

Employees (headcount)

NIR coronary stent inventory (inventory_units)

No 10-K data

On-time delivery rate (on_time_delivery)

No 10-Q data

NIR coronary stent purchase commitment (orders_received)

No 10-K data

2010 Restructuring plan costs (other)

No 10-Q data

2010 plan cash outlays (other)

No 10-Q data

2010 plan gross reductions (other)

No 10-Q data

2010 plan total pre-tax charges (other)

No 10-Q data

2011 Restructuring plan costs (other)

No 10-Q data

2011 plan estimated cash outlays (other)

No 10-Q data

2011 plan estimated total pre-tax charges (other)

No 10-Q data

2011 plan payments made (other)

No 10-Q data

2014 Restructuring plan costs (other)

No 10-Q data

364-day credit facility capacity (other)

No 10-K data

401(k) matching contributions (other)

No 10-Q data

Accounts payable (other)

No 10-Q data

Accounts receivable factoring (other)

No 10-Q data

Accrued expenses (other)

No 10-Q data

Accrued interest and penalties (other)

No 10-K data

Accumulated deficit (other)

No 10-Q data

Accumulated other comprehensive loss (other)

No 10-Q data

Acquisition payments (other)

No 10-Q data

Acquisition-, divestiture-, litigation-, and restructuring-related net charges (other)

No 10-Q data

Acquisition-related cash obligations (other)

No 10-K data

Additional paid-in capital (other)

No 10-Q data

Adjusted EPS (other)

No 10-K data

Adjusted earnings per share (other)

No 10-K data

Adjusted net income (other)

Adjusted net income per diluted share (other)

No 10-K data

Adjusted net income per share (other)

No 10-Q data

Aggregate market value of common stock held by non-affiliates (other)

No 10-Q data

Aggregate market value of non-affiliate stock (other)

No 10-Q data

All other corporate assets (other)

No 10-Q data

Allowance for doubtful accounts (other)

No 10-Q data

Allowance for sales returns (other)

No 10-Q data

Amortization expense (other)

No 10-Q data

Annualized expense reduction (other)

No 10-K data

Available liquidity (other)

No 10-K data

Average borrowing rate (other)

Average debt interest rate (other)

No 10-K data

Average interest rate (other)

No 10-K data

Average interest rate on debt (other)

No 10-K data

Average selling price change (other)

No 10-K data

Bare-metal stent sales (other)

No 10-K data

Bare-metal stent systems sales (other)

No 10-Q data

Binary restenosis rate (other)

No 10-K data

Board Diversity (other)

No 10-Q data

Book Value Per Share (other)

No 10-Q data

Book value per common share (other)

No 10-Q data

CE Mark approvals (other)

No 10-Q data

CRM sales (other)

No 10-Q data

CRM sales percentage (other)

No 10-Q data

CRM-related amortizable intangibles (other)

No 10-Q data

Capital expenditures (other)

No 10-Q data

Cardiac Rhythm Management constant currency net sales (other)

No 10-Q data

Cardiac Rhythm Management constant currency net sales growth rate (other)

No 10-Q data

Cardiac Rhythm Management net sales (other)

No 10-Q data

Cardiac Rhythm Management net sales growth rate (other)

No 10-Q data

Cardiovascular constant currency net sales growth rate (other)

No 10-Q data

Cardiovascular net sales growth rate (other)

No 10-Q data

Cardiovascular operating margin (other)

No 10-K data

Cardiovascular sales share (other)

No 10-Q data

Cardiovascular segment depreciation (other)

No 10-Q data

Cardiovascular segment income before taxes (other)

No 10-Q data

Cardiovascular segment net sales (other)

No 10-Q data

Cardiovascular segment total assets (other)

No 10-Q data

Cases in master settlement agreements (other)

No 10-K data

Cases in settlement agreements (other)

No 10-K data

Cases pending settlement (other)

No 10-K data

Cases with final settlements (other)

No 10-K data

Cash and Cash Equivalents (other)

No 10-Q data

Cash and cash equivalents (other)

Cash and cash equivalents at beginning of period (other)

No 10-Q data

Cash and cash equivalents at end of period (other)

No 10-Q data

Cash and short-term investments (other)

No 10-K data

Cash from operating activities (other)

No 10-K data

Cash from operations (other)

No 10-K data

Cash paid for income taxes (other)

No 10-Q data

Cash paid for interest (other)

No 10-Q data

Cash payments for restructuring (other)

No 10-Q data

Cash provided by operating activities (other)

No 10-Q data

Cash used for financing activities (other)

No 10-Q data

Cash used for investing activities (other)

No 10-Q data

Cash used for share repurchases (other)

No 10-Q data

Cash, cash equivalents and marketable securities (other)

No 10-Q data

Commercial paper maturity (other)

No 10-K data

Commercial paper outstanding (other)

No 10-K data

Commercial paper yield (other)

No 10-K data

Committed NIR stent purchases (other)

Common Shares Outstanding (other)

No 10-Q data

Common Stock Outstanding (other)

Common Stock Shares Outstanding (other)

No 10-Q data

Common Stock shares outstanding (other)

No 10-Q data

Common shares outstanding (other)

Common shares repurchased (other)

No 10-K data

Common stock (other)

No 10-Q data

Common stock equivalents excluded (other)

No 10-Q data

Common stock outstanding (other)

No 10-Q data

Common stock record holders (other)

No 10-Q data

Common stock shares outstanding (other)

No 10-Q data

Common stockholders (other)

No 10-Q data

Comprehensive income (other)

No 10-Q data

Constant currency net sales growth rate (other)

No 10-Q data

Constant currency sales growth (other)

No 10-K data

Contingent consideration expense (other)

No 10-Q data

Contingent consideration exposure (other)

No 10-K data

Contingent consideration liability (other)

No 10-Q data

Contingent consideration payments (other)

No 10-Q data

Contingent stock repurchase obligation (other)

No 10-K data

Coronary balloon revenue (other)

No 10-K data

Coronary stent market share (other)

No 10-K data

Coronary stent market size (other)

Coronary stent revenue (other)

No 10-K data

Coronary stent revenue mix (other)

No 10-K data

Coronary stent revenue share (other)

No 10-K data

Coronary stent revenues (other)

No 10-K data

Coronary stent sales (other)

Coronary stent share of net sales (other)

No 10-K data

Coronary stent systems sales (other)

No 10-Q data

Corporate expenses and currency exchange (other)

No 10-Q data

Cost method investments (other)

No 10-Q data

Cost of products sold (other)

No 10-Q data

Countries Served (other)

No 10-Q data

Countries marketed (other)

No 10-Q data

Countries marketed to (other)

No 10-Q data

Countries served (other)

No 10-Q data

Countries with Direct Marketing (other)

No 10-Q data

Countries with Direct Sales (other)

No 10-Q data

Countries with Distribution Arrangements (other)

No 10-Q data

Countries with Distributors (other)

No 10-Q data

Countries with direct marketing (other)

No 10-Q data

Countries with direct operations (other)

No 10-Q data

Countries with direct sales (other)

No 10-Q data

Countries with direct sales operations (other)

No 10-Q data

Countries with distribution (other)

No 10-Q data

Countries with distribution arrangements (other)

No 10-Q data

Countries with sales (other)

No 10-Q data

Countries with sales presence (other)

No 10-Q data

Credit and security facility (other)

No 10-Q data

Credit facility borrowing capacity (other)

No 10-K data

Cumulative cash payments for restructuring (other)

No 10-Q data

Cumulative restructuring cash payments (other)

No 10-K data

Cumulative restructuring charges (other)

No 10-Q data

Cumulative restructuring costs (other)

No 10-K data

Cumulative restructuring-related costs (other)

No 10-Q data

Currency derivative instruments (other)

No 10-Q data

Currency derivative notional (other)

No 10-K data

Current debt obligations (other)

No 10-Q data

DES adoption rate (other)

No 10-K data

DES average selling price change (other)

DES conversion rate (other)

DES share of coronary stent market (other)

No 10-K data

Days sales outstanding (other)

De-recognized notes receivable (other)

No 10-Q data

De-recognized receivables (other)

No 10-Q data

Dealers and distributors (other)

No 10-Q data

Debt Ratio (other)

No 10-K data

Debt extinguishment charges (other)

No 10-Q data

Debt to EBITDA ratio (other)

No 10-K data

Debt to net worth covenant ratio (other)

No 10-K data

Debt to net worth ratio (other)

No 10-K data

Debt to pro forma EBITDA (other)

No 10-K data

Debt to pro forma EBITDA ratio (other)

No 10-K data

Deferred income taxes (other)

No 10-Q data

Deferred revenue (other)

No 10-K data

Deferred tax assets (other)

No 10-K data

Deferred tax liabilities (other)

No 10-Q data

Defibrillator market share change (other)

No 10-K data

Defined benefit pension obligation (other)

No 10-Q data

Defined benefit plan assets (other)

No 10-Q data

Depreciation expense (other)

Depreciation expense allocated to reportable segments (other)

No 10-Q data

Derivative instruments notional amount (other)

No 10-K data

Derivative liabilities fair value (other)

No 10-K data

Derivative notional outstanding (other)

No 10-K data

Diabetic restenosis rate (other)

No 10-K data

Direct Sales Countries (other)

No 10-Q data

Direct sales countries (other)

No 10-Q data

Distributed products percentage (other)

No 10-Q data

Distribution arrangements (other)

No 10-Q data

Distribution dealers (other)

No 10-Q data

Distributor countries (other)

No 10-Q data

Distributorship sales percentage (other)

No 10-Q data

Divested Businesses net sales (other)

No 10-Q data

Domestic coronary stent market share (other)

No 10-Q data

Drug-eluting stent conversion (other)

No 10-K data

Drug-eluting stent conversion rate (other)

No 10-K data

Drug-eluting stent market share (other)

Drug-eluting stent market size (other)

No 10-K data

Drug-eluting stent penetration (other)

No 10-K data

Drug-eluting stent penetration rate (other)

No 10-Q data

Drug-eluting stent share (other)

No 10-K data

Drug-eluting stent systems sales (other)

No 10-Q data

Drug-eluting stent systems sales percentage (other)

No 10-Q data

EBITDA (other)

No 10-K data

EBITDA to interest expense ratio (other)

No 10-K data

EBITDA to interest ratio (other)

No 10-K data

ESPP expense (other)

No 10-Q data

Effect of foreign exchange rates on cash (other)

No 10-Q data

Effective tax rate (other)

No 10-K data

Effective tax rate excluding certain items (other)

No 10-Q data

Electrophysiology constant currency net sales (other)

No 10-Q data

Electrophysiology constant currency net sales growth rate (other)

No 10-Q data

Electrophysiology net sales (other)

No 10-Q data

Electrophysiology net sales growth rate (other)

No 10-Q data

Electrophysiology sales (other)

No 10-Q data

Electrophysiology sales percentage (other)

No 10-Q data

Emerging Market countries (other)

No 10-Q data

Emerging Markets Count (other)

No 10-Q data

Emerging Markets Net Sales (other)

No 10-K data

Emerging Markets net sales (other)

Emerging Markets net sales growth (other)

No 10-Q data

Emerging Markets net sales percentage (other)

No 10-Q data

Emerging Markets net sales share (other)

No 10-K data

Emerging Markets revenue growth (other)

No 10-K data

Emerging Markets revenue percentage (other)

No 10-Q data

Emerging Markets sales growth (other)

No 10-K data

Emerging Markets share of net sales (other)

No 10-Q data

Emerging market countries (other)

No 10-K data

Emerging markets countries (other)

No 10-K data

Emerging markets net sales growth (other)

Emerging markets net sales mix (other)

No 10-Q data

Emerging markets revenue percentage (other)

No 10-Q data

Emerging markets sales growth (other)

No 10-K data

Emerging markets sales share (other)

No 10-Q data

Emerging markets share of net sales (other)

No 10-Q data

Employee Diversity (other)

No 10-Q data

Endoscopy constant currency net sales (other)

No 10-Q data

Endoscopy constant currency net sales growth rate (other)

No 10-Q data

Endoscopy net sales (other)

No 10-Q data

Endoscopy net sales growth rate (other)

No 10-Q data

Endoscopy sales (other)

No 10-Q data

Endoscopy sales percentage (other)

No 10-Q data

Endosurgery sales share (other)

No 10-Q data

Equity method adjustments (other)

No 10-Q data

Equity method investments (other)

No 10-Q data

Estimated annual expense reduction (other)

No 10-Q data

Estimated cost to complete in-process R&D (other)

No 10-Q data

Estimated future cash outlays (other)

No 10-Q data

Estimated total pre-tax charges (other)

No 10-Q data

Expected capital expenditures (other)

No 10-Q data

Expected term (other)

No 10-Q data

Expected volatility (other)

No 10-Q data

Express2 stent sales (other)

No 10-K data

FCF performance-based DSU awards fair value (other)

No 10-Q data

FDA approvals and clearances (other)

No 10-Q data

FX impact on international revenue (other)

No 10-K data

Facilities discontinued (other)

No 10-K data

Facilities to be closed (other)

No 10-Q data

Fair value headroom (other)

No 10-K data

Fair value of contingent consideration recorded (other)

No 10-Q data

Fair value of derivative assets (other)

No 10-Q data

Fair value of derivative liabilities (other)

No 10-Q data

Fair value of outstanding debt (other)

No 10-Q data

Financial leverage ratio (other)

No 10-K data

Finished goods inventory (other)

No 10-Q data

Fixed charges (other)

No 10-Q data

Fixed interest rate debt (other)

No 10-Q data

Fixed-rate debt (other)

No 10-K data

Fixed-rate debt % of total (other)

No 10-K data

Fixed-rate debt share (other)

No 10-K data

Fixed-rate share of net debt (other)

No 10-K data

Foreign currency derivative instruments (other)

No 10-K data

Foreign currency losses (other)

No 10-Q data

Foreign currency translation adjustment (other)

No 10-Q data

Foreign exchange contract notional (other)

No 10-K data

Foreign exchange contracts notional (other)

No 10-K data

Foreign exchange contracts outstanding (other)

No 10-K data

Foreign patent applications pending (other)

No 10-Q data

Foreign patents held (other)

No 10-Q data

Foreign tax net operating loss carryforwards (other)

No 10-Q data

Forward foreign exchange contracts (other)

No 10-K data

Forward foreign exchange contracts notional (other)

No 10-K data

Forward foreign exchange contracts notional amount (other)

No 10-K data

Funded debt ratio (other)

No 10-K data

Funded debt to net worth ratio (other)

No 10-K data

Future minimum rental commitments (other)

No 10-Q data

Gain on divestiture (other)

No 10-Q data

Gender representation (other)

No 10-Q data

Global CRM market size (other)

No 10-K data

Global operations plan savings (other)

No 10-Q data

Goodwill (other)

No 10-Q data

Goodwill and intangible asset impairment charges (other)

No 10-Q data

Goodwill balance (other)

No 10-Q data

Goodwill impairment charge (other)

No 10-Q data

Goodwill impairment charges (other)

No 10-Q data

Gross debt (other)

No 10-K data

Gross margin (other)

No 10-K data

Gross profit (other)

No 10-Q data

Gross profit margin (other)

Gross unrecognized tax benefits (other)

Holders of record (other)

No 10-Q data

Hospitals and Facilities Served (other)

No 10-Q data

Hospitals and clinics marketed to (other)

No 10-Q data

Hospitals and facilities served (other)

No 10-Q data

Hospitals, clinics, etc. marketed to (other)

No 10-Q data

Hospitals/clinics marketed to (other)

No 10-Q data

ICD systems sales (other)

No 10-Q data

IRS proposed tax liability (other)

No 10-Q data

ISO 50001 certified sites (other)

No 10-Q data

ISO14001 certified facilities (other)

No 10-Q data

Impact of certain receipts/charges (other)

No 10-Q data

Impact of foreign currency fluctuations (other)

No 10-Q data

In-process R&D intangible assets (other)

No 10-Q data

In-process R&D projects acquired (other)

No 10-Q data

Income (loss) before income taxes (other)

No 10-Q data

Income before income taxes (other)

No 10-Q data

Income tax benefit (other)

No 10-Q data

Income tax savings from Costa Rica incentive (other)

No 10-Q data

Institutes for Advancing Science (other)

No 10-Q data

Intangible asset impairment charge (other)

No 10-Q data

Intangible asset impairment charges (other)

No 10-Q data

Interest and penalties accrued (other)

No 10-Q data

Interest and penalties recognized (other)

No 10-Q data

Interest coverage ratio (other)

Interest expense (other)

No 10-Q data

Interest expense and amortization of debt issuance costs (other)

No 10-Q data

Interest income (other)

No 10-Q data

Interest payments (other)

No 10-Q data

Interest portion of rental expense (other)

No 10-Q data

Interest rate derivative contracts (other)

No 10-Q data

Interest rate derivative notional (other)

No 10-K data

Interest rate sensitivity (other)

No 10-K data

Interest rate swap contracts (other)

No 10-K data

International CRM sales (other)

No 10-Q data

International Net Sales (other)

No 10-Q data

International Sales Percentage (other)

No 10-Q data

International dealers/distributors (other)

No 10-Q data

International direct sales countries (other)

No 10-Q data

International distribution countries (other)

No 10-Q data

International drug-eluting stent systems sales (other)

No 10-Q data

International manufacturing share (other)

No 10-Q data

International net sales mix (other)

No 10-Q data

International net sales percentage (other)

No 10-Q data

International net sales share (other)

No 10-Q data

International production share (other)

No 10-Q data

International revenue growth (other)

No 10-K data

International sales percentage (other)

No 10-Q data

International sales share (other)

No 10-Q data

International sales subsidiaries (other)

No 10-Q data

International share of manufacturing (other)

No 10-Q data

International share of net sales (other)

No 10-Q data

Interventional Cardiology constant currency net sales (other)

No 10-Q data

Interventional Cardiology constant currency net sales growth rate (other)

No 10-Q data

Interventional Cardiology net sales (other)

No 10-Q data

Interventional Cardiology net sales growth rate (other)

No 10-Q data

Interventional Cardiology sales percentage (other)

No 10-Q data

Intrinsic value of options exercised (other)

No 10-Q data

Inventories (other)

Inventory (other)

No 10-Q data

Investment impairments (other)

No 10-Q data

Japan DES market size (other)

No 10-K data

Japan TAXUS market share (other)

No 10-K data

Japan drug-eluting stent market size (other)

No 10-K data

Japan net sales (other)

No 10-Q data

Japanese credit facilities capacity (other)

No 10-K data

Japanese credit facility capacity (other)

No 10-K data

LEED certified buildings (other)

No 10-Q data

Legal accrual (other)

Legal and debt exclusion remaining (other)

No 10-Q data

Legal matter accrual (other)

No 10-K data

Legal matters accrual (other)

No 10-K data

Letters of credit (other)

No 10-Q data

Letters of credit outstanding (other)

No 10-K data

Leverage Ratio (other)

No 10-K data

Leverage ratio (other)

Litigation reserve accrual (other)

No 10-K data

Litigation reserves (other)

No 10-K data

Litigation-related charges (other)

No 10-Q data

Litigation-related reserves (other)

No 10-K data

Long-lived assets (other)

No 10-Q data

Long-lived assets in Ireland (other)

No 10-Q data

Long-lived assets in Other foreign countries (other)

No 10-Q data

Long-lived assets in United States (other)

No 10-Q data

Long-term borrowings (other)

No 10-Q data

Long-term debt (other)

No 10-Q data

Long-term debt obligations (other)

No 10-Q data

Loss before income taxes (other)

No 10-Q data

MDL claims approved (other)

No 10-K data

Management Diversity (other)

No 10-Q data

Market Value of Non-Affiliate Stock (other)

No 10-Q data

Market-based DSU awards fair value (other)

No 10-Q data

Maximum contingent consideration (other)

No 10-K data

Maximum leverage ratio (other)

No 10-K data

Maximum potential contingent consideration (other)

No 10-Q data

MedSurg constant currency net sales growth rate (other)

No 10-Q data

MedSurg net sales growth rate (other)

No 10-Q data

MedSurg operating margin (other)

No 10-K data

MedSurg segment depreciation (other)

No 10-Q data

MedSurg segment income before taxes (other)

No 10-Q data

MedSurg segment net sales (other)

No 10-Q data

MedSurg segment total assets (other)

No 10-Q data

Medical device excise tax expense (other)

No 10-Q data

Merger-related accrual (other)

No 10-K data

Mesh cases asserted (other)

No 10-K data

Mesh cases in settlement (other)

No 10-K data

Mesh cases settled final (other)

No 10-K data

Mesh product liability cases (other)

No 10-K data

Minimum royalty obligations (other)

No 10-Q data

Multicultural employees (other)

No 10-Q data

Multicultural in management (other)

No 10-Q data

Multicultural representation (other)

No 10-Q data

Multicurrency borrowing sublimit (other)

No 10-K data

NIR coronary stent purchase commitment (other)

No 10-K data

NIR coronary stent sales percentage (other)

No 10-K data

NIR stent inventory (other)

NIR stent purchase commitment (other)

No 10-K data

NIR stent revenue (other)

No 10-K data

NIR stent sales % of worldwide sales (other)

No 10-K data

NIR stent sales mix (other)

NIR stent sales percentage (other)

No 10-K data

NIR stent sales share (other)

No 10-Q data

NIR stent share of sales (other)

No 10-K data

NIR stent share of worldwide sales (other)

Net NIR stent inventory (other)

No 10-K data

Net change in certain retirement plans (other)

No 10-Q data

Net change in unrealized gains/losses on derivatives (other)

No 10-Q data

Net debt (other)

No 10-K data

Net deferred tax assets (other)

No 10-K data

Net increase in cash and cash equivalents (other)

No 10-Q data

Net loss (other)

No 10-Q data

Net loss per common share (other)

No 10-Q data

Net loss per share (other)

No 10-Q data

Net losses on investments (other)

No 10-Q data

Net receivables >180 days past due (other)

No 10-Q data

Net receivables >360 days past due (other)

No 10-Q data

Net sales (other)

No 10-Q data

Net sales allocated to reportable segments (other)

No 10-Q data

Net sales by business (other)

No 10-K data

Net sales growth (other)

No 10-K data

Net sales growth constant currency (other)

No 10-K data

Net sales growth operational (other)

No 10-K data

Net sales growth organic (other)

No 10-K data

Net sales growth rate (other)

No 10-Q data

Net sales growth reported (other)

No 10-K data

Net sales operational growth (other)

No 10-K data

Net sales organic growth (other)

No 10-K data

Net unrecognized tax benefits affecting effective tax rate (other)

No 10-Q data

Neuromodulation constant currency net sales (other)

No 10-Q data

Neuromodulation constant currency net sales growth rate (other)

No 10-Q data

Neuromodulation goodwill (other)

No 10-Q data

Neuromodulation net sales (other)

No 10-Q data

Neuromodulation net sales growth rate (other)

No 10-Q data

Neuromodulation sales (other)

No 10-Q data

Neuromodulation sales percentage (other)

No 10-Q data

Neurovascular revenue (other)

No 10-Q data

Neurovascular sales percentage (other)

No 10-Q data

New CRM product sales share (other)

No 10-Q data

New CRM products planned (other)

No 10-K data

Non-vested stock awards (other)

No 10-Q data

Nonvascular Sales Percentage (other)

No 10-Q data

Nonvascular sales growth (other)

No 10-K data

Nonvascular sales percentage (other)

No 10-Q data

Nonvascular sales share (other)

No 10-Q data

Notes receivable (other)

No 10-Q data

Number of Reportable Segments (other)

Operating income (other)

No 10-Q data

Operating income allocated to reportable segments (other)

No 10-Q data

Operating income margin (other)

No 10-K data

Operating lease obligations (other)

No 10-Q data

Operational net sales growth (other)

No 10-K data

Operational sales growth (other)

No 10-K data

Organic net sales growth (other)

No 10-K data

Other Intangible Assets (other)

No 10-Q data

Other comprehensive income (other)

No 10-Q data

Other countries net sales (other)

No 10-Q data

Other current liabilities (other)

No 10-Q data

Other expense, net (other)

No 10-Q data

Other intangible assets, net (other)

No 10-Q data

Other long-term assets (other)

No 10-Q data

Other long-term liabilities (other)

No 10-Q data

Other restructuring-related liability (other)

No 10-Q data

Other sales share (other)

No 10-Q data

Other, net (other)

No 10-Q data

Owned Facilities Percentage (other)

No 10-Q data

PNO program annualized run-rate reductions (other)

No 10-Q data

PNO program cash outlays (other)

No 10-Q data

PNO program total pre-tax charges (other)

No 10-Q data

PROMUS DES sales mix (other)

No 10-K data

PROMUS sales mix (other)

No 10-K data

PROMUS share of DES sales (other)

No 10-K data

PROMUS share of net sales (other)

No 10-K data

PROMUS stent sales mix (other)

No 10-K data

PTCA balloon catheter market share (other)

No 10-Q data

PTCA balloon market share (other)

No 10-K data

Pacemaker systems sales (other)

No 10-Q data

Patent Applications (other)

No 10-Q data

Patent Applications Pending (other)

No 10-Q data

Patent applications pending (other)

No 10-Q data

Patents (other)

No 10-Q data

Patents Held (other)

No 10-Q data

Patents Issued (other)

No 10-Q data

Patents held (other)

No 10-Q data

Payments for acquisitions (other)

No 10-Q data

Payments for acquisitions of treasury stock (other)

No 10-Q data

Payments of contingent consideration (other)

No 10-Q data

Payments on borrowings from credit facilities (other)

No 10-Q data

Payments on long-term borrowings (other)

No 10-Q data

Pending Guidant lawsuits (other)

No 10-K data

Pending Patent Applications (other)

No 10-Q data

Pending mesh litigation cases (other)

No 10-K data

Pending product liability cases (other)

No 10-K data

Pending product liability lawsuits (other)

No 10-K data

Pending product liability plaintiffs (other)

No 10-K data

Peripheral Interventions constant currency net sales (other)

No 10-Q data

Peripheral Interventions constant currency net sales growth rate (other)

No 10-Q data

Peripheral Interventions net sales (other)

No 10-Q data

Peripheral Interventions net sales growth rate (other)

No 10-Q data

Peripheral Interventions sales (other)

No 10-Q data

Peripheral Interventions sales percentage (other)

No 10-Q data

Planned capital expenditures (other)

No 10-K data

Plant Network Optimization program costs (other)

No 10-Q data

Positions eliminated (other)

No 10-K data

Potential reduction in unrecognized tax benefits (other)

No 10-Q data

Pre-tax operating savings (other)

No 10-K data

Prepaid expenses and other current assets (other)

No 10-Q data

Pro forma EBITDA to interest (other)

No 10-K data

Pro forma EBITDA to interest expense (other)

No 10-K data

Pro forma EBITDA to interest expense ratio (other)

No 10-K data

Proceeds from borrowings on credit facilities (other)

No 10-Q data

Proceeds from long-term borrowings (other)

No 10-Q data

Proceeds from sale of headquarters (other)

No 10-Q data

Proceeds from stock issuances (other)

No 10-Q data

Product liability cases (other)

No 10-K data

Product liability cases asserted (other)

No 10-K data

Product liability cases pending (other)

No 10-K data

Products made at international facilities (other)

No 10-Q data

Products manufactured at international facilities (other)

No 10-Q data

Products manufactured internationally (other)

No 10-Q data

Property, Plant and Equipment (other)

No 10-Q data

Property, plant and equipment, net (other)

No 10-Q data

Public Float (other)

No 10-Q data

Purchase obligations (other)

No 10-Q data

R&D Expense (other)

No 10-Q data

R&D and SG&A cost reduction target (other)

No 10-K data

R&D as percentage of net sales (other)

No 10-Q data

R&D expense (other)

No 10-Q data

R&D expense as % of net sales (other)

No 10-Q data

R&D expense as percent of net sales (other)

No 10-Q data

R&D expense as percentage of sales (other)

No 10-Q data

R&D expense ratio (other)

No 10-K data

R&D percent of net sales (other)

No 10-K data

R&D percent of sales (other)

No 10-K data

Ratio of earnings to fixed charges (other)

No 10-Q data

Raw materials inventory (other)

No 10-Q data

Recalled device sales (other)

No 10-K data

Receivables past due (other)

No 10-K data

Record holders (other)

No 10-Q data

Record holders of common stock (other)

No 10-Q data

Remaining repurchase authorization (other)

No 10-K data

Remaining share repurchase authorization (other)

Rent expense (other)

No 10-Q data

Reported tax rate (other)

No 10-Q data

Repurchase authorization remaining (other)

No 10-K data

Research and development expense (other)

No 10-Q data

Research and development expenses (other)

No 10-Q data

Research and development ratio (other)

No 10-K data

Research and development spend (other)

No 10-Q data

Research and development spending (other)

No 10-Q data

Restenosis rate (other)

No 10-K data

Restricted stock forfeited (other)

No 10-K data

Restricted stock granted (other)

No 10-K data

Restructuring accrual (other)

No 10-K data

Restructuring and merger-related accrual (other)

No 10-K data

Restructuring cash payments (other)

No 10-K data

Restructuring charge exclusion remaining (other)

No 10-Q data

Restructuring charges (other)

No 10-Q data

Restructuring costs incurred (other)

No 10-K data

Restructuring liability balance (other)

No 10-K data

Restructuring savings target (other)

No 10-K data

Restructuring-related expenses (other)

No 10-Q data

Revenue growth (other)

No 10-K data

Revolver borrowings available (other)

No 10-K data

Revolver borrowings outstanding (other)

No 10-K data

Revolving credit facilities (other)

No 10-K data

Revolving credit facilities total (other)

No 10-K data

Revolving credit facility (other)

No 10-Q data

Revolving credit facility borrowings (other)

No 10-K data

Rhythm Management constant currency net sales growth rate (other)

No 10-Q data

Rhythm Management net sales growth rate (other)

No 10-Q data

Rhythm Management segment depreciation (other)

No 10-Q data

Rhythm Management segment income before taxes (other)

No 10-Q data

Rhythm Management segment net sales (other)

No 10-Q data

Rhythm Management segment total assets (other)

No 10-Q data

Risk-free interest rate (other)

No 10-Q data

Royalty expense (other)

No 10-Q data

Royalty expense ratio (other)

No 10-K data

SG&A expense ratio (other)

No 10-K data

SG&A percent of net sales (other)

No 10-K data

SG&A percent of sales (other)

No 10-K data

STEM Students Reached (other)

No 10-Q data

Sales force representatives (other)

No 10-Q data

Sales generated from business divestitures (other)

No 10-Q data

Schneider purchase price accrual (other)

No 10-K data

Schneider sales contribution (other)

No 10-K data

Segment operating margin (other)

No 10-K data

Selling, general and administrative expenses (other)

No 10-Q data

Senior notes outstanding (other)

No 10-Q data

Shares Outstanding (other)

Shares available for future issuance (other)

No 10-Q data

Shares in treasury (other)

No 10-Q data

Shares issued (other)

No 10-Q data

Shares issued under ESPP (other)

No 10-Q data

Shares outstanding (other)

Shares remaining under repurchase authorization (other)

No 10-K data

Shares repurchased (other)

Shares repurchased under plan (other)

No 10-K data

Shares reserved but not issuable (other)

No 10-Q data

Shares reserved under stock incentive plans (other)

No 10-Q data

Ship hold impact on net sales (other)

No 10-K data

Ship hold sales impact (other)

No 10-K data

Shipping and handling costs (other)

No 10-Q data

Short-term borrowings (other)

No 10-Q data

Stent conversion rate (other)

No 10-K data

Stent systems recalled (other)

No 10-K data

Stock options excluded (other)

No 10-Q data

Stock options exercisable (other)

No 10-Q data

Stock options granted (other)

No 10-Q data

Stock options outstanding (other)

No 10-Q data

Stock record holders (other)

No 10-Q data

Stock repurchased (other)

No 10-K data

Stock-based compensation (other)

No 10-K data

Stock-based compensation expense (other)

No 10-Q data

Stockholders' Equity (other)

No 10-Q data

Stockholders' equity (other)

No 10-Q data

Strategic alliances (other)

No 10-Q data

Subtotal Core Businesses constant currency net sales growth rate (other)

No 10-Q data

Subtotal Core Businesses net sales (other)

No 10-Q data

Subtotal Core Businesses net sales growth rate (other)

No 10-Q data

TAXUS II combined restenosis (other)

No 10-K data

TAXUS II in-segment restenosis (other)

No 10-K data

TAXUS II in-stent restenosis (other)

No 10-K data

TAXUS III in-stent restenosis (other)

No 10-K data

TAXUS III overall restenosis (other)

No 10-K data

TAXUS IV trial patients enrolled (other)

No 10-K data

TAXUS Liberté revenue mix (other)

No 10-K data

TAXUS stent net sales (other)

No 10-K data

TAXUS stent sales (other)

No 10-K data

Target lesion revascularization rate (other)

No 10-K data

Target vessel revascularization rate (other)

No 10-K data

Tax impact of unrealized gain/loss (other)

No 10-Q data

Tax incentive savings (other)

No 10-Q data

Technology centers (other)

No 10-Q data

Term loan facility (other)

No 10-Q data

Termination benefit liability (other)

No 10-Q data

Total Assets (other)

No 10-Q data

Total Debt (other)

No 10-Q data

Total assets (other)

No 10-Q data

Total assets allocated to reportable segments (other)

No 10-Q data

Total contractual obligations (other)

No 10-Q data

Total current assets (other)

No 10-Q data

Total current liabilities (other)

No 10-Q data

Total debt (other)

Total debt to EBITDA ratio (other)

No 10-K data

Total earnings (deficit), adjusted (other)

No 10-Q data

Total liabilities (other)

No 10-Q data

Total long-lived assets (other)

No 10-Q data

Total operating expenses (other)

No 10-Q data

Total shares repurchased (other)

No 10-K data

Total treasury shares repurchased (other)

No 10-K data

Trade accounts receivable, net (other)

No 10-Q data

Treasury shares (other)

No 10-Q data

Treasury shares repurchased (other)

No 10-K data

Treasury stock (other)

No 10-Q data

Treasury stock repurchased (other)

No 10-K data

Treasury stock repurchased cost (other)

No 10-K data

Treasury stock shares (other)

U.S. CRM sales (other)

No 10-Q data

U.S. DES average selling price change (other)

No 10-Q data

U.S. DES market share (other)

No 10-Q data

U.S. DES penetration rate (other)

No 10-Q data

U.S. Defibrillator Market Share Decline (other)

No 10-K data

U.S. ICD share of CRM market (other)

No 10-K data

U.S. PCI procedure volume change (other)

No 10-Q data

U.S. PTCA balloon market share (other)

No 10-Q data

U.S. Patents (other)

No 10-Q data

U.S. Patents Held (other)

No 10-Q data

U.S. coronary stent revenue (other)

No 10-K data

U.S. coronary stent revenues (other)

No 10-Q data

U.S. defibrillator market share change (other)

No 10-Q data

U.S. defibrillator market share decline (other)

No 10-K data

U.S. drug-eluting stent market share (other)

No 10-Q data

U.S. drug-eluting stent penetration rate (other)

No 10-Q data

U.S. drug-eluting stent systems sales (other)

No 10-Q data

U.S. patents held (other)

No 10-Q data

U.S. share of worldwide sales (other)

U.S. tax net operating loss carryforwards (other)

No 10-Q data

US Patents Held (other)

No 10-Q data

US patent applications pending (other)

No 10-Q data

US patents held (other)

No 10-Q data

US revenue growth (other)

No 10-K data

Underfunded pension obligation (other)

No 10-Q data

United States net sales (other)

No 10-Q data

Unrealized costs associated with certain retirement plans (other)

No 10-Q data

Unrealized gain on derivative financial instruments (other)

No 10-Q data

Unrecognized compensation cost (other)

No 10-Q data

Unrecognized tax benefits (other)

Unrecognized tax benefits affecting effective tax rate (other)

No 10-K data

Unremitted foreign earnings (other)

No 10-Q data

Urology and Women's Health constant currency net sales (other)

No 10-Q data

Urology and Women’s Health constant currency net sales growth rate (other)

No 10-Q data

Urology and Women’s Health net sales (other)

No 10-Q data

Urology and Women’s Health net sales growth rate (other)

No 10-Q data

Urology and Women’s Health sales (other)

No 10-Q data

Urology and Women’s Health sales percentage (other)

No 10-Q data

Valuation allowance (other)

No 10-Q data

Vascular Sales Percentage (other)

No 10-Q data

Vascular sales growth (other)

No 10-K data

Vascular sales percentage (other)

No 10-Q data

Vascular sales share (other)

No 10-Q data

Vesting date fair value of stock awards (other)

No 10-Q data

Warranty liabilities (other)

No 10-K data

Warranty liability (other)

No 10-Q data

Weighted average interest rate (other)

No 10-K data

Weighted average interest rate on revolving credit (other)

No 10-K data

Weighted average remaining vesting period (other)

No 10-Q data

Weighted-average annual forfeiture rate (other)

No 10-Q data

Weighted-average exercise price (other)

No 10-Q data

Weighted-average grant-date fair value (other)

No 10-Q data

Weighted-average shares outstanding (other)

No 10-Q data

Women employees (other)

No 10-Q data

Women in management (other)

No 10-Q data

Women on Board of Directors (other)

No 10-Q data

Women representation (other)

No 10-Q data

Work-in-process inventory (other)

No 10-Q data

Workforce diversity (other)

No 10-Q data

Working Capital (other)

No 10-Q data

Working capital (other)

Worldwide CRM Market Size (other)

No 10-K data

Worldwide CRM market size (other)

Worldwide DES market share (other)

No 10-Q data

Worldwide PTCA balloon market share (other)

No 10-Q data

Worldwide constant currency net sales growth rate (other)

No 10-Q data

Worldwide coronary stent market size (other)

Worldwide coronary stent sales (other)

No 10-Q data

Worldwide drug-eluting stent market share (other)

No 10-Q data

Worldwide net sales (other)

No 10-Q data

Worldwide net sales growth rate (other)

No 10-Q data

Worldwide nonvascular sales growth (other)

No 10-K data

Worldwide stent market size (other)

No 10-K data

Worldwide vascular sales decline (other)

No 10-K data

Write-offs of uncollectible accounts (other)

No 10-Q data

Year 2000 Compliance Costs (other)

No 10-K data

Year 2000 compliance costs (other)

No 10-Q data

Year 2000 compliance expenditure (other)

No 10-K data

Year 2000 compliance expenditures (other)

No 10-K data

Year 2000 compliance spend (other)

No 10-K data

Year 2000 compliance spending (other)

No 10-K data

LATITUDE enrolled patients (patients)

Puerto Rico manufacturing facilities (properties)

No 10-Q data

Safety incidents per 100 employees (safety_incidents)

No 10-Q data

Common Stock Outstanding (shares)

No 10-Q data

Common Stock outstanding (shares_outstanding)

No 10-Q data

Facilities (square_footage)

No 10-Q data

Safety Incident Rate (trir)

No 10-Q data

Stent systems shipped (units_shipped)

No 10-K data
Human capital disclosures. Workforce totals and demographics are point-in-time. Flow metrics use the year-to-date period for 10-Q and full year for 10-K. Workforce actions (RIFs, restructurings, acquisition-related changes) are listed in the table at the bottom.

Workforce Totals

No 10-Q data

Demographics

No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data

Workforce Breakdowns

No 10-Q data
No 10-Q data
No 10-Q data

HCM Metrics — Point-in-Time

No point-in-time HCM metrics found.

HCM Metrics — Flow (Annual / YTD)

No 10-Q data
No 10-Q data

Workforce Actions

Period EndTypeStatusAffected% WorkforceAnnouncedExpected CompletionGeographySegment / FunctionChargeSourceNote
2026-06-30restructuringannounced2026-07-212029-12-31GlobalCompany-wide (supply chain, functional transformation, organizational structure)USD 700 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter event. Total pre-tax charges estimated at $700M-$800M, of which $600M-$700M expected as future cash outlays; targeted gross annual pre-tax expense reduction of ~$500M. Headcount reductions expected but no employee count disclosed. Activities to be initiated in 2026 and substantially complete by end of 2029.
2026-06-30acquisition_additioncompleted2026-01-272026-01-27Neuromodulationbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Nalu Medical, Inc. completed 2026-01-27 (announcement date not disclosed; completion date shown). Upfront cash ~$523M net of cash acquired; total preliminary purchase price $588M including fair value of prior ~9% interest. Headcount added not disclosed.
2026-06-30restructuringannounced2026-07-212029-12-31GlobalSupply chain, functional transformation, organizational structureUSD 750 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Board approved 2026 Restructuring Plan on July 21, 2026. Estimated total pre-tax charges of $700-$800 million. Expected to reduce gross annual pre-tax expenses by ~$500 million. Includes transfer costs ($300-$350M), termination benefits ($275-$300M), and other ($125-$150M). Specific employee impact counts not yet disclosed.
2026-06-30restructuringin_progressUSD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31acquisition_additioncompleted2026-01-272026-01-27United StatesNeuromodulationUSD 523 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Completed acquisition of Nalu Medical, Inc.; upfront cash payment of approximately $523 million net of cash acquired. Headcount added not disclosed.
2026-03-31acquisition_additionannounced2026-01-152026-12-31United StatesCardiovascularUSD 14,500 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pending acquisition of Penumbra, Inc. at $374 per share (~$14.5 billion); FTC Second Request received 2026-03-16; expected close in second half of 2026. Headcount to be added not disclosed.
2026-03-31acquisition_additionannounced2026-03-312026-09-30ChinaEndoscopy and UrologyUSD 200 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Scivita Medical Technology Co., Ltd.; $200 million upfront plus up to $30 million in milestones; expected close in Q3 2026. Headcount not disclosed.
2026-03-31restructuringcompleted2023-02-012025-12-31GlobalCorporateUSD 704 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2023 Restructuring Plan (expanded July 2025) with cumulative pre-tax charges of $704 million; activities substantially complete at end of 2025. Q1 2026 restructuring net charges of $3 million and restructuring-related charges of $33 million; reserve balance $40 million at 2026-03-31. Number of employees affected not disclosed in this filing.
2026-03-31restructuringcompleted2023-02-012025-12-31GlobalAll segmentsUSD 3 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		2023 Restructuring Plan, including expansion approved July 2025, substantially complete at end of 2025. Q1 2026 incurred $3M restructuring net charges and $33M restructuring-related net charges.
2026-03-31restructuringin_progressUSD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-12-31restructuringcompleted2023-02-012025-12-31GlobalEnterprise — supply chain, manufacturing/distribution network and functional capabilitiesUSD 343 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2023 Restructuring Plan; FY2025 charges comprise $101M restructuring plus $242M restructuring-related. Board expanded the program on 2025-07-29 by up to $250M additional pre-tax charges. Cumulative pre-tax charges of $668M incurred through 2025-12-31 against an estimated program total of $700M-$800M; activities substantially complete at end of 2025. No employees-affected count disclosed; restructuring reserve balance was $59M at 2025-12-31.
2025-12-31restructuringcompleted2025-05-282025-12-31GlobalCardiovascular — ACURATE neo2 and ACURATE Prime Aortic Valve SystemsUSD 87 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Discontinuation of worldwide sales of the ACURATE aortic valve platform and abandonment of U.S. FDA approval pursuit; total pre-tax restructuring and restructuring-related net charges of approximately $87M in 2025, substantially complete at end of 2025. No employees-affected count disclosed.
2025-12-31acquisition_additioncompleted2025-01-242025-01-24Cardiovascular (Electrophysiology mapping)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		100 percent acquisition; upfront cash payment of $239M net of cash acquired plus up to $50M contingent. No headcount disclosed.
2025-12-31acquisition_additioncompleted2025-04-012025-04-01Cardiovascular — intravascular lithotripsybusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of remaining shares (previously ~26 percent held); $475M upfront net of cash acquired plus up to $200M contingent. No headcount disclosed.
2025-12-31acquisition_additioncompleted2025-05-062025-05-06United StatesCardiovascular — Interventional Oncologybusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		100 percent acquisition; upfront cash payment of approximately $172M net of cash acquired. No headcount disclosed.
2025-12-31acquisition_additioncompleted2025-05-072025-05-07Cardiovascular — renal artery denervation (TIVUS)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of remaining shares (previously ~10 percent held); $362M upfront net of cash acquired plus up to $200M regulatory milestone. No headcount disclosed.
2025-12-31acquisition_additioncompleted2025-07-112025-07-11ChinaMedSurg — Endoscopybusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		100 percent acquisition; upfront cash payment of approximately $182M net of cash acquired. No headcount disclosed.
2025-12-31acquisition_additioncompleted2026-01-272026-01-27Neuromodulation — chronic painsubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Completed 2026-01-27, after fiscal year-end; upfront cash payment of approximately $517M net of cash acquired for the remaining ~91 percent stake previously held since 2017. No headcount disclosed.
2025-12-31acquisition_additionannounced2026-01-152026-12-31United StatesCardiovascular — peripheral vascular thrombectomysubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement announced 2026-01-15 to acquire 100 percent at $374 per share (~$14.500 billion), expected to close during 2026; to be funded with cash on hand plus ~$11.000 billion of new debt and the remainder in common stock. No headcount disclosed.
2025-12-31restructuringcompleted2023-022025-12-31GlobalAll segmentsUSD 700 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2023 Restructuring Plan expanded in July 2025. Total pre-tax charges estimated at $700 million to $800 million. Activities substantially complete by end of 2025. Employee count not explicitly disclosed.
2025-12-31restructuringcompleted2025-05-282025-12-31GlobalCardiovascularUSD 87 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Discontinuation of worldwide sales of ACURATE neo2 and ACURATE Prime Aortic Valve Systems. Total pre-tax restructuring and restructuring-related net charges of approximately $87 million in 2025. Activity substantially complete at end of 2025.
2025-12-31restructuringcompleted2023-02-012025-12-31GlobalGlobal Supply Chain Optimization and functional capabilitiesUSD 668 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		2023 Restructuring Plan, including expansion approved July 2025. Activities substantially complete by end of 2025. Total pre-tax charges incurred $668 million (termination benefits $104M, other restructuring $39M, transfer costs $312M, other restructuring-related $213M). Employee count not explicitly disclosed.
2025-12-31restructuringcompleted2025-05-282025-12-31GlobalCardiovascularUSD 87 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Discontinuation of worldwide sales of ACURATE neo2 and ACURATE Prime Aortic Valve Systems. Activity substantially complete at end of 2025. Total pre-tax charges approximately $87 million. Employee count not explicitly disclosed.
2025-12-31restructuringin_progressUSD 101,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-09-30restructuringin_progress2025-07-292025-12-31GlobalGlobal Supply Chain / corporate functionsUSD 250 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board approved expanding the 2023 Restructuring Plan by up to $250 million in additional pre-tax charges; total estimated program cost $700-$800 million. No employee counts disclosed. Activities expected substantially complete by end of 2025.
2025-09-30restructuringin_progress2025-05-282025-12-31GlobalCardiology — ACURATE neo2 and ACURATE Prime Aortic Valve SystemsUSD 90 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Discontinuation of worldwide ACURATE aortic valve sales resulted in approximately $90 million of restructuring and restructuring-related charges in the first nine months of 2025; remaining activity expected substantially complete by end of 2025. No employee counts disclosed.
2025-09-30acquisition_additionannounced2025-10-172026-06-30United StatesNeuromodulationsubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire 100% of Nalu Medical, Inc.; upfront cash payment of approximately $533 million, to be funded with cash on hand; expected to close in first half of 2026. Company held ~9% equity stake prior to agreement. No headcount disclosed.
2025-09-30acquisition_additioncompleted2025-01-242025-01-24United StatesCardiologybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Cortex, Inc. completed; upfront cash payment of $239 million net of cash acquired plus up to $50 million in future milestone payments. No headcount disclosed.
2025-09-30acquisition_additioncompleted2025-04-012025-04-01United StatesCardiology and Peripheral Interventionsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of remaining shares of Bolt Medical, Inc. completed; upfront cash payment of $475 million net of cash acquired plus up to $200 million (approx. $148 million for portion not previously owned) on a second regulatory milestone. No headcount disclosed.
2025-09-30acquisition_additioncompleted2025-05-062025-05-06United StatesPeripheral Interventionsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Intera Oncology, Inc. completed; upfront cash payment of approximately $172 million net of cash acquired. No headcount disclosed.
2025-09-30acquisition_additioncompleted2025-05-072025-05-07IsraelCardiologybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of remaining shares of SoniVie Ltd. completed; upfront cash payment of $362 million net of cash acquired plus up to $200 million ($180 million for portion not previously owned) on a regulatory milestone. No headcount disclosed.
2025-09-30acquisition_additioncompleted2025-07-112025-07-11ChinaEndoscopybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Anrei Medical (HZ) Co., Ltd. completed; upfront cash payment of approximately $182 million net of cash acquired. No headcount disclosed.
2025-09-30acquisition_additioncompletedbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		One additional business acquired in Q3 2025 for upfront cash payment of $73 million net of cash acquired; filer does not name the business or disclose a closing date. No headcount disclosed.
2025-09-30restructuringin_progress2023-02-222025-12-31GlobalGlobal Supply Chain Optimization and functional capabilitiesUSD 250 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Board approved expansion of 2023 Restructuring Plan by up to $250 million in aggregate additional pre-tax charges. Total estimated charges for the plan range from $700 million to $800 million. Includes termination benefits of $100-120 million.
2025-09-30restructuringin_progress2025-05-282025-12-31WorldwideCardiology (ACURATE platform)USD 90 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Discontinuation of worldwide sales of ACURATE neo2 and ACURATE Prime Aortic Valve Systems. Resulted in total pre-tax restructuring and restructuring-related net charges of approximately $90 million in the first nine months of 2025.
2025-09-30restructuringin_progressUSD -8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progress2025-05-282025-12-31GlobalCardiovascular — Cardiology (Aortic Valve)USD 110 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Discontinuation of ACURATE neo2 and ACURATE Prime Aortic Valve Systems; no employee count disclosed. Majority of charges recorded in Q2 2025.
2025-06-30restructuringannounced2025-07-292025-12-31GlobalCorporate / Global Supply ChainUSD 250 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board approved expansion of 2023 Restructuring Plan by up to $250M in additional pre-tax charges; subsequent event after quarter end. No employee count disclosed.
2025-06-30acquisition_additioncompleted2025-04-012025-04-01United StatesCardiology / Peripheral Interventionsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of remaining shares of Bolt Medical completed April 1, 2025; no headcount disclosed.
2025-06-30acquisition_additioncompleted2025-05-062025-05-06United StatesPeripheral Interventionsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Intera Oncology completed May 6, 2025; no headcount disclosed.
2025-06-30acquisition_additioncompleted2025-05-072025-05-07IsraelCardiologybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of remaining shares of SoniVie completed May 7, 2025; no headcount disclosed.
2025-06-30acquisition_additioncompleted2025-07-112025-07-11ChinaEndoscopysubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Anrei Medical completed July 11, 2025 (subsequent event); no headcount disclosed.
2025-06-30restructuringin_progress2023-02-222025-12-31GlobalGlobal Supply Chain Optimization and functional capabilitiesUSD 250 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Board approved expanding the 2023 Restructuring Plan by up to $250 million in aggregate additional pre-tax charges. Total estimated charges for the plan range from $700 million to $800 million. Employee impacts to be developed per region.
2025-06-30restructuringin_progress2025-05-282025-12-31WorldwideCardiology (ACURATE platform)USD 110 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Discontinuation of worldwide sales of ACURATE neo2 and ACURATE Prime Aortic Valve Systems resulted in total pre-tax restructuring and restructuring-related net charges of approximately $110 million.
2025-06-30restructuringin_progressUSD 83,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31acquisition_additioncompleted2025-01-242025-01-24United StatesCardiologybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Completed acquisition of Cortex, Inc.; no headcount disclosed.
2025-03-31acquisition_additioncompleted2025-04-012025-04-01United StatesCardiology and Peripheral Interventionsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Subsequent event: acquisition of remaining shares of Bolt Medical, Inc.; no headcount disclosed.
2025-03-31acquisition_additionannounced2025-03-032025-06-30IsraelCardiologybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire SoniVie Ltd.; expected to close Q2 2025; no headcount disclosed.
2025-03-31acquisition_additionannounced2024-11-252025-06-30United StatesPeripheral Interventionsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pending acquisition of Intera Oncology, Inc.; expected to close Q2 2025; no headcount disclosed.
2025-03-31restructuringin_progress2023-02-22GlobalGlobal Supply ChainUSD 49 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2023 Restructuring Plan ongoing; Q1 2025 charges of $10M restructuring plus $39M restructuring-related; no employee counts disclosed.
2025-03-31restructuringin_progressUSD 10 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Reported $10 million in restructuring net charges for Q1 2025. Employee count not disclosed.
2025-03-31restructuringin_progressUSD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-12-31restructuringin_progress2023-02-222025-12-31GlobalEnterprise-wide; Global Supply Chain Optimization and functional capability optimizationUSD 212 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2024 activity only: restructuring-related charges of $212M (recorded in COGS, SG&A and R&D) plus ASC 420 restructuring charges of $16M; restructuring reserve balance $26M at year-end. Program totals of $450M-$550M pre-tax charges and $225M-$275M annual expense savings are cumulative program estimates, not FY2024 figures. Filer expects limited role reductions and no net change in overall employee base; no affected-employee count disclosed.
2024-12-31acquisition_additioncompleted2024-09-172024-09-17United StatesPeripheral Interventionsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Silk Road Medical, Inc. for approximately $1.126B net of cash acquired; acquired headcount not disclosed.
2024-12-31acquisition_additioncompleted2024-11-152024-11-15United StatesUrologybusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Axonics, Inc. for approximately $3.409B net of cash acquired; acquired headcount not disclosed. Designated a Qualified Acquisition under the credit agreement.
2024-12-31acquisition_additioncompleted2024-03-312024-03-31United StatesEndoscopyMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of the endoluminal vacuum therapy portfolio of B. Braun Medical Inc. during the first quarter of 2024; exact closing date and acquired headcount not disclosed (date shown as quarter-end placeholder).
2024-12-31acquisition_additionannounced2024-11-252025-06-30United StatesPeripheral Interventionsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Intera Oncology, Inc. for approximately $175M upfront; expected to close in the first half of 2025 (expected_completion_date is an approximation of the stated half-year window).
2024-12-31acquisition_additionannounced2025-01-082025-06-30United StatesCardiology and Peripheral Interventionssubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire the remaining ~74 percent of Bolt Medical, Inc.; ~$443M upfront plus up to ~$221M in regulatory milestone payments; expected to close in the first half of 2025 (expected_completion_date approximates the stated half-year window).
2024-12-31acquisition_additioncompleted2025-01-242025-01-24United StatesCardiologysubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Subsequent-event acquisition completed after fiscal year-end: $248M upfront net of cash acquired plus up to ~$50M in regulatory milestone payments; acquired headcount not disclosed.
2024-12-31restructuringin_progress2023-02-222025-12-31GlobalAll segmentsUSD 450 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2023 Restructuring Plan approved Feb 22, 2023. Total pre-tax charges estimated $450M-$550M. Substantially completed by end of 2025. Limited role reductions expected; overall employee base to remain relatively unchanged.
2024-12-31acquisition_additioncompleted2024-11-152024-11-15GlobalUrologybusiness_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Axonics, Inc. completed Nov 15, 2024. Headcount not explicitly disclosed.
2024-12-31acquisition_additioncompleted2024-09-172024-09-17GlobalPeripheral Interventionsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Silk Road Medical, Inc. completed Sep 17, 2024. Headcount not explicitly disclosed.
2024-12-31restructuringin_progress2023-02-222025-12-31GlobalAll segmentsUSD 229 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		2023 Restructuring Plan. Total pre-tax charges estimated at $450M-$550M. $229M recorded in 2024. Limited role reductions expected; overall employee base to remain relatively unchanged.
2024-12-31acquisition_additioncompleted2024-11-152024-11-15GlobalUrologyItem_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Axonics, Inc. completed in Q4 2024. Headcount not explicitly disclosed.
2024-12-31acquisition_additioncompleted2024-09-172024-09-17GlobalPeripheral InterventionsItem_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Silk Road Medical, Inc. completed in Q3 2024. Headcount not explicitly disclosed.
2024-12-31restructuringin_progressUSD 16,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-09-30restructuringin_progress2023-02-22GlobalGlobal Supply Chain OptimizationUSD 8 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		2023 Restructuring Plan approved Feb 22, 2023. Q3 2024 restructuring charges of $8M recorded. Reserve balance $31M as of Sept 30, 2024. Employee count not disclosed.
2024-09-30acquisition_additioncompletedPeripheral InterventionsUSD 1,126 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Silk Road Medical completed in Q3 2024. Purchase price $1.126B. Headcount added not disclosed.
2024-09-30acquisition_additionannounced2024-01-082024-12-31UrologyUSD 3,670 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Agreement to acquire Axonics announced Jan 8, 2024. Purchase price ~$3.67B. Expected completion Q4 2024. Headcount added not disclosed.
2024-09-30restructuringin_progressUSD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progress2023-02-22GlobalGlobal Supply Chain / Manufacturing and DistributionUSD 5 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six-month 2024 restructuring charges of $5M; reserve balance $29M at 6/30/24. No employee count disclosed.
2024-06-30acquisition_additionannounced2024-06-182024-12-31United StatesPeripheral InterventionsUSD 1,260 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Silk Road Medical acquisition announced; purchase price ~$1.260B. No headcount disclosed.
2024-06-30acquisition_additionin_progress2024-01-082024-12-31United StatesUrologyUSD 3,670 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Axonics acquisition pending FTC Second Request review; purchase price ~$3.670B. No headcount disclosed.
2024-06-30restructuringin_progress2023-02-22GlobalGlobal Supply Chain Optimization and functional capabilitiesUSD 1 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		2023 Restructuring Plan approved Feb 2023. Q2 2024 recorded $1M restructuring charges and $49M restructuring-related charges. Reserve balance $29M as of June 30, 2024. Employee count not disclosed.
2024-06-30acquisition_additionannounced2024-06-182024-12-31Peripheral Interventionssubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Agreement to acquire Silk Road Medical for $1.26B. Expected completion in H2 2024. Headcount not disclosed.
2024-06-30acquisition_additionannounced2024-01-082024-12-31Urologysubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Agreement to acquire Axonics for $3.67B. Received FTC Second Request. Expected completion in H2 2024. Headcount not disclosed.
2024-06-30restructuringin_progressUSD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31acquisition_additionannounced2024-01-082024-12-31United StatesUrologybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire 100% of Axonics, Inc. for $71.00/share (~$3.670B). Headcount added not disclosed. FTC Second Request received 2024-04-03; expected close in H2 2024. Axonics to be integrated into Urology division.
2024-03-31restructuringin_progress2023-02-22GlobalGlobal Supply Chain / Manufacturing and DistributionUSD 3 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2023 Restructuring Plan: $3M restructuring charges recorded in Q1 2024; restructuring reserve $35M at 2024-03-31. Additional $43M restructuring-related charges recorded in Q1 2024 primarily in COGS and SG&A. Number of employees affected not disclosed.
2024-03-31restructuringin_progress2023-02-22GlobalGlobal Supply Chain OptimizationUSD 3 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		2023 Restructuring Plan approved Feb 22, 2023. Q1 2024 recorded $3M restructuring charges and $43M restructuring-related charges. Reserve balance $35M as of Mar 31, 2024. Employee count not disclosed.
2024-03-31acquisition_additionannounced2024-01-082024-12-31United StatesUrologyUSD 3,670 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Agreement to acquire 100% of Axonics, Inc. for approx $3.67B. Expected completion in second half of 2024. Headcount impact not disclosed.
2024-03-31restructuringin_progressUSD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-12-31restructuringin_progress2023-02-222025-12-31GlobalGlobal supply chain and corporate functionsUSD 69 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Program estimated to result in total pre-tax charges of approximately $450M-$550M and gross annual pre-tax expense savings of $225M-$275M. FY2023 charges were $69M restructuring plus $115M restructuring-related; restructuring reserve was $41M at year-end. Filer expects limited role reductions and no net change in overall employee base; no affected-employee count disclosed.
2023-12-31acquisition_additioncompleted2023-02-20ChinaPeripheral Interventionsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Majority stake (~65%) in Acotec Scientific Holdings Limited acquired for $381M payment, net of cash acquired; consolidated with a noncontrolling interest. Headcount added not disclosed.
2023-12-31acquisition_additioncompleted2023-04-04United StatesEndoscopybusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of 100% of Apollo Endosurgery, Inc. for $636M upfront cash, net of cash acquired. Headcount added not disclosed.
2023-12-31acquisition_additioncompleted2023-11-17United StatesNeuromodulationbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of 100% of Relievant Medsystems, Inc. for $794M upfront cash plus $273M fair value of sales-based milestones. Headcount added not disclosed.
2023-12-31divestiture_reductioncompletedPathology businessMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Pathology business divested during the second quarter of 2023; headcount removed not disclosed.
2023-12-31acquisition_additionannounced2024-01-08United StatesUrologysubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Axonics, Inc. at $71.00 cash per share, approximately $3.670 billion, expected to close in the first half of 2024, funded with cash on hand and new debt. Headcount added not disclosed.
2023-12-31restructuringin_progress2023-02-222025-12-31GlobalGlobal Supply Chain Optimization and Functional CapabilitiesUSD 500 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Board approved global restructuring program on Feb 22, 2023. Expected total pre-tax charges of $450M-$550M. Limited role reductions expected; overall employee base to remain relatively unchanged as new jobs created in growth areas.
2023-12-31acquisition_additioncompleted2023-02-202023-02-20ChinaPeripheral InterventionsMD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquired majority stake in Acotec Scientific Holdings Limited. Headcount not explicitly disclosed.
2023-12-31acquisition_additioncompleted2023-04-042023-04-04GlobalEndoscopyMD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquired Apollo Endosurgery, Inc. Headcount not explicitly disclosed.
2023-12-31acquisition_additioncompleted2023-11-172023-11-17GlobalNeuromodulationMD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquired Relievant Medsystems, Inc. Headcount not explicitly disclosed.
2023-12-31restructuringin_progress2023-02-222025-12-31GlobalGlobal Supply Chain Optimization and functional capabilitiesUSD 450 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		2023 Restructuring Plan approved Feb 22, 2023. Estimated total pre-tax charges $450M-$550M. Limited role reductions expected; overall employee base to remain relatively unchanged.
2023-12-31restructuringin_progressUSD 69,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-09-30restructuringin_progress2023-02-22GlobalMultipleUSD 51 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board-approved global restructuring plan; $51M restructuring charges YTD plus $82M restructuring-related charges in COGS/SG&A. No employee count disclosed.
2023-09-30acquisition_additioncompleted2023-02-202023-02-20ChinaPeripheral Interventions (Cardiovascular)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Majority stake (~65%) in Acotec Scientific Holdings; consolidated on one-quarter lag. No headcount added disclosed.
2023-09-30acquisition_additioncompleted2023-04-042023-04-04United StatesEndoscopy (MedSurg)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Apollo Endosurgery for $636M net of cash. No headcount added disclosed.
2023-09-30acquisition_additionannounced2023-09-192024-06-30United StatesNeuromodulation (MedSurg)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Relievant Medsystems for $850M upfront plus contingent payments; expected close H1 2024. No headcount disclosed.
2023-09-30restructuringin_progress2023-02-22GlobalUSD 15 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		2023 Restructuring Plan approved Feb 22, 2023. Q3 2023 charges of $15M recorded. Employee count not disclosed.
2023-09-30restructuringin_progress2023-02-22GlobalUSD 51 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		2023 Restructuring Plan. YTD 2023 charges of $51M recorded. Employee count not disclosed.
2023-09-30restructuringin_progressUSD 15,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progress2023-02-22GlobalGlobalUSD 36 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board approved 2023 Restructuring Plan on Feb 22, 2023. Q2 restructuring charges $16M; YTD $36M, plus restructuring-related charges of $26M (Q2) and $50M (YTD) in COGS and SG&A. No employee headcount affected disclosed.
2023-06-30acquisition_additioncompleted2023-04-042023-04-04United StatesEndoscopy (MedSurg)USD 636 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Apollo Endosurgery, Inc. completed April 4, 2023 for $636M cash net of cash acquired. No headcount added disclosed.
2023-06-30acquisition_additioncompleted2023-02-202023-02-20ChinaPeripheral Interventions (Cardiovascular)USD 519 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Majority stake (~65%) in Acotec Scientific Holdings Limited acquired Feb 20, 2023 for HK$20.00/share (~$519M). Consolidated on one-quarter lag. No headcount added disclosed.
2023-06-30restructuringin_progress2023-02-22GlobalUSD 16 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		2023 Restructuring Plan approved Feb 22, 2023. Q2 2023 charges of $16M recorded. No employee count disclosed.
2023-06-30restructuringin_progress2023-02-22GlobalUSD 36 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		2023 Restructuring Plan approved Feb 22, 2023. YTD 2023 charges of $36M recorded. No employee count disclosed.
2023-06-30restructuringin_progressUSD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-03-31restructuringin_progress2023-02-22GlobalUSD 20 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board approved 2023 Restructuring Plan on 2023-02-22; $20M restructuring charges plus $24M restructuring-related charges recorded in Q1 2023. No employee count or completion date disclosed.
2023-03-31acquisition_additioncompleted2023-02-202023-02-20ChinaPeripheral Interventionsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of ~65% majority stake in Acotec Scientific Holdings Limited for $519M; consolidated on one-quarter lag so results omitted from Q1 2023 income statement. No headcount disclosed.
2023-03-31acquisition_additioncompleted2023-04-042023-04-04United StatesEndoscopysubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Subsequent-event acquisition of Apollo Endosurgery, Inc. for ~$615M ($10.00/share cash). No headcount disclosed.
2023-03-31restructuringin_progress2023-02-22GlobalUSD 44 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Board approved 2023 Restructuring Plan on Feb 22, 2023. Recorded $20M restructuring charges and $24M restructuring-related charges in Q1 2023. Employee count affected not disclosed.
2023-03-31restructuringin_progressUSD 20,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-12-31restructuringcompleted2018-11-152022-12-31GlobalGlobal supply chain and functional capabilitiesUSD 110 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2019 Restructuring Plan, approved 2018-11-15 and extended 2021-02-22; activities substantially completed during 2022. Charge shown is fiscal 2022 activity only ($24M restructuring plus $86M restructuring-related); cumulative program charges of $461M. Employees affected not disclosed.
2022-12-31restructuringannounced2023-02-222025-12-31GlobalGlobal supply chain network and functional capabilitiesUSD 450 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Approved by the Board on 2023-02-22, after fiscal year-end. Estimated total pre-tax charges range from $450M to $550M (value shown is the low end), of which $350M to $450M expected to be cash; targeted gross annual pre-tax expense savings of $225M to $275M by end of 2025. Filer expects limited role reductions and a relatively unchanged overall employee base; no headcount figure disclosed.
2022-12-31acquisition_additioncompleted2022-02-142022-02-14Canada / United StatesCardiology division (electrophysiology and structural heart)USD 1,463 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Baylis Medical Company Inc. for $1.463 billion net of cash acquired; acquired headcount not disclosed. Business represented less than 1% of total assets and approximately 1% of 2022 net sales.
2022-12-31acquisition_additionannounced2022-06-152023-06-30South KoreaEndoscopy divisionUSD 230 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Agreement to purchase approximately 64 percent of M.I. Tech Co., Ltd. for KRW 291.2 billion (approximately $230M); targeted to close in Q2 2023 subject to regulatory approvals. Headcount not disclosed.
2022-12-31acquisition_additionannounced2022-11-292023-06-30United StatesEndoscopy divisionUSD 615 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire 100 percent of Apollo Endosurgery, Inc. at $10.00 per share (approximately $615M); expected to close in the first half of 2023. Headcount not disclosed.
2022-12-31acquisition_additioncompleted2023-02-202023-02-20ChinaPeripheral Interventions divisionUSD 520 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Completed after fiscal year-end: acquisition of approximately 65 percent of Acotec Scientific Holdings Limited for HK$20.00 per share (approximately $520M), funded with cash on hand. Headcount not disclosed.
2022-12-31restructuringannounced2023-02-222025-12-31GlobalGlobal Supply Chain Optimization and functional capabilitiesUSD 500 (millions)subsequent_events
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2023 Restructuring Plan approved Feb 22, 2023. Estimated total pre-tax charges of $450M-$550M. Subsequent event relative to FY2022 filing.
2022-12-31restructuringcompleted2018-11-152022-12-31GlobalSupply chain network optimization and functional capabilitiesUSD 461 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2019 Restructuring Plan substantially completed in 2022. Cumulative pre-tax charges of $461M.
2022-12-31restructuringin_progress2018-11-152022-12-31GlobalGlobal Supply Chain and Functional CapabilitiesUSD 110 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		2019 Restructuring Plan charges recorded in 2022: $24 million restructuring charges and $86 million restructuring-related charges. Program substantially completed in 2022.
2022-12-31restructuringannounced2023-02-222025-12-31GlobalGlobal Supply Chain and Functional CapabilitiesUSD 500 (millions)subsequent_events
f5-10k / Qwen3.6-27B-Q8_0		2023 Restructuring Plan announced Feb 22, 2023. Estimated total pre-tax charges of $450 million to $550 million. Limited role reductions expected; overall employee base to remain relatively unchanged.
2022-12-31restructuringin_progressUSD 24,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-09-30restructuringin_progress2018-11-012022-12-31GlobalMultipleUSD 450 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2019 Restructuring Plan; total pre-tax charges estimated at $450-475M, with $400-425M expected cash outlays. Board approved increased cost estimates on 2022-02-22. No employee count disclosed. Majority of activity expected substantially complete by end of 2022.
2022-09-30acquisition_additioncompleted2022-02-142022-02-14United StatesCardiology (Electrophysiology and Structural Heart)USD 1,463 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Baylis Medical Company Inc. for $1.463B net of cash acquired. No headcount added disclosed.
2022-09-30acquisition_additionannounced2022-06-152022-12-31South KoreaEndoscopyUSD 230 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to purchase approximately 64% of M.I. Tech Co., Ltd. for KRW 291.2 billion (~$230M). Expected to close Q4 2022. No headcount disclosed.
2022-09-30restructuringin_progress2018-11-012022-12-31GlobalGlobalUSD 18 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		2019 Restructuring Plan. Q3 2022 restructuring charges were $4 million. Total pre-tax charges expected to be $450-$475 million. Majority of activity expected to be substantially complete by end of 2022. Employee count not disclosed.
2022-09-30acquisition_additioncompleted2022-02-14GlobalCardiologybusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Baylis Medical Company Inc. completed Feb 14, 2022. Integrated into Cardiology division. Employee count not disclosed.
2022-09-30acquisition_additionannounced2022-06-152022-12-31KoreaEndoscopybusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Agreement to purchase majority stake of M.I. Tech Co., Ltd. announced June 15, 2022. Expected to close in Q4 2022. Employee count not disclosed.
2022-09-30restructuringin_progressUSD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-06-30restructuringin_progress2018-11-012022-12-31GlobalVariousUSD 14 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		2019 Restructuring Plan; Board approved increased cost estimates in Feb 2022. Total pre-tax charges expected $450M-$500M. Q2 2022 restructuring charges were $11M; restructuring-related charges were $24M.
2022-06-30acquisition_additioncompleted2022-02-14GlobalCardiologybusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Baylis Medical Company Inc. completed Feb 14, 2022. Headcount not explicitly disclosed.
2022-06-30divestiture_reductioncompleted2802021-03-01GlobalSpecialty Pharmaceuticalsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Divestiture of Specialty Pharmaceuticals business completed March 1, 2021. Agreement included transfer of approximately 280 employees globally.
2022-06-30restructuringin_progressUSD 11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-03-31restructuringin_progress2018-11-012022-12-31GlobalEnterpriseUSD 425 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2019 Restructuring Plan; on 2022-02-22 the Board approved increased cost estimates to total pre-tax charges of $425M–$525M, with $375M–$475M expected cash outlays. No employee count disclosed. Majority of activity expected substantially complete by end of 2022.
2022-03-31acquisition_additioncompleted2022-02-142022-02-14GlobalCardiology (Cardiovascular segment)USD 1,471 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Baylis Medical Company Inc. completed 2022-02-14 for $1.471B net of cash acquired. No headcount added disclosed.
2022-03-31restructuringin_progress2018-11-012022-12-31GlobalVariousUSD 29 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		2019 Restructuring Plan. Q1 2022 charges of $4M restructuring and $25M restructuring-related. Total pre-tax charges expected $425M-$525M. Majority of activity expected substantially complete by end of 2022.
2022-03-31acquisition_additioncompleted2022-02-142022-02-14GlobalCardiologybusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Baylis Medical Company Inc. completed Feb 14, 2022. Headcount not explicitly disclosed.
2022-03-31divestiture_reductioncompleted2802021-03-012021-03-01GlobalSpecialty Pharmaceuticalsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Divestiture of Specialty Pharmaceuticals business completed March 1, 2021. Agreement included transfer of approximately 280 employees globally.
2022-03-31restructuringin_progressUSD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-12-31restructuringin_progress2018-11-152022-12-31GlobalEnterprise-wide; supply chain network optimization and functional capability buildUSD 172 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2021 charges of $172M for restructuring and restructuring-related net charges under this program; program total estimated at $425M-$525M pre-tax with $375M-$475M cash outlays, expected to reduce gross annual pre-tax expenses by $250M-$300M by end of 2023; cost estimates increased and approved 2022-02-22; employees affected not disclosed
2021-12-31restructuringcompleted2020-11-172021-12-31GlobalCardiovascular — LOTUS Valve platform (aortic valve system)USD 20 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Restructuring and restructuring-related net charges of $20M in FY2021 ($55M in FY2020) following global voluntary recall and retirement of the LOTUS platform; activities completed in 2021 with total pre-tax charges of approximately $80M; employees affected not disclosed
2021-12-31divestiture_reductioncompleted2802020-12-012021-03-01GlobalSpecialty Pharmaceuticalsdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Divestiture of Specialty Pharmaceuticals business completed 2021-03-01 for approximately $800M; agreement included transfer of five facilities and approximately 280 employees globally
2021-12-31acquisition_additioncompleted2021-12-31GlobalCardiac Rhythm Management, Electrophysiology, Urology and Pelvic Health, Peripheral Interventionsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Four acquisitions completed in FY2021 (Preventice, Farapulse, Lumenis surgical business, Devoro Medical) for aggregate purchase price of $3.3 billion net of cash acquired; headcount added not disclosed
2021-12-31acquisition_additionannounced2022-02-142022-02-14GlobalElectrophysiology and structural heartUSD 1,750 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Subsequent event after FY2021 year-end: acquisition of Baylis Medical Company Inc. completed 2022-02-14 for upfront cash payment of $1.750 billion funded with cash on hand; headcount added not disclosed
2021-12-31restructuringin_progress2018-11-152022-12-31GlobalVariousUSD 172 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2019 Restructuring Plan. Total pre-tax charges of $172 million recorded in 2021. Program extended to end of 2022.
2021-12-31divestiture_reductioncompleted2802020-12-012021-03-01GlobalSpecialty Pharmaceuticalsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Divestiture of Specialty Pharmaceuticals business completed March 1, 2021. Agreement included transfer of approximately 280 employees globally.
2021-12-31acquisition_additioncompletedGlobalVariousbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Completed acquisitions of Preventice, Farapulse, Lumenis, and Devoro Medical in 2021. Specific headcount additions not disclosed.
2021-12-31restructuringin_progress2018-11-152022-12-31GlobalAll segmentsUSD 191 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		2019 Restructuring Plan. Total pre-tax charges of $191 million recorded in 2021. Program extended to end of 2022. Employee count affected not explicitly disclosed for 2021 activity.
2021-12-31divestiture_reductioncompleted2802020-12-012021-03-01GlobalSpecialty Pharmaceuticalsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Divestiture of Specialty Pharmaceuticals business completed March 1, 2021. Agreement included transfer of approximately 280 employees globally.
2021-12-31restructuringin_progressUSD 40,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-12-31restructuringin_progressRestructuring Plan [Member]USD 40,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-09-30divestiture_reductioncompleted2802021-03-01GlobalSpecialty Pharmaceuticalsother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Divestiture of Specialty Pharmaceuticals business to SERB affiliates; agreement included transfer of five facilities and approximately 280 employees globally.
2021-09-30divestiture_reductioncompleted2802021-03-012021-03-01GlobalSpecialty Pharmaceuticalsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Divestiture of Specialty Pharmaceuticals business to Stark International Lux S.A.R.L. and SERB SAS included transfer of approximately 280 employees globally.
2021-09-30restructuringin_progress2018-11-012022-12-31GlobalCorporateUSD 9 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		2019 Restructuring Plan (extended and expanded Feb 2021). Q3 2021 restructuring charges were $9 million. Total pre-tax charges expected $375M-$475M. Employee count not disclosed for this specific period's activity.
2021-09-30restructuringcompleted2020-11-172021-03-31GlobalCardiovascularUSD 2 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Recall and retirement of LOTUS Edge Aortic Valve System. Q3 2021 restructuring charges were immaterial; $2 million recorded in first nine months of 2021. Activities substantially completed in Q1 2021. Employee count not disclosed.
2021-09-30restructuringin_progressUSD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30divestiture_reductioncompleted2802021-03-012021-03-01GlobalSpecialty Pharmaceuticalsother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Divestiture of Specialty Pharmaceuticals to affiliates of SERB; transfer involved five facilities and approximately 280 employees globally. Purchase price approximately $800 million.
2021-06-30restructuringin_progress2018-11-012022-12-31GlobalEnterprise-wideMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2019 Restructuring Plan, extended and expanded by the Board in February 2021; expected total pre-tax charges of approximately $375-475 million, with $3 million restructuring charges and $35 million restructuring-related charges in Q2 2021. No employee counts disclosed; majority of activity expected substantially complete by end of 2022.
2021-06-30restructuringcompleted2020-11-172021-03-31GlobalCardiovascular — LOTUS Valve platformUSD 80 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Recall of unused LOTUS Edge Aortic Valve inventory and retirement of the LOTUS platform; total pre-tax restructuring and restructuring-related net charges of approximately $80 million. Activities substantially completed in Q1 2021; no employee counts disclosed.
2021-06-30acquisition_additioncompleted2021-03-012021-03-01United StatesRhythm and Neuro — Cardiac Rhythm Managementbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Preventice Solutions completed March 1, 2021 ($925 million upfront plus up to $300 million commercial milestone). Headcount added not disclosed in this filing.
2021-06-30acquisition_additioncompleted2021-08-062021-08-06United StatesCardiovascular — Electrophysiologysubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of remaining shares of Farapulse completed August 6, 2021, after quarter end; $450 million upfront plus up to $125 million milestones and revenue-based payments. Headcount added not disclosed.
2021-06-30divestiture_reductioncompleted2802021-03-012021-03-01GlobalSpecialty Pharmaceuticalsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Divestiture of Specialty Pharmaceuticals business to Stark International Lux S.A.R.L. and SERB SAS included transfer of approximately 280 employees globally.
2021-06-30restructuringin_progress2018-11-012022-12-31GlobalVariousUSD 3 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		2019 Restructuring Plan (extended Feb 2021). Q2 2021 restructuring charges were $3 million. Total pre-tax charges expected $375M-$475M. Employee count not disclosed for this period's activity.
2021-06-30restructuringcompleted2020-11-172021-03-31GlobalInterventional CardiologyUSD 2 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Retirement of LOTUS Edge Aortic Valve System. Q2 2021 restructuring charges were immaterial; $2M recorded in first six months. Activities substantially completed in Q1 2021. Employee count not disclosed.
2021-06-30restructuringin_progressUSD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-03-31divestiture_reductioncompleted2802021-03-01GlobalSpecialty Pharmaceuticalsother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Divestiture of Specialty Pharmaceuticals to SERB affiliates; agreement transferred five facilities and approximately 280 employees globally.
2021-03-31restructuringin_progress2018-11-012022-12-31GlobalCorporateMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2019 Restructuring Plan, extended and expanded February 2021; expected total pre-tax charges of $375-475 million. Employee headcount affected not disclosed in this filing.
2021-03-31restructuringcompleted2020-11-172021-03-31GlobalCardiovascular — Interventional CardiologyMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Retirement of LOTUS Valve platform following product recall; estimated total pre-tax charges of $80-85 million. Substantially completed in Q1 2021; employee counts not disclosed.
2021-03-31acquisition_additioncompleted2021-03-01GlobalCardiac Rhythm Managementbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Preventice Solutions, Inc. completed on March 1, 2021. Headcount not explicitly disclosed.
2021-03-31divestiture_reductioncompleted2802021-03-01GlobalSpecialty Pharmaceuticalsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Divestiture of Specialty Pharmaceuticals business completed on March 1, 2021, including transfer of approximately 280 employees globally.
2021-03-31restructuringin_progress2018-11-012022-12-31GlobalCorporateUSD 3 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		2019 Restructuring Plan (extended and expanded Feb 2021). $3M restructuring charges recorded in Q1 2021. Employee count not disclosed for this period.
2021-03-31restructuringcompleted2020-11-17GlobalInterventional CardiologyUSD 2 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Retirement of LOTUS Edge Aortic Valve System. $2M restructuring charges and $15M restructuring-related charges recorded in Q1 2021. Activities substantially completed in Q1 2021. Employee count not disclosed.
2021-03-31restructuringin_progressUSD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-12-31restructuringin_progress2018-11-152022-12-31GlobalSupply chain network optimization and functional capability buildingUSD 116 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2019 Restructuring Plan; $116M is FY2020 restructuring and restructuring-related net charges (cumulative through 2020-12-31: $179M). Total program estimated at $375M-$475M pre-tax charges, targeting $200M-$250M annual expense reduction by end of 2023. Program extended one year by Board on 2021-02-22; majority of activity expected complete by end of 2022. No employee headcount affected disclosed.
2020-12-31restructuringin_progress2020-11-172021-03-31GlobalCardiovascular — LOTUS Aortic Valve System platformUSD 55 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Voluntary recall and retirement of entire LOTUS platform. $55M restructuring/restructuring-related charges recorded in FY2020; total estimated program charges $80M-$90M pre-tax. Additional $119M inventory charges in cost of products sold and $8M intangible asset impairment also recorded in FY2020. Remaining activity expected substantially complete early 2021. No employee headcount affected disclosed.
2020-12-31divestiture_reductionannounced2802020-12-012021-06-30GlobalSpecialty PharmaceuticalsUSD 800 (millions)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Agreement to sell Specialty Pharmaceuticals business to affiliates of SERB for $800M purchase price; transfer of five facilities and approximately 280 employees globally. Expected to close in first half of 2021. $73M goodwill impairment recorded in FY2020.
2020-12-31acquisition_additionannounced2021-01-212021-06-30United StatesCardiac Rhythm ManagementUSD 720 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Preventice Solutions, Inc.; net cash payment of approximately $720M at closing plus up to $230M commercial milestone. Company held ~22% equity stake prior to announcement. No employee headcount disclosed.
2020-12-31restructuringin_progress2018-11-012022-12-31GlobalAll segmentsUSD 375 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2019 Restructuring Plan extended to end of 2022. Total pre-tax charges estimated at $375 million to $475 million. Employee count not disclosed.
2020-12-31restructuringcompleted2016-06-012019-12-31GlobalAll segmentsUSD 271 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2016 Restructuring Plan substantially completed in 2019. Total pre-tax charges of $271 million. Employee count not disclosed.
2020-12-31restructuringin_progress2020-11-172021-03-31GlobalCardiovascularUSD 80 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		LOTUS Edge Aortic Valve System recall and discontinuation. Estimated total pre-tax charges of $80 million to $90 million. $55 million recorded in 2020. Employee count not disclosed.
2020-12-31restructuringin_progress2018-11-152022-12-31GlobalAll segmentsUSD 116 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		2019 Restructuring Plan. Total pre-tax charges of $116 million recorded in 2020. Program extended to end of 2022.
2020-12-31restructuringcompleted2016-06-062019-12-31GlobalAll segmentsUSD 0 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		2016 Restructuring Plan. Substantially completed in 2019. No new charges recorded in 2020.
2020-12-31restructuringin_progress2020-11-172021-03-31GlobalCardiovascularUSD 55 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		LOTUS Edge discontinuation. $55 million in restructuring and restructuring-related net charges recorded in 2020.
2020-12-31restructuringin_progressUSD 52,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-12-31restructuringin_progressRestructuring Plan [Member]USD 52,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-09-30restructuringin_progress2018-11-01GlobalUSD 3 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		2019 Restructuring Plan charges for Q3 2020. Total plan expected charges $200M-$300M.
2020-09-30restructuringin_progress2016-06-01GlobalUSD 0 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		2016 Restructuring Plan substantially completed in 2019; no specific charges disclosed for Q3 2020, but included in aggregate restructuring line item.
2020-09-30restructuringin_progressUSD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progress2018-11-01GlobalMultipleMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board-approved global restructuring program with expected total pre-tax charges of $200M-$300M and $180M-$280M cash outlays; no employee count disclosed. Restructuring charges of $13M recorded in first six months of 2020.
2020-06-30otherin_progress2020-04-012020-09-30GlobalMultipleMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Temporary four-day work week for many employees globally, temporary pay reductions including significant cuts to Executive Committee salaries and Board cash retainers, hiring freeze on all but critical roles, and temporary closure or reduced production at certain manufacturing sites. Measures concluded at the beginning of Q3 2020. No employee counts disclosed.
2020-06-30restructuringin_progress2018-11-01GlobalVariousUSD 13 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		2019 Restructuring Plan approved Nov 2018. $13M charge recorded in Q2 2020. Total expected pre-tax charges $200M-$300M. Employee count affected not disclosed in this period.
2020-06-30othercompleted2020-04-012020-06-30GlobalVariousMD&A
f5-10q / Qwen3.6-27B-Q8_0		Implemented temporary four-day work week and reduced employee compensation, including executive salaries and board retainers. Measures concluded at beginning of Q3 2020.
2020-06-30restructuringin_progressUSD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progress2018-11-01GlobalMultipleUSD 10 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2019 Restructuring Plan; $10M charge in Q1 2020. Plan expected total pre-tax charges of $200-300M. No quarterly employee count disclosed.
2020-03-31otherin_progress2020-04-01GlobalMost employees (non-sales)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Temporary four-day work week for most employees and reduced compensation, including significant salary cuts for Executive Committee and Board. Implemented entering Q2 2020.
2020-03-31plant_closurein_progress2020-04-01GlobalManufacturingMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Certain manufacturing sites temporarily closed to align build plans with reduced demand. No site count or employee count disclosed.
2020-03-31otherin_progress2020-04-01GlobalAll functionsMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Hiring freeze on all but the most critical new hires, plus reductions in travel, meetings, customer events, clinical programs, and certain R&D projects in response to COVID-19.
2020-03-31restructuringin_progress2018-11-01GlobalGlobalUSD 10 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Charges related to the 2019 Restructuring Plan. Employee count not disclosed.
2020-03-31othercompleted2020-03-31GlobalAllMD&A
f5-10q / Qwen3.6-27B-Q8_0		Implemented temporary four-day work week for most employees and reduced employee compensation, including significant cuts in salaries of Executive Committee and Board of Directors.
2020-03-31restructuringin_progressUSD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-12-31restructuringin_progress2018-11-152021-12-31GlobalSupply chain network optimization and growth-capability functionsUSD 47 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cumulative charges incurred through 2019-12-31 per footnote table (program initiated 2019); total program estimated at $200M-$300M pre-tax with $180M-$280M cash outlays, majority of activity expected complete by end of 2021. Employees affected not disclosed.
2019-12-31restructuringcompleted2016-06-062019-12-31GlobalManufacturing network optimization, real estate and global infrastructureUSD 271 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cumulative through fiscal year-end since program inception in 2016; plan substantially completed in 2019. Employees affected not disclosed.
2019-12-31acquisition_additioncompleted2019-08-19United Kingdom / globalPeripheral Interventions, Specialty Pharmaceuticals (Cardiovascular and standalone segment)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition closed 2019-08-19 for $3.619 billion net of cash acquired; acquired headcount not disclosed.
2019-12-31acquisition_additioncompleted2019-06-11United StatesNeuromodulation (Rhythm and Neuro)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Upfront cash payment of $465 million plus sales-based contingent payments; acquired headcount not disclosed.
2019-12-31acquisition_additioncompleted2019-01-29United StatesInterventional Cardiology (Cardiovascular)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Upfront cash payment of $325 million for remaining stake plus up to $125 million commercial milestone; acquired headcount not disclosed.
2019-12-31divestiture_reductioncompleted2019-08-21GlobalDrug-eluting and bland embolic microsphere portfolio (Peripheral Interventions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sold in connection with the BTG acquisition for $90 million upfront; transferred headcount not disclosed.
2019-12-31restructuringin_progress2018-11-152021-12-31GlobalGlobalUSD 250 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2019 Restructuring Plan announced Nov 2018. Total pre-tax charges estimated $200M-$300M. Majority of activity expected to be complete by end of 2021. No specific employee count disclosed for this program in the filing.
2019-12-31restructuringin_progress2018-11-012021-12-31GlobalSupply Chain and Functional CapabilitiesUSD 250 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		2019 Restructuring Plan announced Nov 2018. Expected total pre-tax charges $200M-$300M. Majority of activity expected to be complete by end of 2021. No specific employee count disclosed for this plan in the filing.
2019-12-31restructuringcompleted2016-06-012019-12-31GlobalCommercialization, Technology and ManufacturingUSD 271 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		2016 Restructuring Plan substantially completed in 2019. Total pre-tax charges $271M. No specific employee count disclosed.
2019-12-31restructuringin_progressUSD 38,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-09-30restructuringin_progressUSD 3 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Restructuring charges of $3 million recorded for the three months ended September 30, 2019. Employee count not disclosed.
2019-09-30restructuringin_progressUSD 10 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Restructuring charges of $10 million recorded for the nine months ended September 30, 2019. Employee count not disclosed.
2019-09-30acquisition_additioncompleted2019-08-19United KingdomBTG Acquisitionbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of BTG plc closed on August 19, 2019. Headcount added not explicitly disclosed in this filing.
2019-09-30acquisition_additioncompleted2019-06-30Vertiflexbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Vertiflex completed in Q2 2019. Headcount added not explicitly disclosed in this filing.
2019-09-30acquisition_additioncompleted2019-06-30Millipedebusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Millipede completed in Q2 2019. Headcount added not explicitly disclosed in this filing.
2019-09-30restructuringin_progressUSD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressUSD 1 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Restructuring charges of $1 million recorded for the three months ended June 30, 2019. Employee count not disclosed.
2019-06-30restructuringin_progressUSD 7 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Restructuring charges of $7 million recorded for the six months ended June 30, 2019. Employee count not disclosed.
2019-06-30restructuringin_progressUSD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressUSD 6 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Charges related primarily to the 2016 Restructuring Plan. Employee count not disclosed.
2019-03-31restructuringin_progressUSD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-12-31restructuringin_progress2018-11-152021-12-31GlobalSupply chain network optimization and corporate functionsrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Board approved 2018-11-15. Total estimated pre-tax charges of $200 million to $300 million (range; value not single-point disclosed), of which approximately $180 million to $280 million are expected to be cash. Expected to reduce gross annual pre-tax operating expenses by $100 million to $150 million by end of 2022. Activities initiated in 2019 with majority complete by end of 2021; no employees-affected count disclosed. No charges recorded in 2018.
2018-12-31restructuringin_progress2016-06-062020-12-31GlobalManufacturing network, real estate and global infrastructureUSD 96 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Charge shown is total restructuring and restructuring-related charges recorded in 2018 as disclosed in the footnote total row; cumulative charges through 2018-12-31 were $236 million and cumulative cash payments were $197 million. Majority of costs under this plan completed by end of 2018; plan expected to reduce gross annual expenses by $165 million to $175 million by end of 2020. Employees-affected count not disclosed.
2018-12-31acquisition_additioncompleted2018-04-162018-04-16United StatesUrology and Pelvic HealthUSD 150 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Upfront cash payment of $150 million plus up to approximately $125 million in clinical and commercial milestones. Acquired headcount not disclosed.
2018-12-31acquisition_additioncompleted2018-04-302018-04-30United StatesUrology and Pelvic HealthUSD 240 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Upfront cash payment of approximately $240 million plus up to approximately $85 million in commercial milestones. Acquired headcount not disclosed.
2018-12-31acquisition_additioncompleted2018-07-052018-07-05United StatesElectrophysiologyUSD 202 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Upfront cash payment of $202 million for the remaining stake; company held approximately 35 percent interest prior to acquisition. Acquired headcount not disclosed.
2018-12-31acquisition_additioncompleted2018-08-022018-08-02United StatesInterventional CardiologyUSD 220 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Upfront cash payment of $220 million plus $50 million reimbursement milestone achieved in Q3 2018. Acquired headcount not disclosed.
2018-12-31acquisition_additioncompleted2018-10-162018-10-16United StatesUrology and Pelvic HealthUSD 500 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Upfront cash payment of $500 million plus up to $100 million in revenue-based milestone payments. Acquired headcount not disclosed.
2018-12-31acquisition_additioncompleted2018-12-312018-12-31United StatesMultiple businessesUSD 158 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Consolidated record for other individually immaterial acquisitions completed during 2018: $158 million cash at closing plus up to $62 million aggregate contingent consideration. Announcement date shown as fiscal year-end as individual closing dates were not disclosed. Acquired headcount not disclosed.
2018-12-31acquisition_additionannounced2018-11-202019-06-30United KingdomInterventional oncology, vascular and acute care pharmaceuticalsUSD 4,225 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Recommended cash offer of 840 pence per BTG share, valuing BTG at approximately £3.311 billion (approximately $4.225 billion at the 2018-12-31 exchange rate). Offer made 2019-01-24; FTC second request received 2019-02-14. Expected effective in the first half of 2019; scheme must become effective no later than 2019-08-20. Expected completion date is an estimate based on the filer's stated expectation, not a disclosed date. Acquired headcount not disclosed.
2018-12-31acquisition_additioncompleted2019-01-292019-01-29United StatesInterventional CardiologyUSD 325 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Subsequent event: option to acquire remaining Millipede shares exercised in Q4 2018 after first-in-human study; closing announced 2019-01-29. Upfront cash payment of $325 million paid January 2019 plus up to $125 million commercial milestone. Company held approximately 20 percent interest prior to acquisition. Acquired headcount not disclosed.
2018-12-31restructuringannounced2018-11-152021-12-31GlobalSupply Chain Network Optimization and Functional CapabilitiesUSD 250 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2019 Restructuring Plan announced Nov 2018. Expected total pre-tax charges $200M-$300M. Majority of activity expected to be complete by end of 2021. No specific employee count disclosed for this plan in the 2018 10-K.
2018-12-31restructuringin_progress2016-06-062020-12-31GlobalGlobal Commercialization, Technology and Manufacturing CapabilitiesUSD 300 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2016 Restructuring Plan. Expected total pre-tax charges $275M-$325M. Savings expected by end of 2020. Cumulative cash payments of $197M made as of Dec 31, 2018. No specific employee count disclosed.
2018-12-31restructuringannounced2018-11-012021-12-31GlobalSupply Chain and Functional CapabilitiesUSD 250 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		2019 Restructuring Plan announced in November 2018. Expected total pre-tax charges of $200 million to $300 million. Majority of activity expected to be complete by end of 2021. No specific employee count disclosed.
2018-12-31restructuringin_progress2016-06-062020-12-31GlobalCommercialization, Technology and ManufacturingUSD 300 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		2016 Restructuring Plan. Expected total pre-tax charges of $275 million to $325 million. Expected to reduce gross annual expenses by $165 million to $175 million by end of 2020. No specific employee count disclosed for the plan total.
2018-12-31restructuringin_progressUSD 36,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressRestructuring Plan [Member]USD 36,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-09-30restructuringin_progress2016-06-062018-12-31GlobalEnterprise-wide (Plant Network Optimization, global infrastructure, commercial and manufacturing)USD 58 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2016 Restructuring Plan; nine-month charge comprises $20M restructuring charges and $38M restructuring-related expenses. Total estimated program cost $275M–$325M; majority of costs expected by end of 2018. Employee headcount affected not disclosed.
2018-09-30acquisition_additioncompleted2018-07-052018-07-05Electrophysiologybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Cryterion Medical, Inc. (single-shot cryoablation platform); upfront cash payment of $202M for remaining stake. Headcount added not disclosed.
2018-09-30acquisition_additioncompleted2018-08-022018-08-02Interventional Cardiologybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Claret Medical, Inc. (Sentinel cerebral embolic protection); $220M upfront plus $50M reimbursement milestone achieved in Q3. Headcount added not disclosed.
2018-09-30acquisition_additioncompleted2018-08-08Peripheral Interventionsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of VENITI, Inc. (VICI Venous Stent); $108M upfront plus up to $52M regulatory milestone. Closed in Q3 2018; exact closing date not stated. Headcount added not disclosed.
2018-09-30acquisition_additioncompleted2018-10-162018-10-16Urology and Pelvic Healthsubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Subsequent-event acquisition of Augmenix, Inc. (SpaceOAR Hydrogel System); $500M upfront plus up to $100M revenue milestones. Closed October 16, 2018, after quarter end. Headcount added not disclosed.
2018-09-30restructuringin_progress2016-06-062018-12-31GlobalVariousUSD 15 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2016 Restructuring Plan. Q3 2018 charges: $6M termination benefits, $10M transfer costs, ($1M) other. Total estimated costs $275M-$325M. Majority of costs expected incurred by end of 2018. Employee count not disclosed.
2018-09-30acquisition_additioncompleted2018-04-30United StatesUrology and Pelvic Healthbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of NxThera, Inc. closed April 30, 2018. Employee count not disclosed.
2018-09-30acquisition_additioncompleted2018-04-16United StatesUrology and Pelvic Healthbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of nVision Medical Corporation closed April 16, 2018. Employee count not disclosed.
2018-09-30acquisition_additioncompleted2018-07-05United StatesElectrophysiologybusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Cryterion Medical, Inc. closed July 5, 2018. Employee count not disclosed.
2018-09-30acquisition_additioncompleted2018-08-02United StatesInterventional Cardiologybusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Claret Medical, Inc. closed August 2, 2018. Employee count not disclosed.
2018-09-30acquisition_additioncompleted2018-08-08United StatesPeripheral Interventionsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of VENITI, Inc. closed in Q3 2018. Employee count not disclosed.
2018-09-30restructuringin_progressEmployee Severance [Member] / 2016 Restructuring Plan [Member]USD 69,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressOther Restructuring [Member] / 2016 Restructuring Plan [Member]USD 15,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progress2016 Restructuring Plan [Member]USD 84,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressUSD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressTransfer costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressEmployee Severance [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressOther Restructuring [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progress2016-06-062018-12-31GlobalVariousUSD 18 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2016 Restructuring Plan. Q2 2018 charges of $18M (YTD $18M) for termination benefits and other costs. Employee count not disclosed.
2018-06-30restructuringin_progressEmployee Severance [Member] / 2016 Restructuring Plan [Member]USD 63,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressOther Restructuring [Member] / 2016 Restructuring Plan [Member]USD 18,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progress2016 Restructuring Plan [Member]USD 82,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressUSD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressTransfer costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressEmployee Severance [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressOther Restructuring [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progress2016-06-062018-12-31GlobalVariousUSD 13 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2016 Restructuring Plan charges of $13 million recorded in Q1 2018. Plan expected to be substantially complete by end of 2018. Employee count not disclosed.
2018-03-31restructuringin_progressTransfer costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressEmployee Severance [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressOther Restructuring [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressUSD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressEmployee Severance [Member] / 2016 Restructuring Plan [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-12-31restructuringin_progress2016-06-062018-12-31GlobalGlobal infrastructure, commercial, technology and manufacturing (Plant Network Optimization)USD 95 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2017 charges of $95M ($37M restructuring charges plus $58M restructuring-related expenses), all attributable to the 2016 Restructuring Plan; $25M of FY2017 charges were termination benefits and $70M cash payments were made in FY2017. Program estimate revised in Q1 2018 to total pre-tax charges of $275M-$325M, reducing gross annual expenses by $165M-$175M by end of 2020. Employees affected not disclosed.
2017-12-31acquisition_additioncompleted2017-05-16SwitzerlandCardiovascular — Interventional Cardiology (structural heart / TAVR)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired for approximately $430 million cash; headcount added not disclosed. Integration expected substantially complete by end of 2018.
2017-12-31acquisition_additioncompleted2017-10-10United StatesRhythm Management (Electrophysiology — atrial fibrillation)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Approximately $175 million cash up-front plus up to $125 million contingent payments; headcount added not disclosed. Integration began Q4 2017, expected substantially complete by end of 2019.
2017-12-31restructuringin_progress2016-06-012018-12-31GlobalVariousUSD 95 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2016 Restructuring Plan. Total pre-tax charges of $275M-$325M expected. $95M recorded in 2017 (including $37M restructuring charges and $58M restructuring-related charges). Program expected to be substantially complete by end of 2018.
2017-12-31acquisition_additioncompleted2017-05-162017-05-16SwitzerlandInterventional CardiologyItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Symetis SA completed May 16, 2017. Integration expected to be substantially complete by end of 2018.
2017-12-31acquisition_additioncompleted2017-10-102017-10-10United StatesRhythm ManagementItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Apama Medical Inc. completed October 10, 2017. Integration expected to be substantially complete by end of 2019.
2017-12-31restructuringin_progress2016-06-012018-12-31GlobalVariousUSD 37 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		2016 Restructuring Plan. Total pre-tax charges estimated at $275M-$325M. $37M recorded in 2017. Activities include facility consolidations and transfer of product lines. Employee count affected not explicitly disclosed for 2017 activity.
2017-12-31restructuringcompleted2013-10-222016-12-31GlobalVariousUSD 0 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		2014 Restructuring Plan. Substantially completed by end of 2016. No new charges recorded in 2017.
2017-12-31restructuringin_progressUSD 37,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressTransfer costs [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressEmployee Severance [Member]USD 25,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressEmployee Severance [Member] / 2014 Restructuring plan [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressEmployee Severance [Member] / 2016 Restructuring Plan [Member]USD 25,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressOther Restructuring [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressReduced Depreciation [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-09-30restructuringin_progress2016-06-062018-12-31GlobalGlobalUSD 12 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2016 Restructuring Plan. Q3 2017 charges of $12M recorded. Total estimated pre-tax charges $175M-$225M. Expected completion by end of 2018. Employee count not disclosed.
2017-09-30acquisition_additioncompleted2017-05-16SwitzerlandInterventional CardiologyUSD 430 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Symetis SA completed May 16, 2017 for approx $430M cash. Headcount not disclosed.
2017-09-30acquisition_additionannounced2017-10-10United StatesRhythm ManagementUSD 175 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Apama Medical Inc. completed Oct 10, 2017 (subsequent event). Upfront cash $175M. Headcount not disclosed.
2017-09-30restructuringin_progressUSD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30restructuringin_progressAccelerated Depreciation [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30restructuringin_progressTransfer costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30restructuringin_progressEmployee Severance [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30restructuringin_progressOther Restructuring [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30restructuringin_progressEmployee Severance [Member] / 2016 Restructuring Plan [Member]USD 14,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30restructuringin_progress2016-06-062018-12-31GlobalGlobal infrastructure, manufacturing and commercial operationsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2016 Restructuring Plan; total estimated pre-tax charges of $175M to $225M ($160M to $210M cash), of which $82M recorded through 2017-06-30 ($33M restructuring charges, $49M restructuring-related expenses). No headcount affected disclosed. Includes Plant Network Optimization plant consolidation.
2017-06-30acquisition_additioncompleted2017-05-162018-12-31Switzerland (global)Interventional Cardiology (Cardiovascular)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Symetis SA acquired 2017-05-16 for approximately $430M cash ($392M net cash paid); no employee headcount added disclosed. Integration expected substantially complete by end of 2018.
2017-06-30restructuringin_progress2016-06-062018-12-31GlobalGlobalUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2016 Restructuring Plan. Q2 2017 restructuring charges of $1 million. Total estimated pre-tax charges $175-$225 million. Employee count not disclosed.
2017-06-30acquisition_additioncompleted2017-05-162018-12-31SwitzerlandInterventional Cardiologybusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Symetis SA completed May 16, 2017 for approx $430 million. Headcount not disclosed.
2017-06-30acquisition_additioncompleted2016-11-222017-12-31United StatesEndoscopybusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of EndoChoice Holdings, Inc. completed Nov 22, 2016. Headcount not disclosed.
2017-06-30acquisition_additioncompleted2016-07-272017-12-31United StatesNeuromodulationbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Cosman Medical, Inc. completed July 27, 2016. Headcount not disclosed.
2017-06-30restructuringin_progressUSD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30restructuringin_progressAccelerated Depreciation [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30restructuringin_progressTransfer costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30restructuringin_progressEmployee Severance [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30restructuringin_progressOther Restructuring [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30restructuringin_progressEmployee Severance [Member] / 2016 Restructuring Plan [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-03-31restructuringin_progress2016-06-062018-12-31GlobalGlobal commercialization, technology and manufacturingUSD 175 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2016 Restructuring Plan; total pre-tax charges estimated at $175M–$225M. No employee headcount affected disclosed. $66M in costs recorded through March 31, 2017.
2017-03-31acquisition_additionannounced2017-03-292017-06-30SwitzerlandInterventional CardiologyUSD 435 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Symetis SA for $435M cash; expected to close Q2 2017. No headcount addition disclosed.
2017-03-31restructuringin_progress2016-06-062018-12-31GlobalGlobal commercialization, technology and manufacturingUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2016 Restructuring Plan approved June 6, 2016. Q1 2017 charges of $4M recorded. Total estimated pre-tax charges $175M-$225M. Plan expected to be substantially completed by end of 2018. Employee count affected not disclosed.
2017-03-31restructuringin_progressAccelerated Depreciation [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-03-31restructuringin_progressTransfer costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-03-31restructuringin_progressEmployee Severance [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-03-31restructuringin_progressEmployee Severance [Member] / 2016 Restructuring Plan [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-03-31restructuringin_progressOther Restructuring [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-03-31restructuringin_progressUSD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-12-31restructuringin_progress2016-06-062018-12-31GlobalGlobal infrastructure, commercial, technical and manufacturing operationsUSD 175 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Total estimated pre-tax charges of $175M to $225M (upper bound not entered as a separate value); $47M of related costs recorded in 2016, of which $28M classified as restructuring charges. Approximately $160M to $210M expected to be cash, with $27M paid in 2016. Program expected to reduce gross annual expenses by $115M to $150M by the end of 2020. Number of employees affected not disclosed.
2016-12-31restructuringcompleted2013-10-222016-12-31GlobalManufacturing plant network optimization and corporate functionsUSD 261 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cumulative through fiscal year-end: total pre-tax charges of $261M and $244M of cash outlays since commitment; $31M of costs recorded in 2016. Activities substantially complete by end of 2015 except Plant Network Optimization actions completed by end of 2016. Number of employees affected not disclosed.
2016-12-31acquisition_additioncompleted2016-07-272016-07-27United StatesNeuromodulationbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired for $71M up-front cash plus up to $20M contingent consideration; headcount added not disclosed. Integration expected substantially complete by end of 2017.
2016-12-31acquisition_additioncompleted2016-11-012016-11-01United StatesEndoscopybusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Asset acquisition for $30M up-front plus up to $70M contingent consideration; headcount added not disclosed.
2016-12-31acquisition_additioncompleted2016-11-152016-11-15United StatesUrology and Pelvic Healthbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Portfolio acquisition for $20M up-front plus up to $35M contingent consideration; headcount added not disclosed.
2016-12-31acquisition_additioncompleted2016-11-222016-11-22United StatesEndoscopybusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired at $8.00 per share, approximately $214M, plus repayment of $43M senior term loan; headcount added not disclosed. Integration expected substantially complete by end of 2017.
2016-12-31acquisition_additioncompleted2016-12-122016-12-12CanadaInterventional Cardiology (structural heart)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of manufacturing assets and capabilities plus a 15% equity investment for $75M total upfront; headcount added not disclosed. Integration expected substantially complete by end of 2018.
2016-12-31otherannounced2016-10-012017-12-31GlobalCardiac Rhythm Management sales forceItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Company notified Preventice of intent to terminate the exclusive sales and marketing agreement in October 2016 and will transition the sales force back to Preventice during 2017; number of employees affected not disclosed. Announcement month stated as October 2016; exact day not disclosed.
2016-12-31restructuringin_progress2016-06-062018-12-31GlobalAll segmentsUSD 175 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2016 Restructuring Plan announced June 2016. Total pre-tax charges estimated $175 million to $225 million. Activities initiated in Q2 2016, expected substantially complete by end of 2018. Employee count not explicitly disclosed.
2016-12-31acquisition_additioncompleted2016-12-122016-12-12GlobalInterventional CardiologyItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Neovasc, Inc. advanced biological tissue business completed Dec 12, 2016. Integration expected substantially complete by end of 2018.
2016-12-31acquisition_additioncompleted2016-11-222016-11-22United StatesEndoscopyItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of EndoChoice Holdings, Inc. completed Nov 22, 2016. Integration expected substantially complete by end of 2017.
2016-12-31acquisition_additioncompleted2016-11-152016-11-15United StatesUrology and Pelvic HealthItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of gynecology and urology portfolio of Distal Access, LLC completed Nov 15, 2016. Integration expected substantially complete by end of 2017.
2016-12-31acquisition_additioncompleted2016-11-012016-11-01United StatesEndoscopyItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of LumenR Tissue Retractor System from LumenR LLC completed Nov 1, 2016.
2016-12-31acquisition_additioncompleted2016-07-272016-07-27GlobalNeuromodulationItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Cosman Medical, Inc. completed July 27, 2016. Integration expected substantially complete by end of 2017.
2016-12-31restructuringin_progress2016-06-012018-12-31GlobalVariousUSD 175 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		2016 Restructuring Plan announced June 2016. Expected total pre-tax charges of $175 million to $225 million. Activities initiated in Q2 2016, expected substantially complete by end of 2018. Employee count not explicitly disclosed in this filing.
2016-12-31restructuringcompleted2013-10-222016-12-31GlobalVariousUSD 261 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		2014 Restructuring Plan. Total pre-tax charges of $261 million. Substantially completed by end of 2015, except for certain PNO actions completed by end of 2016. Employee count not explicitly disclosed in this filing.
2016-12-31restructuringin_progressUSD 28,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressImpairment of an asset in value [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressTransfer costs [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressEmployee Severance [Member]USD 19,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressEmployee Severance [Member] / 2014 Restructuring plan [Member]USD -5,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressEmployee Severance [Member] / 2016 Restructuring Plan [Member]USD 24,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressEmployee Severance [Member] / Other Restructuring [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressOther Restructuring [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressReduced Depreciation [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-09-30restructuringin_progress2016-06-062018-12-31GlobalGlobal commercialization, technology, and manufacturingUSD 200 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Total pre-tax charges estimated at $175M–$225M; termination benefits estimated at $65M–$80M. No employee headcount disclosed. $26M in related costs recorded through 2016-09-30.
2016-09-30restructuringin_progress2013-10-222016-12-31GlobalManufacturing and corporate functions (Plant Network Optimization)USD 263 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Total pre-tax charges estimated at $255M–$270M; substantially completed end of 2015 except ongoing Plant Network Optimization actions expected to complete by end of 2016. No employee headcount disclosed. $259M in related costs recorded since inception.
2016-09-30acquisition_additioncompleted2016-07-272016-07-27United StatesNeuromodulationbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Cosman Medical for $71M up-front cash plus up to $20M contingent consideration. No employee headcount disclosed. Integration expected substantially complete by end of 2017.
2016-09-30acquisition_additionannounced2016-09-272016-12-31United StatesEndoscopybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire EndoChoice for approximately $210M; expected to close Q4 2016. No employee headcount disclosed.
2016-09-30acquisition_additionannounced2016-11-012016-12-31United StatesEndoscopysubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired LumenR Tissue Retractor System from LumenR LLC on 2016-11-01 (subsequent event). No employee headcount disclosed.
2016-09-30otherannounced2016-10-012017-10-01GlobalCardiac Rhythm Management (Preventice sales force)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		In October 2016, management notified Preventice of intent to terminate the commercial agreement; sales force to transition back to Preventice within twelve months. No employee count disclosed.
2016-09-30restructuringin_progress2016-06-062018-12-31GlobalVarious (Commercial, Technology, Manufacturing)USD 175 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2016 Restructuring Plan approved June 6, 2016. Total pre-tax charges estimated $175M-$225M. $26M recorded through Sept 30, 2016. Employee count not disclosed.
2016-09-30restructuringin_progress2013-10-222016-12-31GlobalVarious (Manufacturing, Commercial)USD 255 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2014 Restructuring Plan approved Oct 22, 2013. Total pre-tax charges estimated $255M-$270M. $259M recorded through Sept 30, 2016. Employee count not disclosed.
2016-09-30restructuringin_progressUSD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressImpairment of an asset in value [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressTransfer costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressEmployee Severance [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressOther Restructuring [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressAccelerated Depreciation [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressEmployee Severance [Member] / 2014 Restructuring plan [Member]USD -3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressEmployee Severance [Member] / 2016 Restructuring Plan [Member]USD 19,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progress2016-06-062018-12-31GlobalGlobal commercialization, technology and manufacturingUSD 200 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2016 Restructuring Plan; total pre-tax charges estimated at $175M–$225M; $19M recorded through June 30, 2016; no employee count disclosed.
2016-06-30restructuringin_progress2013-10-222016-12-31GlobalManufacturing, organizational structureUSD 263 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2014 Restructuring Plan; substantially completed end of 2015 except Plant Network Optimization actions through end of 2016; total pre-tax charges estimated at $255M–$270M; no employee count disclosed.
2016-06-30acquisition_additionannounced2016-07-272016-12-31United StatesNeuromodulationsubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Cosman Medical, Inc. on July 27, 2016; integration expected during second half of 2016; no headcount disclosed.
2016-06-30restructuringin_progress2016-06-062018-12-31GlobalVarious (Commercialization, Technology, Manufacturing)USD 19 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2016 Restructuring Plan approved June 6, 2016. Total estimated pre-tax charges $175M-$225M. $19M recorded through June 30, 2016. Employee count not disclosed.
2016-06-30restructuringin_progress2013-10-222016-12-31GlobalVarious (Manufacturing, Organizational)USD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2014 Restructuring Plan approved Oct 22, 2013. Total estimated pre-tax charges $255M-$270M. $7M recorded in Q2 2016. Employee count not disclosed.
2016-06-30restructuringin_progressUSD 14,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressAccelerated Depreciation [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressTransfer costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressEmployee Severance [Member]USD 14,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressOther Restructuring [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressEmployee Severance [Member] / 2014 Restructuring plan [Member]USD -3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressEmployee Severance [Member] / 2016 Restructuring Plan [Member]USD 18,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progress2013-10-222016-12-31GlobalEnterprise-wide (includes Plant Network Optimization)USD 3 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		No employee count disclosed. Q1 2016 restructuring charges were $3M plus $10M restructuring-related expenses in other lines; cumulative charges since inception $242M against a total estimated program cost of $255M-$270M. Plan substantially completed end of 2015 except Plant Network Optimization actions expected to finish by end of 2016.
2016-03-31restructuringin_progress2013-10-222016-12-31GlobalOperationsUSD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2014 Restructuring Plan ongoing; $3M charges recorded in Q1 2016. Plan expected to be substantially completed by end of 2016.
2016-03-31restructuringin_progressAccelerated Depreciation [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progressTransfer costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progressEmployee Severance [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progressOther Restructuring [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progressUSD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progressEmployee Severance [Member] / 2014 Restructuring plan [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-12-31restructuringin_progress2013-10-222016-12-31GlobalCompany-wide (plant network optimization, organizational reporting structures, commercial model changes)USD 83 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2014 Restructuring Plan; FY2015 activity of $83 million comprises $26 million restructuring charges plus $57 million restructuring-related expenses recorded in other income statement lines. Activities substantially completed by end of 2015 except plant network optimization, expected to complete by end of 2016. Cumulative costs of $229 million recorded since inception against an estimated $255-270 million total; plan expected to reduce gross annual expenses by approximately $200 million by end of 2016. Employees affected not disclosed.
2015-12-31acquisition_additioncompleted2015-08-03GlobalUrology and Pelvic Healthbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		AMS Portfolio Acquisition of the American Medical Systems male urology portfolio from Endo International plc; $1.616 billion up-front cash plus up to $50 million contingent on 2016 sales. Headcount added not disclosed; represents approximately 2% of total revenues as of December 31, 2015.
2015-12-31acquisition_additioncompleted2015-04-02United StatesEndoscopybusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Xlumena, Inc.; $63 million up-front plus $13 million on FDA clearance of HOT AXIOS and sales-based milestones through 2018. Headcount added not disclosed; integration expected substantially complete by end of 2016.
2015-12-31acquisition_additioncompleted2015-12-31United StatesPeripheral Interventionsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of the interventional radiology business of CeloNova Biosciences; $70 million up-front plus regulatory and sales milestone payments. Headcount added not disclosed.
2015-12-31restructuringin_progress2013-10-222016-12-31GlobalVariousUSD 26 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2014 Restructuring Plan. $26 million in restructuring charges recorded in 2015. Plan substantially completed by end of 2015 except for plant network optimization expected to complete by end of 2016. Total pre-tax charges estimated at $255-$270 million.
2015-12-31acquisition_additioncompleted2015-08-032015-08-03GlobalUrology and Pelvic HealthItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of American Medical Systems male urology portfolio (AMS Portfolio Acquisition) completed August 3, 2015. Headcount not explicitly disclosed.
2015-12-31acquisition_additioncompleted2015-04-022015-04-02GlobalEndoscopyItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Xlumena, Inc. completed April 2, 2015. Headcount not explicitly disclosed.
2015-12-31acquisition_additioncompleted2015-12-312015-12-31GlobalPeripheral InterventionsItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of interventional radiology portfolio of CeloNova Biosciences completed December 31, 2015. Headcount not explicitly disclosed.
2015-12-31restructuringin_progress2013-10-222016-12-31GlobalVariousUSD 255 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		2014 Restructuring Plan. Estimated total pre-tax charges of $255 million to $270 million. Activities substantially completed by end of 2015 except for plant network optimization expected to complete by end of 2016. Employee count not explicitly disclosed for this specific action in the filing.
2015-12-31restructuringin_progressUSD 26,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressTransfer costs [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressEmployee Severance [Member]USD 23,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressEmployee Severance [Member] / 2011 Restructuring Plan [Member]USD -4,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressEmployee Severance [Member] / 2014 Restructuring plan [Member]USD 27,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressOther Restructuring [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressReduced Depreciation [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-09-30restructuringin_progress2013-10-222015-12-31GlobalMultipleUSD 275 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2014 Restructuring plan; total estimated pre-tax charges $250-300M; $204M recorded since inception; no employee count disclosed; Plant Network Optimization actions expected complete by end of 2016.
2015-09-30acquisition_additioncompleted2015-08-03United StatesUrology and Pelvic Healthbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		AMS Portfolio Acquisition from Endo International plc completed 2015-08-03 for $1.616B up-front cash; no headcount addition disclosed.
2015-09-30acquisition_additioncompleted2015-04-02United StatesEndoscopybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Xlumena, Inc. acquisition completed 2015-04-02; upfront payment $63M plus milestones; no headcount addition disclosed.
2015-09-30restructuringin_progress2013-10-222016-12-31GlobalVarious (Plant Network Optimization, organizational rationalization)USD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2014 Restructuring Plan. Q3 2015 charges of $7 million. Total estimated pre-tax charges $250-$300 million. Substantially complete by end of 2015, except PNO actions expected by end of 2016. Employee count not disclosed.
2015-09-30restructuringcompleted2011-07-262013-12-31GlobalVarious (process standardization, relocation, organizational rationalization)USD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2011 Restructuring Plan (including Expansion). Substantially completed by end of 2013. No charges recorded in Q3 2015. Employee count not disclosed.
2015-09-30acquisition_additioncompleted2015-08-03GlobalUrology and Pelvic Healthbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of American Medical Systems male urology portfolio (AMS Portfolio Acquisition) from Endo International plc. Headcount not disclosed.
2015-09-30acquisition_additioncompleted2015-04-02GlobalEndoscopybusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Xlumena, Inc. Headcount not disclosed.
2015-09-30restructuringin_progressUSD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-30restructuringin_progressAccelerated Depreciation [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-30restructuringin_progressTransfer costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-30restructuringin_progressEmployee Severance [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-30restructuringin_progressOther Restructuring [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-30restructuringin_progressEmployee Severance [Member] / 2011 Restructuring Plan [Member]USD -4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-30restructuringin_progressEmployee Severance [Member] / 2014 Restructuring plan [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progress2013-10-222015-12-31GlobalMultipleUSD 250 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2014 Restructuring plan; total pre-tax charges estimated at $250M-$300M; $183M recorded to date; no headcount figures disclosed. Ongoing Plant Network Optimization actions expected complete by end of 2016.
2015-06-30acquisition_additioncompleted2015-04-022015-04-02United StatesEndoscopy (MedSurg)USD 94 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Xlumena, Inc.; purchase price $94M; no headcount added disclosed.
2015-06-30acquisition_additioncompleted2015-08-032015-08-03United StatesUrology and Women's Health (MedSurg)USD 1,600 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		AMS male urology portfolio acquisition from Endo International; $1.6B up-front cash plus up to $50M contingent on 2016 sales; no headcount added disclosed.
2015-06-30restructuringin_progress2013-10-222015-12-31GlobalVarious (Manufacturing, G&A, Sales)USD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2014 Restructuring Plan. Q2 2015 restructuring charges of $3M (termination benefits). Total estimated pre-tax charges $250M-$300M. Substantially complete by end of 2015, except PNO actions complete by end of 2016. Employee count not disclosed.
2015-06-30restructuringcompleted2011-07-262013-12-31GlobalVariousUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2011 Restructuring Plan (including Expansion). Substantially completed by end of 2013. No restructuring charges recorded in Q2 2015. Employee count not disclosed.
2015-06-30restructuringin_progressUSD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progressAccelerated Depreciation [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progressImpairment of an asset in value [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progressTransfer costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progressEmployee Severance [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progressOther Restructuring [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progressEmployee Severance [Member] / 2011 Restructuring Plan [Member]USD -3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progressEmployee Severance [Member] / 2014 Restructuring plan [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31restructuringin_progress2013-10-222015-12-31GlobalMultiple (Plant Network Optimization, organizational restructuring)USD 6 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2014 Restructuring plan; $6M restructuring charges in Q1 2015 plus $16M in other line items. Total plan estimated at $250-300M. No employee count disclosed.
2015-03-31acquisition_additionannounced2015-03-022015-09-30United StatesUrology (Men's Health and Prostate Health)USD 1,600 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		AMS Portfolio Acquisition from Endo International; $1.6B upfront plus $50M milestone. Headcount not disclosed.
2015-03-31acquisition_additioncompleted2015-04-012015-04-01United StatesEndoscopyUSD 63 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Xlumena, Inc. acquired in April 2015 (post-quarter); ~$63M upfront plus $13M FDA-clearance milestone. Headcount not disclosed.
2015-03-31restructuringin_progress2013-10-222015-12-31GlobalVariousUSD 6 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2014 Restructuring Plan. Total estimated pre-tax charges $250M-$300M. Q1 2015 charges of $6M recorded. Employee count affected not disclosed in this filing.
2015-03-31restructuringcompleted2011-07-262013-12-31GlobalVariousUSD -3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2011 Restructuring Plan (including Expansion). Substantially completed by end of 2013. Q1 2015 credit of $3M recorded. Employee count affected not disclosed in this filing.
2015-03-31restructuringin_progressAccelerated Depreciation [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31restructuringin_progressImpairment of an asset in value [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31restructuringin_progressTransfer costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31restructuringin_progressEmployee Severance [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31restructuringin_progressEmployee Severance [Member] / 2011 Restructuring Plan [Member]USD -3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31restructuringin_progressEmployee Severance [Member] / 2014 Restructuring plan [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31restructuringin_progressOther Restructuring [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31restructuringin_progressUSD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-12-31restructuringin_progress2013-10-222015-12-31GlobalEnterprise-wide (plant network optimization, organizational and commercial model changes)USD 113 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Charge shown is the amount recorded during fiscal year 2014 under the 2014 Restructuring plan (includes restructuring charges and restructuring-related expenses recorded in other income statement lines). Cumulative costs of $142 million recorded since plan inception; total estimated plan cost of $250-300 million with estimated termination benefits of $115-135 million; expected to reduce gross annual pre-tax operating expenses by $175-225 million by end of 2015. Number of employees affected not disclosed.
2014-12-31restructuringcompleted2011-07-262013-12-31GlobalEnterprise-wide (process standardization, shared services, organizational rationalization)USD 4 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2011 Restructuring plan, including the January 2013 Expansion, was substantially completed by the end of 2013; only $4 million of charges were recorded in fiscal year 2014. Cumulative plan cost of $289 million since inception. Employees affected not disclosed.
2014-12-31acquisition_additioncompleted2014-08-292014-08-29GlobalPeripheral Interventions and Interventional Cardiologybusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of the Interventional Division of Bayer AG for $414 million cash; acquired headcount not disclosed.
2014-12-31acquisition_additioncompleted2014-05-072014-05-07United StatesUrology and Women's Healthbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of the remaining 72% equity of IoGyn, Inc. for a net cash payment of $65 million; acquired headcount not disclosed.
2014-12-31restructuringin_progress2013-10-222015-12-31GlobalVariousUSD 250 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2014 Restructuring plan announced Oct 2013. Estimated total pre-tax charges $250M-$300M. Substantially completed by end of 2015. No specific employee count disclosed for the program in this filing.
2014-12-31restructuringcompleted2011-07-262013-12-31GlobalVariousUSD 289 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2011 Restructuring plan (including Expansion). Substantially completed by end of 2013. Estimated total pre-tax charges $289M-$292M. No specific employee count disclosed.
2014-12-31restructuringcompleted2010-02-062012-12-31GlobalVariousUSD 160 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2010 Restructuring plan. Complete by end of 2012. Total pre-tax charges $160M. No specific employee count disclosed.
2014-12-31restructuringcompleted2009-01-012012-12-31GlobalManufacturingUSD 126 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Plant Network Optimization (PNO) program. Substantially completed during 2012. Total pre-tax charges $126M. No specific employee count disclosed.
2014-12-31restructuringin_progress2013-10-012015-12-31GlobalVariousUSD 250 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		2014 Restructuring Plan announced October 2013. Estimated total pre-tax charges of $250 million to $300 million. Activities expected to be substantially completed by end of 2015. Employee count affected not explicitly disclosed in this filing.
2014-12-31restructuringin_progressUSD 69,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progressTransfer costs [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progressEmployee Severance [Member]USD 42,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progressEmployee Severance [Member] / 2010 Restructuring Plan [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progressEmployee Severance [Member] / 2011 Restructuring Plan [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progressEmployee Severance [Member] / 2014 Restructuring plan [Member]USD 41,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progressEmployee Severance [Member] / Plant Network Optimization [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progressOther Restructuring [Member]USD 27,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progressReduced Depreciation [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-09-30restructuringin_progress2013-10-222015-12-31GlobalMultipleUSD 200 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2014 Restructuring plan; total pre-tax charges estimated at $175M–$225M (midpoint shown); no employee headcount disclosed. Includes Plant Network Optimization and organizational streamlining.
2014-09-30acquisition_additioncompleted2014-08-292014-08-29GlobalCardiovascular — Peripheral Interventions / Interventional CardiologyUSD 414 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Interventional Division of Bayer AG for $414M cash; no headcount added disclosed.
2014-09-30acquisition_additioncompleted2014-05-072014-05-07United StatesMedSurg — Urology and Women's HealthUSD 65 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of remaining 72% equity of IoGyn, Inc. for $65M net cash; no headcount added disclosed.
2014-09-30restructuringin_progress2013-10-222015-12-31GlobalVarious (Manufacturing, G&A, Commercial)USD 175 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2014 Restructuring Plan approved Oct 22, 2013. Total estimated pre-tax charges $175M-$225M. Expected to be substantially completed by end of 2015. Includes Plant Network Optimization and organizational rationalization. Employee count not disclosed.
2014-09-30restructuringcompleted2011-07-262013-12-31GlobalVarious (Administrative, Functional)USD 289 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2011 Restructuring Plan (including Expansion). Total estimated pre-tax charges $289M-$292M. Activities substantially completed by end of 2013. Employee count not disclosed.
2014-09-30acquisition_additioncompleted2014-08-292014-08-29GlobalPeripheral Intervention, Interventional CardiologyUSD 414 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Interventional Division of Bayer AG completed Aug 29, 2014 for $414M cash. Employee count not disclosed.
2014-09-30acquisition_additioncompleted2014-05-072014-05-07GlobalUrology and Women's HealthUSD 65 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of remaining equity of IoGyn, Inc. completed May 7, 2014 for $65M net cash. Employee count not disclosed.
2014-09-30restructuringin_progressUSD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-30restructuringin_progressEmployee Severance [Member] / 2014 Restructuring plan [Member]USD 18,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-30restructuringin_progressEmployee Severance [Member]USD 19,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-30restructuringin_progressEmployee Severance [Member] / 2011 Restructuring Plan [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-30restructuringin_progressAccelerated Depreciation [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-30restructuringin_progressImpairment of an asset in value [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-30restructuringin_progressTransfer costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-30restructuringin_progressOther Restructuring [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-30restructuringin_progress2013-10-222015-12-31GlobalEnterprise-wideUSD 200 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2014 Restructuring Plan approved Oct 22, 2013; estimated total pre-tax charges of $175M–$225M with $160M–$210M in cash outlays. No employee headcount affected is disclosed. Includes Plant Network Optimization and organizational streamlining; expected substantially complete by end of 2015.
2014-06-30acquisition_additioncompleted2014-05-072014-05-07United StatesUrology and Women's Healthbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		IoGyn, Inc. acquisition completed May 7, 2014 for $96M total consideration; no headcount added is disclosed.
2014-06-30acquisition_additionannounced2014-05-152014-12-31GlobalCardiovascularbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire the Interventional Division of Bayer AG for $415M cash at closing; expected to close in H2 2014. No headcount disclosed.
2014-06-30restructuringin_progress2013-10-222015-12-31GlobalVarious (Manufacturing, Organizational)USD 15 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2014 Restructuring Plan. Q2 2014 charges of $15M (including $8M termination benefits). Total estimated pre-tax charges $175M-$225M. Employee count not disclosed.
2014-06-30restructuringin_progress2011-07-262013-12-31GlobalVarious (Administrative, Functional)USD -2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2011 Restructuring Plan (including Expansion). Q2 2014 credit of $2M. Plan substantially completed by end of 2013. Employee count not disclosed.
2014-06-30acquisition_additioncompleted2014-05-072014-05-07GlobalUrology and Women's HealthUSD 65 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of remaining equity of IoGyn, Inc. Net cash payment $65M. Employee count not disclosed.
2014-06-30restructuringin_progressUSD 15,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-30restructuringin_progressEmployee Severance [Member] / 2014 Restructuring plan [Member]USD 19,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-30restructuringin_progressEmployee Severance [Member]USD 19,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-30restructuringin_progressEmployee Severance [Member] / 2011 Restructuring Plan [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-30restructuringin_progressTransfer costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-30restructuringin_progressImpairment of an asset in value [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-30restructuringin_progressAccelerated Depreciation [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-30restructuringin_progressOther Restructuring [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-31restructuringin_progress2013-10-222015-12-31GlobalEnterprise-wide (Plant Network Optimization, organizational rationalization)USD 20 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2014 restructuring charges of $20M plus $8M restructuring-related expenses in other line items. Total program estimated pre-tax charges of $175M–$225M; $160M–$210M expected cash outlays. No employee headcount affected disclosed. Expected to reduce gross annual pre-tax operating expenses by $150M–$200M exiting 2015.
2014-03-31restructuringcompleted2011-07-262013-12-31GlobalEnterprise-wide (shared services, process standardization, organizational rationalization)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Activities substantially completed by end of 2013. Total program charges of $289M–$292M; $280M cash payments made to date. Q1 2014 residual charges of $5M total ($2M restructuring, $3M restructuring-related). No employee headcount affected disclosed.
2014-03-31acquisition_additionannounced2014-05-072014-05-07United StatesUrology and Women's HealthUSD 65 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Completed acquisition of remaining 72% of IoGyn, Inc. equity on May 7, 2014 for net cash payment of $65M. Prior minority interest of ~28% held. No headcount added disclosed.
2014-03-31restructuringin_progress2013-10-222015-12-31GlobalVarious (Manufacturing, Organizational)USD 20 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2014 Restructuring Plan initiated in Q4 2013. Q1 2014 charges of $20M recorded. Total estimated pre-tax charges $175M-$225M. Employee count not disclosed.
2014-03-31restructuringcompleted2011-07-262013-12-31GlobalVarious (Administrative, Functional)USD 5 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2011 Restructuring Plan (including Expansion). Substantially completed by end of 2013. Q1 2014 charges of $5M recorded. Employee count not disclosed.
2014-03-31restructuringin_progressUSD 20,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-31restructuringin_progressEmployee Severance [Member] / 2014 Restructuring plan [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-31restructuringin_progressEmployee Severance [Member] / 2011 Restructuring Plan [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-31restructuringin_progressEmployee Severance [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-31restructuringin_progressOther Restructuring [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-31restructuringin_progressTransfer costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-31restructuringin_progressAccelerated Depreciation [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-31restructuringin_progressImpairment of an asset in value [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-12-31restructuringin_progress2013-10-222015-12-31GlobalEnterprise-wide; includes plant network optimization and organizational reporting structuresUSD 175 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Total estimated pre-tax charges of $175M to $225M ($160M to $210M cash), of which $30M of costs were recorded in Q4 2013 ($29M as restructuring charges). Expected to reduce gross annual pre-tax operating expenses by approximately $150M to $200M exiting 2015. Employees affected not disclosed.
2013-12-31restructuringcompleted2013-01-252013-12-31GlobalEnterprise-wide shared services, administrative and functional activities, corporate functionsUSD 100 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Expansion of the 2011 Restructuring plan approved 2013-01-25; $100M of total costs recorded in 2013 (cumulative program costs of $284M since inception). Activities substantially completed by end of 2013. Employees affected not disclosed.
2013-12-31acquisition_additioncompleted2013-11-012013-11-01GlobalElectrophysiologyUSD 274 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of the electrophysiology business of C.R. Bard Inc. for $274 million cash; acquired headcount not disclosed.
2013-12-31divestiture_reductioncompleted2011-01-032013-12-31GlobalNeurovascularother
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of Neurovascular business to Stryker closed January 2011; related supply and transition services agreements substantially ended during 2013, with residual revenue of $58M in 2013. Headcount removed not disclosed; announcement date reflects original divestiture closing.
2013-12-31restructuringin_progress2013-10-222015-12-31GlobalVariousUSD 175 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2014 Restructuring plan announced Oct 22, 2013. Estimated total pre-tax charges $175M-$225M. Activities initiated in Q4 2013, expected substantially completed by end of 2015. Includes plant network optimization and organizational rationalization.
2013-12-31restructuringcompleted2011-07-262013-12-31GlobalVariousUSD 284 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2011 Restructuring plan (including expansion approved Jan 25, 2013). Key activities substantially completed by end of 2013. Total costs recorded since inception $284M.
2013-12-31restructuringin_progress2013-10-222015-12-31GlobalVariousUSD 175 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		2014 Restructuring Plan announced October 2013. Estimated total pre-tax charges of $175 million to $225 million. Employee count not explicitly disclosed in filing.
2013-12-31restructuringcompleted2011-07-262013-12-31GlobalVariousUSD 284 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		2011 Restructuring Plan (including Expansion). Key activities substantially completed by end of 2013. Total costs recorded since inception $284 million. Employee count not explicitly disclosed.
2013-12-31restructuringin_progressUSD 101,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progressEmployee Severance [Member] / 2011 Restructuring Plan [Member]USD 37,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progressEmployee Severance [Member] / 2010 Restructuring Plan [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progressEmployee Severance, Other [Member] / 2010 Restructuring Plan [Member]USD -3,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progressEmployee Severance, Other [Member] / Plant Network Optimization [Member]USD -2,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progressEmployee Severance [Member] / Plant Network Optimization [Member]USD -6,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progressEmployee Severance [Member]USD 60,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progressEmployee Severance [Member] / 2014 Restructuring plan [Member]USD 29,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progressEmployee Severance, Other [Member]USD -5,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progressEmployee Severance, Other [Member] / 2011 Restructuring Plan [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progressEmployee Severance, Other [Member] / 2014 Restructuring plan [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progressImpairment of an asset in value [Member]USD -15,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progressAccelerated Depreciation [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progressRestructuring Related To Plan [Member]USD 101,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progressOther Restructuring [Member]USD 56,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-09-30restructuringannounced2013-10-222015-12-31GlobalCompany-wide (manufacturing plant network and corporate/commercial structures)USD 175 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board approved 2013-10-22, after quarter end. Estimated total pre-tax charges range from $175M to $225M, of which $160M to $210M expected to be cash outlays; no employee count disclosed. Activities begin Q4 2013, substantially complete by end of 2015. Expected to reduce gross annual pre-tax operating expenses by approximately $150M to $200M exiting 2015.
2013-09-30restructuringin_progress2011-07-262013-12-31GlobalCompany-wide (shared services, corporate functions, divisions)USD 300 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Estimated total pre-tax charges range from $300M to $355M ($270M to $300M cash); no employee count disclosed. Includes an Expansion approved 2013-01-25. Cumulative charges of $260M recorded through 2013-09-30; $235M cash paid, offset by $53M proceeds on facility/asset sales, including a $19M gain on sale of the Natick, MA headquarters as the company consolidates into Marlborough, MA. Expected to reduce gross annual pre-tax operating expenses by approximately $340M to $375M exiting 2013.
2013-09-30acquisition_additioncompleted2013-11-01Electrophysiologybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Completed acquisition of the electrophysiology business of C.R. Bard Inc. for $275 million in cash on 2013-11-01 (subsequent event). Target generated $111 million of sales in 2012. No headcount added disclosed; separate announcement date not stated in the filing.
2013-09-30restructuringin_progress2011-07-262013-12-31GlobalVariousUSD 26 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2011 Restructuring plan (including Expansion). Q3 2013 charges: $5M termination benefits, $1M accelerated depreciation, $20M other. Total program charges to date: $260M.
2013-09-30restructuringannounced2013-10-222015-12-31GlobalVariousUSD 175 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		2014 Restructuring plan announced Oct 22, 2013. Estimated total pre-tax charges $175M-$225M. Activities start Q4 2013.
2013-09-30restructuringin_progressUSD 55,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-30restructuringin_progressEmployee Severance [Member]USD 26,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-30restructuringin_progressTransfer costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-30restructuringin_progressAccelerated Depreciation [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-30restructuringin_progressImpairment of an asset in value [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-30restructuringin_progressOther Restructuring [Member]USD 14,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-30restructuringin_progress2011-07-262013-12-31GlobalCorporate and operational functionsUSD 300 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2011 Restructuring plan including January 2013 Expansion; total estimated pre-tax charges of $300M–$355M. No employee headcount affected disclosed.
2013-06-30restructuringin_progress2013-01-252013-12-31GlobalCorporate and operational functionsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board-approved Expansion of the 2011 Restructuring plan; charges bundled with parent program. No employee headcount affected disclosed.
2013-06-30plant_closurein_progressUnited States — Natick, MassachusettsCorporate headquartersrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Consolidation of Natick, MA headquarters into Marlborough, MA global headquarters campus; $19M gain on sale recorded in H1 2013. No employee count disclosed.
2013-06-30acquisition_additioncompleted2012-06-082012-06-08United StatesRhythm Management (Cardiac Rhythm Management)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cameron Health acquisition completed June 8, 2012; referenced in current filing but no headcount added disclosed.
2013-06-30acquisition_additionannounced2013-06-012013-12-31GlobalElectrophysiologyUSD 275 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Bard EP (C.R. Bard electrophysiology business) for $275M cash; expected to close H2 2013. No headcount disclosed.
2013-06-30divestiture_reductionin_progress2011-01-012013-09-30GlobalNeurovascularother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Neurovascular business sale to Stryker; final $10M contingent payment expected Q3 2013. No headcount reduction disclosed.
2013-06-30restructuringin_progress2011-07-262013-12-31GlobalCorporate and Global Shared ServicesUSD 26 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2011 Restructuring plan (including Expansion). Charges include termination benefits and other costs. Employee count not disclosed.
2013-06-30restructuringcompleted2010-02-062012-12-31GlobalCorporate and InternationalUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2010 Restructuring plan. Completed by end of 2012. No charges recorded in Q2 2013.
2013-06-30restructuringcompleted2009-01-012012-12-31GlobalManufacturingUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plant Network Optimization program. Substantially completed during 2012. No charges recorded in Q2 2013.
2013-06-30restructuringin_progressUSD 26,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-30restructuringin_progressEmployee Severance [Member]USD 21,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-30restructuringin_progressEmployee Severance [Member] / 2011 Restructuring Plan [Member]USD 25,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-30restructuringin_progressEmployee Severance [Member] / 2010 Restructuring Plan [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-30restructuringin_progressEmployee Severance [Member] / Plant Network Optimization [Member]USD -4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-30restructuringin_progressAccelerated Depreciation [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-30restructuringin_progressTransfer costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-30restructuringin_progressImpairment of an asset in value [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-30restructuringin_progressOther Restructuring [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-31restructuringin_progress2013-01-252013-12-31GlobalCorporate and shared servicesUSD 300 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board approved Expansion of 2011 Restructuring plan on 2013-01-25. Total estimated pre-tax charges for plan including Expansion: $300M–$355M, with $270M–$300M expected as future cash outlays. No employee count disclosed. Activities expected substantially complete by end of 2013.
2013-03-31restructuringin_progress2011-07-262013-12-31GlobalCorporate and shared servicesrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Original 2011 Restructuring plan approved 2011-07-26. Q1 2013 charges: $10M net restructuring charges (including $19M gain on Natick HQ sale), plus $5M in other lines. Cumulative restructuring charges since inception: $180M; restructuring-related expenses: $21M. Termination benefit liability accrued at 2013-03-31: $24M. No employee count disclosed.
2013-03-31plant_closurecompleted2013-01-012013-03-31United StatesCorporate headquartersrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of Natick, Massachusetts headquarters completed in Q1 2013 with $19M gain; consolidating into Marlborough, MA global headquarters campus. $53M proceeds received. No employee count disclosed.
2013-03-31restructuringcompleted2010-02-062012-12-31GlobalCorporate and international structureUSD 160 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2010 Restructuring plan completed by end of 2012. Total pre-tax charges: $160M; cash outlays: $145M (fully paid). No Q1 2013 activity. No employee count disclosed.
2013-03-31restructuringcompleted2009-01-012012-12-31GlobalManufacturingUSD 130 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plant Network Optimization program substantially completed during 2012. Estimated total pre-tax charges: $130M; cash outlays: $105M–$110M. Q1 2013 activity: $(2)M credit to termination benefits. No employee count disclosed.
2013-03-31restructuringin_progress2011-07-262013-12-31GlobalCorporate and ManufacturingUSD 10 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2011 Restructuring plan (including Expansion). Q1 2013 recorded net restructuring charges of $10 million. Total estimated pre-tax charges $300-$355 million. Employee count not disclosed.
2013-03-31restructuringcompleted2010-02-062012-12-31GlobalCorporate and ManufacturingUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2010 Restructuring plan. Completed by end of 2012. No charges recorded in Q1 2013.
2013-03-31restructuringcompleted2009-01-012012-12-31GlobalManufacturingUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plant Network Optimization program. Substantially completed during 2012. No charges recorded in Q1 2013.
2013-03-31restructuringin_progressUSD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-31restructuringin_progressAccelerated Depreciation [Member]restructuring_footnote
f5-10q / no-ai-xblr
2013-03-31restructuringin_progressEmployee Severance [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-31restructuringin_progressTransfer costs [Member]restructuring_footnote
f5-10q / no-ai-xblr
2013-03-31restructuringin_progressImpairment of an asset in value [Member]USD -17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-31restructuringin_progressOther Restructuring [Member]USD 19,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-31restructuringin_progressEmployee Severance [Member] / 2011 Restructuring Plan [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-31restructuringin_progressEmployee Severance [Member] / 2010 Restructuring Plan [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-31restructuringin_progressEmployee Severance [Member] / Plant Network Optimization [Member]USD -2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-12-31restructuringin_progress2011-07-262013-12-31GlobalCorporate functions, shared services, international structureUSD 149 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2011 Restructuring plan; $149M of total costs recorded in 2012 (restructuring charges plus related expenses in other lines); $184M cumulative since inception; total program estimated at $300M-$355M pre-tax; headcount reductions not quantified
2012-12-31restructuringannounced2013-01-252013-12-31GlobalCorporate functions, divisions and geographic regionsUSD 140 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Expansion of the 2011 Restructuring plan approved after fiscal year-end; estimated pre-tax charges of $140M to $160M, of which $100M to $120M expected to be cash; expected to reduce gross annual pre-tax operating expenses by $100M to $115M exiting 2013
2012-12-31restructuringcompleted2010-02-062012-12-31GlobalBusinesses, corporate functions and international structureUSD 3 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2010 Restructuring plan activities completed by end of 2012; $3M of total costs recorded in 2012; cumulative pre-tax charges of $160M with $145M cash outlays since inception; gross reductions in pre-tax operating expenses of approximately $250M
2012-12-31plant_closurecompleted2009-012012-12-31GlobalManufacturingUSD 8 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Plant Network Optimization program substantially completed during 2012; $8M of total costs recorded in 2012; estimated total pre-tax charges of $132M to $135M since inception; annualized manufacturing cost reductions of approximately $65M exiting 2012
2012-12-31acquisition_additioncompleted2012-06-082012-06-08United StatesCardiac Rhythm Managementbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Cameron Health, Inc. (S-ICD system); acquired headcount not disclosed
2012-12-31acquisition_additioncompleted2012-10-042012-10-04United StatesInterventional Cardiologybusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of BridgePoint Medical, Inc.; acquired headcount not disclosed
2012-12-31acquisition_additioncompleted2012-10-082012-10-08United StatesElectrophysiologybusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Rhythmia Medical, Inc.; acquired headcount not disclosed
2012-12-31acquisition_additioncompleted2012-11-192012-11-19United StatesPeripheral Interventionsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Vessix Vascular, Inc.; acquired headcount not disclosed
2012-12-31restructuringin_progress2011-07-262013-12-31GlobalVariousUSD 136 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2011 Restructuring Plan. Total pre-tax charges recorded in 2012 were $136 million. Program expected to be substantially completed by end of 2013.
2012-12-31restructuringcompleted2010-02-062012-12-31GlobalVariousUSD 0 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2010 Restructuring Plan. Activities completed by end of 2012. No specific 2012 charges disclosed separately from total restructuring charges.
2012-12-31restructuringcompleted2009-01-012012-12-31GlobalManufacturingUSD 0 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Plant Network Optimization Program. Substantially completed during 2012.
2012-12-31restructuringcompleted2011-07-262013-12-31GlobalCorporate and various divisionsUSD 136 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		2011 Restructuring Plan. Activities substantially completed by end of 2013. $136 million in restructuring charges recorded in 2012. Employee count not explicitly disclosed for 2012 activity.
2012-12-31restructuringcompleted2010-02-062012-12-31GlobalCorporate and various divisionsrestructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		2010 Restructuring Plan. Activities completed by end of 2012. No specific 2012 charges or employee counts disclosed for this plan in the footnote.
2012-12-31restructuringcompleted2009-01-012012-12-31GlobalManufacturingrestructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Plant Network Optimization Program. Substantially completed during 2012. No specific 2012 charges or employee counts disclosed for this program in the footnote.
2012-12-31restructuringin_progressUSD 136,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progressImpairment of an asset in value [Member]USD 14,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progressEmployee Severance [Member]USD 79,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progressOther Restructuring [Member]USD 43,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progressRestructuring Related To Plan [Member]USD 136,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progressEmployee Severance [Member] / 2011 Restructuring Plan [Member]USD 78,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progressEmployee Severance [Member] / Plant Network Optimization [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progressEmployee Severance [Member] / 2010 Restructuring Plan [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-09-30restructuringin_progress2011-07-262013-12-31GlobalCorporate and shared servicesUSD 155 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Total pre-tax charges estimated at $155M-$210M; $133M recorded since inception; no employee count disclosed.
2012-09-30restructuringin_progress2010-02-062012-12-31GlobalCardiovascular, CRM integration and international structureUSD 165 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Total pre-tax charges estimated at $165M-$185M; $160M recorded since inception; no employee count disclosed.
2012-09-30plant_closurein_progress2009-01-012012-12-31GlobalManufacturingUSD 130 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Facility consolidation and production-line transfers; total pre-tax charges estimated at $130M-$145M; no employee count disclosed.
2012-09-30acquisition_additioncompleted2012-06-082012-06-08United StatesCardiac Rhythm ManagementUSD 481 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Total purchase price $481M; no headcount added disclosed.
2012-09-30acquisition_additionannounced2012-10-092012-10-31United StatesElectrophysiology and Interventional CardiologyUSD 100 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Combined upfront consideration ~$100M plus up to $265M contingent; no headcount added disclosed.
2012-09-30divestiture_reductioncompleted2011-01-012011-01-31GlobalNeurovascularother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing supply/distribution relationship retained; no headcount removed disclosed.
2012-09-30restructuringin_progress2011-07-262013-12-31GlobalCorporate and ManufacturingUSD 54 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2011 Restructuring plan: $44M termination benefits, $10M other charges in Q3 2012. Total estimated charges $155M-$210M. No employee count disclosed.
2012-09-30restructuringin_progress2010-02-062012-12-31GlobalCorporate and ManufacturingUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2010 Restructuring plan: $2M termination benefits in Q3 2012. Total estimated charges $165M-$185M. No employee count disclosed.
2012-09-30restructuringin_progress2009-01-012012-12-31GlobalManufacturingUSD -1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plant Network Optimization program: $(1)M credit for termination benefits in Q3 2012. Total estimated charges $130M-$145M. No employee count disclosed.
2012-09-30acquisition_additioncompleted2012-06-08GlobalCardiac Rhythm Managementbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Cameron Health, Inc. completed June 8, 2012. Employee count not disclosed.
2012-09-30acquisition_additionannounced2012-10-01GlobalElectrophysiologysubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Rhythmia Medical, Inc. completed in October 2012. Employee count not disclosed.
2012-09-30acquisition_additionannounced2012-10-01GlobalInterventional Cardiologysubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Bridgepoint Medical, Inc. completed in October 2012. Employee count not disclosed.
2012-09-30restructuringin_progressUSD 93,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-30restructuringin_progressOther Restructuring [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-30restructuringin_progressImpairment of an asset in value [Member]restructuring_footnote
f5-10q / no-ai-xblr
2012-09-30restructuringin_progressTransfer costs [Member]restructuring_footnote
f5-10q / no-ai-xblr
2012-09-30restructuringin_progressEmployee Severance [Member]USD 44,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-30restructuringin_progressAccelerated Depreciation [Member]restructuring_footnote
f5-10q / no-ai-xblr
2012-09-30restructuringin_progressEmployee Severance [Member] / Plant Network Optimization [Member]USD -1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-30restructuringin_progress2011 Restructuring Plan [Member]USD 99,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-30restructuringin_progressOther Restructuring [Member] / 2011 Restructuring Plan [Member]USD 34,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-30restructuringin_progressEmployee Severance [Member] / 2011 Restructuring Plan [Member]USD 65,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-30restructuringin_progressOther Restructuring [Member] / 2010 Restructuring Plan [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-30restructuringin_progress2010 Restructuring Plan [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progress2011-07-262013-12-31GlobalCorporate and shared servicesUSD 155 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Total estimated pre-tax charges of $155M to $210M; $78M recorded to date; no employee count disclosed.
2012-06-30restructuringin_progress2010-02-062012-12-31GlobalCardiovascular, CRM, and corporate functionsUSD 165 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Total estimated pre-tax charges of $165M to $185M; $159M recorded to date; no employee count disclosed.
2012-06-30plant_closurein_progress2009-01-012012-12-31GlobalManufacturingUSD 130 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Total estimated pre-tax charges of $130M to $145M; $129M recorded to date; involves facility closures and production line transfers; no employee count disclosed.
2012-06-30acquisition_additioncompleted2012-06-082012-06-08United States / EMEACardiac Rhythm Managementbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Cameron Health completed June 8, 2012; purchase price $481M; no headcount added disclosed.
2012-06-30restructuringin_progress2011-07-262013-12-31GlobalCorporate and ManufacturingUSD 28 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2011 Restructuring plan: $22M termination benefits, $6M other charges in Q2 2012. Total estimated pre-tax charges $155M-$210M. Employee count not disclosed.
2012-06-30restructuringin_progress2010-02-062012-12-31GlobalCorporate and ManufacturingUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2010 Restructuring plan: $1M other charges in Q2 2012. Total estimated pre-tax charges $165M-$185M. Employee count not disclosed.
2012-06-30restructuringin_progress2009-01-012012-12-31GlobalManufacturingUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plant Network Optimization program: $2M termination benefits, $2M transfer costs in Q2 2012. Total estimated pre-tax charges $130M-$145M. Employee count not disclosed.
2012-06-30acquisition_additioncompleted2012-06-082012-06-08GlobalCardiac Rhythm ManagementUSD 134 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Cameron Health, Inc. completed June 8, 2012. Cash paid $134M. Headcount added not explicitly disclosed.
2012-06-30restructuringin_progressUSD 28,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progressAccelerated Depreciation [Member]restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progressEmployee Severance [Member]USD 22,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progressTransfer costs [Member]restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progressImpairment in Value of Asset [Member]restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progressOther Restructuring [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringin_progress2011-07-262013-12-31GlobalCorporate and shared servicesUSD 155 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Total estimated pre-tax charges of $155M to $210M; $50M recorded to date. Includes termination benefits ($125M–$150M) and other costs. No employee headcount disclosed.
2012-03-31restructuringin_progress2010-02-062012-12-31GlobalCardiovascular, CRM, and corporate functionsUSD 165 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Total estimated pre-tax charges of $165M to $185M; $158M recorded to date. Includes termination benefits ($95M–$100M). No employee headcount disclosed.
2012-03-31plant_closurein_progress2009-01-012012-12-31GlobalManufacturingUSD 130 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Total estimated pre-tax charges of $130M to $145M; $127M recorded to date. Involves transferring production lines and closing certain facilities. No employee headcount disclosed.
2012-03-31acquisition_additionannounced2012-03-012012-09-30United StatesCardiac Rhythm ManagementUSD 150 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Option exercised in March 2012 to acquire Cameron Health. Upfront payment of $150M at closing, plus $150M upon FDA approval and up to $1.05B in revenue milestones. No headcount disclosed. Closing expected Q2 or Q3 2012.
2012-03-31restructuringin_progress2011-07-262013-12-31GlobalCorporate and ManufacturingUSD 10 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2011 Restructuring plan: $10M charge in Q1 2012. Total estimated charges $155M-$210M. Activities include standardizing processes, relocating administrative activities, and rationalizing organizational structures.
2012-03-31restructuringin_progress2010-02-062012-12-31GlobalCardiovascular, CRM, and Corporaterestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2010 Restructuring plan: No specific charge amount disclosed for Q1 2012 in the aggregate line item, but included in total $10M restructuring charges. Total estimated charges $165M-$185M. Activities include integration of Cardiovascular and CRM businesses and international structure realignment.
2012-03-31restructuringin_progress2009-01-012012-12-31GlobalManufacturingrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plant Network Optimization program: No specific charge amount disclosed for Q1 2012 in the aggregate line item, but included in total $10M restructuring charges. Total estimated charges $130M-$145M. Activities include transferring production lines and closing facilities.
2012-03-31restructuringin_progressUSD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringin_progressAccelerated Depreciation [Member]restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringin_progressEmployee Severance [Member]USD -1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringin_progressTransfer costs [Member]restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringin_progressImpairment in Value of Asset [Member]restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringin_progressOther Restructuring [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-12-31restructuringin_progress2011-07-262013-12-31GlobalCorporate functions, shared services and administrative activitiesUSD 35 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Costs of $35 million recorded since inception of the plan; total estimated pre-tax charges of $155 million to $210 million, of which $125 million to $150 million is termination benefits. Headcount reductions not quantified; activities initiated in Q3 2011.
2011-12-31restructuringin_progress2010-02-062012-12-31GlobalCardiovascular and CRM integration, international structure, corporate functionsUSD 49 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Current-fiscal-year activity only: $49 million of costs recorded in 2011; $159 million cumulative since inception. Estimated total pre-tax charges of $165 million to $185 million. Headcount reductions not quantified.
2011-12-31restructuringin_progress2009-012012-12-31GlobalManufacturing operationsUSD 45 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Current-fiscal-year activity only: $45 million of costs recorded in 2011; $124 million cumulative since inception. Estimated total pre-tax charges of $130 million to $145 million. Company intends to close one U.S. manufacturing plant during 2012 (approximately 350,000 owned square feet); associated headcount not disclosed.
2011-12-31divestiture_reductioncompleted2010-10-282011-01-03GlobalNeurovascular businessdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of Neurovascular business to Stryker Corporation for $1.5 billion cash, closed January 3, 2011; pre-tax gain of $778 million recorded. Transferred employees not quantified; transition services and supply agreements run through end of 2012, with certain manufacturing facility transfers expected during 2013.
2011-12-31acquisition_additioncompleted2011-01-042011-03-03United StatesInterventional Cardiology, Neuromodulation, Peripheral Interventions, ElectrophysiologyUSD 370 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Consolidated record for four 2011 acquisitions (Sadra Medical, Intelect Medical, ReVascular Therapeutics, Atritech); $370 million cash paid net of cash acquired plus $287 million contingent consideration. Employees acquired not disclosed.
2011-12-31restructuringin_progress2011-07-262013-12-31GlobalCorporate and various business unitsUSD 155 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2011 Restructuring plan approved July 26, 2011. Estimated total pre-tax charges $155 million to $210 million. Activities include standardizing processes, relocating administrative activities, and rationalizing reporting structures. Substantially complete by end of 2013.
2011-12-31restructuringin_progress2010-02-062012-12-31GlobalCardiovascular, CRM, and InternationalUSD 165 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2010 Restructuring plan approved Feb 6, 2010. Estimated total pre-tax charges $165 million to $185 million. Activities include integration of Cardiovascular and CRM businesses and realignment of international structure. Substantially complete by end of 2012.
2011-12-31restructuringin_progress2009-01-012012-12-31GlobalManufacturingUSD 130 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Plant Network Optimization program approved Jan 2009. Estimated total pre-tax charges $130 million to $145 million. Activities include simplifying manufacturing plant structure and transferring production lines. Substantially complete by end of 2012.
2011-12-31divestiture_reductioncompleted2011-01-012011-01-01GlobalNeurovascularItem 1. Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Sale of Neurovascular business to Stryker Corporation closed in January 2011. Specific headcount transferred not disclosed.
2011-12-31restructuringin_progress2011-07-262013-12-31GlobalCorporate and Business UnitsUSD 155 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		2011 Restructuring plan approved July 26, 2011. Estimated total pre-tax charges $155M-$210M. No specific headcount reduction disclosed in filing.
2011-12-31restructuringin_progress2010-02-062012-12-31GlobalCardiovascular, CRM, and CorporateUSD 165 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		2010 Restructuring plan approved Feb 6, 2010. Estimated total pre-tax charges $165M-$185M. No specific headcount reduction disclosed in filing.
2011-12-31restructuringin_progress2009-01-012012-12-31GlobalManufacturingUSD 130 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Plant Network Optimization program approved Jan 2009. Estimated total pre-tax charges $130M-$145M. No specific headcount reduction disclosed in filing.
2011-12-31divestiture_reductioncompleted2011-01-032011-01-03GlobalNeurovascularItem_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Sale of Neurovascular business to Stryker Corporation closed January 2011. Specific headcount transferred not disclosed.
2011-12-31restructuringin_progressUSD 89,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progressAccelerated Depreciation [Member]restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progressretention incentives [Member]restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progressEmployee Severance [Member]USD 55,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progressImpairment in Value of Asset [Member]restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progressOther Restructuring [Member]USD 34,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progressRestructuring Related To Plan [Member]USD 89,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progressTransfer costs [Member]restructuring_footnote
f5-10k / no-ai-xblr
2011-09-30restructuringin_progress2011-07-262013-09-30GlobalCorporate and shared servicesUSD 155 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board-approved plan with estimated total pre-tax charges of $155M–$210M; $150M–$200M expected as cash outlays. No employee count disclosed. Expected to reduce annual pre-tax operating expenses by $225M–$275M exiting 2013.
2011-09-30restructuringin_progress2010-02-062012-12-31GlobalCardiovascular, CRM, R&D, corporate functionsUSD 165 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Estimated total pre-tax charges of $165M–$185M; $150M–$160M expected as cash outlays, of which $135M paid to date. No employee count disclosed.
2011-09-30restructuringin_progress2009-01-012012-12-31GlobalManufacturingUSD 130 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program to simplify manufacturing plant structure by transferring production lines and closing facilities. Estimated total pre-tax charges of $130M–$145M; $110M–$120M expected as cash outlays, of which $62M paid to date. No employee count disclosed.
2011-09-30acquisition_additioncompleted2011-01-042011-01-04United StatesInterventional CardiologyUSD 193 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of remaining 86% equity for $193M net of cash; up to $193M contingent consideration through 2016. No headcount disclosed.
2011-09-30acquisition_additioncompleted2011-01-052011-01-05United StatesNeuromodulationUSD 60 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of remaining 85% equity for $60M. No contingent consideration. No headcount disclosed.
2011-09-30acquisition_additioncompleted2011-02-152011-02-15United StatesPeripheral InterventionsUSD 19 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of 100% equity for $19M; up to $16M contingent consideration through 2014. No headcount disclosed.
2011-09-30acquisition_additioncompleted2011-03-032011-03-03United StatesElectrophysiology / Interventional CardiologyUSD 98 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of 100% equity for $98M net of cash; up to $275M contingent consideration through 2015. No headcount disclosed.
2011-09-30divestiture_reductioncompleted2011-01-012011-01-01GlobalNeurovascularother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of Neurovascular business to Stryker for $1.5B cash; pre-tax gain of $760M. BSC provides transitional services for ~24 months. No employee count disclosed.
2011-09-30restructuringin_progress2011-07-262013-07-26GlobalCorporate and ManufacturingUSD 155 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2011 Restructuring plan approved July 26, 2011. Estimated total pre-tax charges $155M-$210M. Activities initiated in Q3 2011, expected substantially complete within 24 months. Includes standardizing processes, relocating administrative activities, and rationalizing organizational structures.
2011-09-30restructuringin_progress2010-02-062012-12-31GlobalCardiovascular, CRM, and CorporateUSD 165 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2010 Restructuring plan approved Feb 6, 2010. Estimated total pre-tax charges $165M-$185M. Activities initiated in Q1 2010, expected substantially complete by end of 2012. Includes integration of Cardiovascular and CRM businesses and centralization of R&D.
2011-09-30restructuringin_progress2009-01-012012-12-31GlobalManufacturingUSD 130 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plant Network Optimization program approved Jan 2009. Estimated total pre-tax charges $130M-$145M. Activities initiated in Q1 2009, expected substantially complete by end of 2012. Intended to simplify manufacturing plant structure.
2011-09-30divestiture_reductioncompleted2011-01-012011-01-01GlobalNeurovascularbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Sale of Neurovascular business to Stryker Corporation closed in January 2011. Headcount associated with divested business removed. No specific employee count disclosed.
2011-09-30restructuringin_progressUSD 77,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-09-30restructuringin_progressImpairment in Value of Asset [Member]restructuring_footnote
f5-10q / no-ai-xblr
2011-09-30restructuringin_progressEmployee Severance [Member]USD 49,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-09-30restructuringin_progressOther Restructuring [Member]USD 28,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-09-30restructuringin_progressAccelerated Depreciation [Member]restructuring_footnote
f5-10q / no-ai-xblr
2011-09-30restructuringin_progressTransfer costs [Member]restructuring_footnote
f5-10q / no-ai-xblr
2011-06-30restructuringannounced2011-07-262013-12-31GlobalCorporate and administrative functionsUSD 155 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2011 Restructuring plan; total pre-tax charges estimated at $155M–$210M; $150M–$200M expected as cash outlays. No employee count disclosed. Includes termination benefits of $125M–$150M.
2011-06-30restructuringin_progress2010-02-062012-12-31GlobalCardiovascular, CRM, R&D, corporate functionsUSD 165 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2010 Restructuring plan; total pre-tax charges estimated at $165M–$185M; $161M recorded to date. No employee count disclosed. Includes integration of Cardiovascular and CRM businesses.
2011-06-30plant_closurein_progress2009-01-012012-12-31GlobalManufacturingUSD 130 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plant Network Optimization program; total pre-tax charges estimated at $130M–$145M; $108M recorded to date. Involves facility closures and production line transfers. No employee count disclosed.
2011-06-30divestiture_reductioncompleted2011-01-012011-01-01GlobalNeurovascular businessother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of Neurovascular business to Stryker for $1.5B closed January 2011. No headcount reduction figure disclosed. Business generated $340M in 2010 revenue (~4% of consolidated net sales).
2011-06-30acquisition_additioncompleted2011-01-042011-01-04United StatesInterventional CardiologyUSD 193 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Sadra Medical (percutaneous aortic valve replacement). $193M paid at closing; up to $193M contingent consideration through 2016. No headcount disclosed.
2011-06-30acquisition_additioncompleted2011-01-052011-01-05United StatesNeuromodulationUSD 60 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Intelect Medical (deep-brain stimulation). $60M paid at closing. No headcount disclosed.
2011-06-30acquisition_additioncompleted2011-02-152011-02-15United StatesPeripheral InterventionsUSD 19 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of ReVascular Therapeutics (chronic total occlusion crossing device). $19M paid at closing; up to $16M contingent consideration through 2014. No headcount disclosed.
2011-06-30acquisition_additioncompleted2011-03-032011-03-03United StatesElectrophysiology / Interventional CardiologyUSD 98 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Atritech (WATCHMAN left atrial appendage closure). $98M paid at closing; up to $275M contingent consideration through 2015. No headcount disclosed.
2011-06-30restructuringin_progress2010-02-062012-12-31GlobalCorporate and ManufacturingUSD 18 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2010 Restructuring plan. Q2 2011 charges include $8M termination benefits and $10M other. Total estimated pre-tax charges $165M-$185M.
2011-06-30restructuringin_progress2009-01-012012-12-31GlobalManufacturingUSD 12 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plant Network Optimization program. Q2 2011 charges include $2M termination benefits and $11M transfer costs. Total estimated pre-tax charges $130M-$145M.
2011-06-30restructuringannounced2011-07-262013-12-31GlobalCorporate and Manufacturingsubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		2011 Restructuring plan announced July 26, 2011. Estimated total pre-tax charges $155M-$210M. Activities to start Q3 2011.
2011-06-30restructuringin_progressUSD 56,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-06-30restructuringin_progressImpairment in Value of Asset [Member]restructuring_footnote
f5-10q / no-ai-xblr
2011-06-30restructuringin_progressEmployee Severance [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-06-30restructuringin_progressTransfer costs [Member]restructuring_footnote
f5-10q / no-ai-xblr
2011-06-30restructuringin_progressOther Restructuring [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-06-30restructuringin_progressAccelerated depreciation [Member]restructuring_footnote
f5-10q / no-ai-xblr
2011-03-31restructuringin_progress2010-02-062012-12-31WorldwideMultiple (Cardiovascular/CRM integration, R&D centralization, international structure, corporate functions)USD 38 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board-approved plan expected to eliminate approximately 1,000 to 1,300 positions worldwide by end of 2012; total estimated pre-tax charges $180-200M ($165-175M cash); $38M restructuring charges recorded in Q1 2011; $148M costs recorded since inception; $93M cash paid to date.
2011-03-31plant_closurein_progress2009-01-312012-12-31WorldwideManufacturing (plant network consolidation)USD 12 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plant Network Optimization program transfers production lines and closes certain facilities; total estimated pre-tax charges $130-145M ($110-120M cash); $12M recorded in Q1 2011 (restructuring and restructuring-related); $91M costs and $47M cash payments since inception. Date is month-level (January 2009).
2011-03-31restructuringin_progress2007-10-312010-12-31WorldwideCorporate (expense and headcount reduction)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2007 Restructuring plan; production line transfers completed December 31, 2010. Total pre-tax expenses $427M with $380M cash outlays ($371M paid). No restructuring charge recorded in Q1 2011; $1M cash payment in quarter; $9M liability remaining at March 31, 2011. Date is month-level (October 2007).
2011-03-31acquisition_additioncompleted2011-01-04United StatesInterventional Cardiology (structural heart)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of remaining 86% of Sadra for $193M net of cash; up to $193M contingent consideration through 2016. Headcount added not disclosed.
2011-03-31acquisition_additioncompleted2011-01-05United StatesNeuromodulation (deep-brain stimulation)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of remaining 85% of Intelect for $60M; no contingent consideration. Headcount added not disclosed.
2011-03-31acquisition_additioncompleted2011-02-15United StatesPeripheral Interventionsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of 100% of RVT for $20M; up to $16M contingent consideration through 2014. Headcount added not disclosed.
2011-03-31acquisition_additioncompleted2011-03-03United StatesElectrophysiology / Interventional Cardiology (WATCHMAN device)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of 100% of Atritech for $100M net of cash; up to $275M contingent consideration through 2015. Headcount added not disclosed.
2011-03-31divestiture_reductioncompleted2011-01-31WorldwideNeurovascular businessother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of Neurovascular business to Stryker for $1.5B cash closed January 2011; pre-tax gain of $760M recorded. Headcount removed not disclosed; date is month-level (January 2011).
2011-03-31restructuringin_progress2010-02-062012-12-31WorldwideCardiovascular, CRM, Corporate, R&D, InternationalUSD 38 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2010 Restructuring plan. Expected to eliminate 1,000 to 1,300 positions worldwide by end of 2012. Q1 2011 charges included $28M termination benefits and $10M fixed asset write-offs. Total estimated pre-tax charges $180M-$200M.
2011-03-31restructuringin_progress2009-01-012012-12-31WorldwideManufacturingUSD 12 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plant Network Optimization program. Simplifies manufacturing plant structure. Q1 2011 charges included $1M termination benefits, $3M accelerated depreciation, and $8M transfer costs. Total estimated pre-tax charges $130M-$145M.
2011-03-31divestiture_reductioncompleted2011-01-012011-01-01WorldwideNeurovascularMD&A
f5-10q / Qwen3.6-27B-Q8_0		Sale of Neurovascular business to Stryker Corporation closed in January 2011. Headcount removed not explicitly quantified in this filing.
2011-03-31restructuringin_progressRestructuring Plan By Year [Member]USD 427,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-03-31restructuringin_progressUSD 38,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-03-31restructuringin_progressTermination Benefits [Member]USD 28,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-03-31restructuringin_progressOther Restructuring [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-03-31restructuringin_progressMinimum Limit [Member] / Restructuring Plan By Year Two [Member]USD 38,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2010-12-31restructuringin_progress2010-02-062012-12-31WorldwideCardiovascular and CRM integration; corporate functions; research and development; international structureUSD 190 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2010 Restructuring plan; estimated total pre-tax charges of $180M to $200M (midpoint shown); expected elimination of approximately 1,000 to 1,300 positions worldwide by end of 2012; $110M of costs recorded since inception through 2010-12-31.
2010-12-31plant_closurein_progress2009-01-012012-12-31United StatesManufacturingUSD 143 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Plant Network Optimization program; estimated total pre-tax charges of $135M to $150M (midpoint shown); intends to close one U.S. manufacturing plant by end of 2012 representing approximately 350,000 owned square feet; $79M of costs recorded since inception through 2010-12-31.
2010-12-31divestiture_reductioncompleted2010-10-282011-01-03WorldwideNeurovascularsubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of Neurovascular business to Stryker closed 2011-01-03 for $1.5B cash; headcount transferred not disclosed; transition services and supply agreements effective up to 24 months.
2010-12-31acquisition_additioncompleted2010-10-262010-10-26United StatesEndoscopybusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Asthmatx, Inc. completed for approximately $194M cash plus up to $250M contingent consideration; headcount added not disclosed.
2010-12-31acquisition_additioncompleted2011-01-042011-01-04United StatesInterventional Cardiologysubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of remaining 86% of Sadra Medical for approximately $193M cash plus up to $193M contingent consideration; headcount added not disclosed.
2010-12-31acquisition_additioncompleted2011-01-052011-01-05United StatesNeuromodulationsubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of remaining 85% of Intelect Medical for approximately $60M cash; headcount added not disclosed.
2010-12-31acquisition_additionannounced2011-01-19United StatesElectrophysiologysubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive merger agreement to acquire Atritech, Inc. signed; $100M payable at closing plus up to $275M contingent consideration; subject to customary closing conditions.
2010-12-31restructuringin_progress1,1502010-02-062012-12-31WorldwideMultiple (Cardiovascular, CRM, Corporate, R&D)USD 190 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2010 Restructuring plan: elimination of approximately 1,000 to 1,300 positions worldwide. Total pre-tax charges estimated at $180 million to $200 million. Midpoint used for count and charge.
2010-12-31restructuringin_progress2009-01-012012-12-31WorldwideManufacturingUSD 143 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Plant Network Optimization program: total pre-tax charges estimated at $135 million to $150 million. Midpoint used for charge. Employee count not explicitly disclosed for this specific program in the text.
2010-12-31divestiture_reductioncompleted2011-01-032011-01-03WorldwideNeurovascularsubsequent_events
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Sale of Neurovascular business to Stryker Corporation closed January 3, 2011. Employee count not disclosed.
2010-12-31restructuringin_progress2010-02-062012-12-31WorldwideCardiovascular, CRM, Corporate FunctionsUSD 180 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		2010 Restructuring plan: Estimated total pre-tax charges of $180M-$200M. Expected elimination of 1,000-1,300 positions worldwide by end of 2012. Specific headcount affected in 2010 not explicitly isolated from total program estimate in narrative, though Note I details charges.
2010-12-31restructuringin_progress2009-01-012012-12-31WorldwideManufacturingUSD 135 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Plant Network Optimization program: Estimated total pre-tax charges of $135M-$150M. Initiated Q1 2009, expected complete by end of 2012.
2010-12-31restructuringcompleted2007-10-012010-12-31WorldwideVariousUSD 427 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		2007 Restructuring plan: Total pre-tax expenses of $427M. Major activities completed by Dec 31, 2009, with production line transfers completed Dec 31, 2010.
2010-12-31restructuringin_progressUSD 116,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2010-12-31restructuringin_progressTermination Benefits [Member]USD 70,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2010-12-31restructuringin_progressFixed asset write-offs [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2010-12-31restructuringin_progressOthers [Member]USD 35,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2010-09-30restructuringin_progress2010-02-062011-12-31GlobalMultiple — Cardiovascular/CRM integration, corporate functions, R&D, international structureUSD 190 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2010 Restructuring plan; expected to eliminate approximately 1,000 to 1,300 positions by end of 2011; total pre-tax charges estimated at $180M to $200M (midpoint shown); $92M recorded to date; $48M cash paid to date
2010-09-30restructuringin_progress2009-01-012011-12-31GlobalManufacturing — plant network optimizationUSD 143 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plant Network Optimization program; total pre-tax charges estimated at $135M to $150M (midpoint shown); $70M recorded to date; no specific headcount disclosed
2010-09-30restructuringin_progress2007-10-012010-12-31GlobalMultiple — businesses, corporate functions, product franchises, R&DUSD 430 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2007 Restructuring plan; total pre-tax expenses estimated at $425M to $435M (midpoint shown); $424M recorded to date; production line transfers continue through end of 2010; no specific headcount disclosed
2010-09-30divestiture_reductionannounced2010-10-012011-03-31GlobalNeurovascularsubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to sell Neurovascular business to Stryker for $1.5B; no headcount disclosed; transition services expected ~24 months post-closing
2010-09-30acquisition_additionannounced2010-10-272010-10-27United StatesEndoscopysubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Asthmatx Inc. completed October 27, 2010 for ~$194M cash plus up to $250M contingent consideration; no headcount disclosed
2010-09-30restructuringin_progress2010-02-062011-12-31WorldwideCardiovascular, CRM, Corporate, InternationalUSD 180 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2010 Restructuring plan approved Feb 6, 2010. Expected to eliminate 1,000 to 1,300 positions by end of 2011. Total pre-tax charges estimated at $180M-$200M. Charges recorded YTD 2010: $92M.
2010-09-30restructuringin_progress2009-01-012011-12-31WorldwideManufacturingUSD 135 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plant Network Optimization program initiated Q1 2009. Total pre-tax charges estimated at $135M-$150M. Charges recorded YTD 2010: $30M.
2010-09-30restructuringin_progress2007-10-012010-12-31WorldwideCorporate, Product FranchisesUSD 425 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2007 Restructuring plan. Total pre-tax expenses estimated at $425M-$435M. Charges recorded YTD 2010: $17M.
2010-09-30acquisition_additioncompleted2010-10-272010-10-27United StatesEndoscopyUSD 194 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Asthmatx, Inc. completed Oct 27, 2010. Paid $194M cash. Headcount not disclosed.
2010-09-30restructuringin_progressUSD 98,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2010-09-30restructuringin_progressRetention incentives [Member]restructuring_footnote
f5-10q / no-ai-xblr
2010-09-30restructuringin_progressTermination Benefits [Member]USD 66,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2010-09-30restructuringin_progressOther [Member]USD 24,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2010-09-30restructuringin_progressFixed asset write-offs [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2010-06-30restructuringin_progress2010-02-062011-12-31WorldwideCardiovascular and CRM integration; other businesses, corporate functions, R&D organization, international structurerestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board approved plan calls for elimination of approximately 1,000 to 1,300 positions worldwide by end of 2011; total pre-tax charges estimated at $180 million to $200 million (range disclosed, not a single figure). $93 million of restructuring charges recorded in six months ended 2010-06-30; $86 million cumulative plan cost to date.
2010-06-30plant_closurein_progress2009-012011-12-31WorldwideManufacturing (plant network)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program simplifies manufacturing plant structure via production-line transfers and facility closures; total pre-tax charges estimated at $135 million to $150 million (range). No employee count disclosed; $59 million cumulative cost to date.
2010-06-30restructuringin_progress2007-102010-12-31WorldwideBusinesses, corporate functions and product franchises; production line transfersrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		All major activities completed as of 2009-12-31; production-line transfers continue through 2010. Total pre-tax expenses estimated at $425 million to $435 million (range); no position count disclosed in this filing. $424 million of related costs recorded since inception.
2010-06-30restructuringin_progress2010-02-062011-12-31WorldwideCardiovascular, CRM, Corporate, R&D, InternationalUSD 86 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2010 Restructuring plan approved Feb 6, 2010. Expected to eliminate 1,000-1,300 positions by end of 2011. YTD charges of $86M include $60M termination benefits, $7M asset write-offs, $19M other. Total expected pre-tax charges $180M-$200M.
2010-06-30restructuringin_progress2009-01-012011-12-31WorldwideManufacturingUSD 18 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plant Network Optimization program initiated Q1 2009. YTD charges of $18M include $2M termination benefits, $3M accelerated depreciation, $13M transfer costs. Total expected pre-tax charges $135M-$150M.
2010-06-30restructuringin_progress2007-10-012010-12-31WorldwideVariousUSD 17 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2007 Restructuring plan initiated Q4 2007. YTD charges of $17M include $3M termination benefits, $10M asset write-offs, $4M other. Total expected pre-tax expenses $425M-$435M.
2010-06-30restructuringin_progressUSD 93,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2010-06-30restructuringin_progressRestructuring charges [Member]USD 93,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2010-06-30restructuringin_progressFixed asset write-offs [Member] / Restructuring charges [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2010-06-30restructuringin_progressTermination Benefits [Member] / Restructuring charges [Member]USD 65,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2010-06-30restructuringin_progressOther [Member] / Restructuring charges [Member]USD 21,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2010-06-30restructuringin_progressRetention incentives [Member] / Restructuring charges [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2010-03-31restructuringin_progress2010-02-062011-12-31WorldwideMultiple — integration of Cardiovascular and CRM businesses, corporate functions, R&D centralization, international structureUSD 190 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board approved plan to eliminate approximately 1,000 to 1,300 positions by end of 2011; total pre-tax charges estimated at $180M to $200M, with $170M to $180M in future cash outlays. Filing discloses a range rather than a single count.
2010-03-31restructuringin_progress2009-01-012011-12-31WorldwideManufacturing — plant network consolidationUSD 143 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plant Network Optimization program approved January 2009; total pre-tax charges estimated at $135M to $150M. No specific headcount reduction disclosed in this filing. Activities expected substantially complete by end of 2011.
2010-03-31restructuringin_progress2007-10-012010-12-31WorldwideMultiple — businesses, corporate functions, product franchisesUSD 430 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2007 Restructuring plan eliminated approximately 2,300 positions worldwide. Major activities substantially completed as of December 31, 2009; production line transfers continue through 2010. Total pre-tax expenses estimated at $425M to $435M. Headcount count reflects cumulative plan total, not current-quarter action.
2010-03-31restructuringin_progress2010-02-062011-12-31WorldwideCardiovascular, CRM, Corporate, R&D, InternationalUSD 65 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2010 Restructuring plan approved Feb 6, 2010. Expected to eliminate 1,000-1,300 positions by end of 2011. Q1 2010 charges of $65M recorded. Total expected pre-tax charges $180M-$200M.
2010-03-31restructuringin_progress2009-01-012011-12-31WorldwideManufacturingUSD 9 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plant Network Optimization program initiated Q1 2009. Q1 2010 charges of $9M recorded. Total expected pre-tax charges $135M-$150M.
2010-03-31restructuringin_progress2007-10-012010-12-31WorldwideVariousUSD 12 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2007 Restructuring plan initiated Q4 2007. Eliminated approx 2,300 positions. Q1 2010 charges of $12M recorded. Total expected pre-tax expenses $425M-$435M.
2010-03-31restructuringin_progressUSD 65,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2009-12-31restructuringin_progress2,3002007-102010-12-31WorldwideMultiple businesses, product franchises and corporate functionsUSD 407 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Headcount and charge are cumulative through fiscal year-end since plan inception; $90 million of costs recorded in FY2009. Total estimated plan cost $425-435 million. Headcount reductions complete; production line transfers continue through 2010
2009-12-31plant_closurein_progress2009-012011-12-31Worldwide (U.S. and Ireland facilities referenced)ManufacturingUSD 40 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Charge is FY2009 (program inception year); total estimated program cost $135-150 million. Reduces plants from 17 to 12 and relocates about 15% of production value; includes two Ireland and three U.S. plant closures (about 500,000 sq ft) shared with the 2007 plan, targeted by end of 2012. Affected headcount not quantified
2009-12-31restructuringannounced2010-02-062011-12-31WorldwideCardiovascular and CRM integration, other businesses, corporate functions, R&D and international structuresubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Announced after fiscal year-end. Approximately 1,000 to 1,300 positions expected to be eliminated by end of 2011; estimated total pre-tax charges of $180-200 million, of which $170-190 million will be cash
2009-12-31restructuringin_progress2007-102010-12-31WorldwideVariousUSD 63 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2007 Restructuring plan resulted in elimination of approx. 2,300 positions worldwide. $63M restructuring charges recorded in 2009. Plan substantially completed as of Dec 31, 2009, with transfer of production lines continuing through 2010.
2009-12-31restructuringin_progress2009-012011-12-31WorldwideManufacturingUSD 40 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Plant Network Optimization program initiated in Q1 2009. $40M restructuring-related costs recorded in 2009. Program expected to be substantially complete by end of 2011.
2009-12-31restructuringin_progress2007-10-012010-12-31WorldwideVariousUSD 90 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		2007 Restructuring Plan. Total pre-tax expenses estimated at $425-$435 million. Plan resulted in elimination of approximately 2,300 positions worldwide. $90 million in charges recorded in 2009. Major activities substantially completed as of Dec 31, 2009, except production line transfers continuing through 2010.
2009-12-31restructuringin_progress2009-01-012011-12-31WorldwideManufacturingUSD 40 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Plant Network Optimization program. Intended to simplify manufacturing plant structure. Total pre-tax charges estimated at $135-$150 million. $40 million in charges recorded in 2009. Expected to be substantially complete by end of 2011.
2009-12-31divestiture_reductioncompleted2,0002007-01-012008-03-31WorldwideAuditory, Cardiac Surgery, Vascular Surgery, Venous Access, Fluid Management, TriVascular EVARdiscontinued_operations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Sale of non-strategic businesses completed in Q1 2008. Eliminated 2,000 positions in connection with these divestitures.
2009-12-31restructuringannounced1,3002010-02-062011-12-31WorldwideCardiovascular, CRM, Corporate FunctionsUSD 200 (millions)subsequent_events
f5-10k / Qwen3.6-27B-Q8_0		2010 Restructuring Plan announced Feb 6, 2010. Expected to eliminate 1,000 to 1,300 positions. Total pre-tax charges estimated at $180-$200 million. Subsequent event.
2009-12-31restructuringin_progressUSD 63,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2009-09-30restructuringin_progress2,3002007-10-012010-06-30WorldwideMultiple (businesses, corporate functions, product franchises)USD 425 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2007 Restructuring plan approved October 2007; total pre-tax expenses estimated at $425–450M with cash payments of $385–405M. Cumulative restructuring charges of $298M and restructuring-related costs of $113M recorded since commitment across both plans.
2009-09-30restructuringin_progress2009-01-012011-12-31WorldwideManufacturingUSD 135 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plant Network Optimization program approved January 2009; involves transferring production lines and closing certain facilities. Total pre-tax charges estimated at $135–150M. Headcount impact not separately quantified.
2009-09-30restructuringin_progress2007-10-012010-06-30WorldwideVarious (Businesses, Corporate Functions, Product Franchises)USD 9 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2007 Restructuring plan. Total plan expected to eliminate approx. 2,300 positions. Q3 2009 charges of $9M recorded. Cumulative charges $298M.
2009-09-30restructuringin_progress2009-01-012011-12-31WorldwideManufacturingUSD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plant Network Optimization program. Intended to simplify manufacturing plant structure. Q3 2009 charges of $7M recorded.
2009-09-30divestiture_reductioncompleted2,0002007-01-012008-03-31WorldwideAuditory, Vascular Surgery, Cardiac Surgery, Venous Access, Fluid Managementother
f5-10q / Qwen3.6-27B-Q8_0		Sale of non-strategic businesses completed in Q1 2008. 2,000 positions eliminated in connection with these divestitures.
2009-09-30restructuringin_progressUSD 44,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2009-06-30restructuringin_progress2,3002007-10-012010-12-31WorldwideMultiple — businesses, corporate functions, product franchisesUSD 425 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cumulative positions eliminated since plan inception in Q4 2007; total pre-tax expense estimated at $425–450M. Not a quarterly-period figure.
2009-06-30plant_closurein_progress2009-01-012011-12-31WorldwideManufacturingUSD 135 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plant Network Optimization plan approved January 2009; involves transferring production lines and closing certain facilities. Total pre-tax charges estimated at $135–150M. No employee count disclosed.
2009-06-30restructuringin_progress2,3002007-10-012010-12-31WorldwideCorporate and ManufacturingUSD 425 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2007 Restructuring plan approved in Oct 2007; eliminated approx 2,300 positions. Total pre-tax expenses estimated $425M-$450M. Substantially complete in 2010.
2009-06-30restructuringin_progress2009-01-012011-12-31WorldwideManufacturingUSD 135 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plant Network Optimization plan approved Jan 2009. Simplifies manufacturing plant structure. Total pre-tax charges estimated $135M-$150M. Substantially complete by end of 2011. Employee count not explicitly disclosed for this specific plan.
2009-06-30divestiture_reductioncompleted2,0002007-01-012008-03-31WorldwideNon-strategic businessesMD&A
f5-10q / Qwen3.6-27B-Q8_0		Sale of Auditory, Vascular Surgery, Cardiac Surgery, Venous Access and Fluid Management businesses completed in Q1 2008. Eliminated 2,000 positions in connection with these divestitures.
2009-06-30restructuringin_progressUSD 36,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2009-03-31restructuringin_progress2,3002007-102010WorldwideMultiple businesses, corporate functions and product franchisesUSD 425 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2007 Restructuring plan; ~2,300 positions eliminated cumulatively since plan inception. Total estimated pre-tax expense range $425M-$450M, expected cash payments $395M-$415M. Q1 2009 charges: $23M restructuring charges plus $14M restructuring-related expenses recorded in other income statement lines; cumulative costs incurred $354M across both plans as of 2009-03-31.
2009-03-31plant_closurein_progress2009-012011Not specifiedManufacturing (Plant Network Optimization)USD 135 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plant Network Optimization plan approved by Board in January 2009; transfers production lines among facilities and closes certain facilities. Total estimated pre-tax charges $135M-$150M, of which $120M-$130M will result in future cash outlays. Activities initiated in Q1 2009; expected annual manufacturing cost reductions of $65M-$80M in 2012. No employee count disclosed.
2009-03-31restructuringin_progress2007-10-012010-12-31WorldwideMultiple (Businesses, Corporate Functions, Product Franchises)USD 23 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2007 Restructuring plan. Total estimated pre-tax expenses $425M-$450M. Q1 2009 recorded $23M restructuring charges ($18M termination benefits, $5M other). Plan resulted in elimination of approx. 2,300 positions worldwide.
2009-03-31restructuringin_progress2009-01-012011-12-31WorldwideManufacturingrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plant Network Optimization plan. Intended to simplify manufacturing plant structure. Total estimated pre-tax charges $135M-$150M. Q1 2009 recorded $19M in restructuring-related expenses ($15M termination benefits, $1M accelerated depreciation, $3M transfer costs). No specific headcount reduction target disclosed for this plan.
2009-03-31divestiture_reductioncompleted2,0002007-01-012008-03-31WorldwideAuditory, Vascular Surgery, Cardiac Surgery, Venous Access, Fluid ManagementMD&A
f5-10q / Qwen3.6-27B-Q8_0		Sale of non-strategic businesses completed in Q1 2008. Eliminated 2,000 positions in connection with these divestitures.
2008-12-31restructuringin_progress2,3002007-102010-12-31WorldwideMultiple businesses, corporate functions and product franchisesUSD 133 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Expense and head count reduction plan approved October 2007; 2,300 positions eliminated is cumulative through fiscal year-end 2008, not 2008-only. FY2008 charges were $78M restructuring charges plus $55M restructuring-related expenses recorded in other income statement lines ($133M total); cumulative costs since plan inception were $317M. Plan expected substantially complete worldwide in 2010.
2008-12-31divestiture_reductioncompleted2,0002008-03-31WorldwideAuditory, Cardiac Surgery, Vascular Surgery, Venous Access, Fluid Management and TriVascular EVAR businessesItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Divestitures completed in the first quarter of 2008; pre-tax proceeds of approximately $1.3 billion. Announcement date not specified beyond 'during 2007'.
2008-12-31othercompleted5002008-12-31Primarily United StatesDirect sales-related positionsItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Targeted reinvestment of savings from head count reductions into sales growth roles.
2008-12-31plant_closureannounced3002009-01-272011-12-31WorldwideManufacturing (plant network reduction from 17 plants to 12; approximately 15% of value of production relocated)USD 143 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Board approved January 27, 2009, after fiscal year-end; subsequent-event program. Estimated total pre-tax charges of $135M to $150M (midpoint shown), with $120M to $130M in future cash outlays; approximately 300 positions expected to be reduced by end of 2011. Expected annual manufacturing cost reductions of $65M to $80M in 2012.
2008-12-31restructuringin_progress2,3002007-102010-12-31WorldwideMultiple functionsUSD 425 (millions)Item_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Expense and head count reduction plan approved in Oct 2007, eliminating approx 2,300 positions. Total pre-tax expenses estimated at $425-$450 million. Substantially complete worldwide in 2010.
2008-12-31divestiture_reductioncompleted2,00020072008-03-31WorldwideNon-strategic businessesItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Eliminated 2,000 positions in connection with divestiture of non-strategic businesses completed in early 2008.
2008-12-31restructuringannounced3002009-012011-12-31WorldwideManufacturingUSD 135 (millions)subsequent_events
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Plant Network Optimization plan announced in early 2009. Estimated reduction of approx 300 positions by end of 2011. Total pre-tax charges estimated at $135-$150 million.
2008-12-31restructuringin_progress2,3002007-102010-12-31WorldwideVariousUSD 78 (millions)Item_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Expense and head count reduction plan committed to in October 2007, resulting in elimination of approximately 2,300 positions. Expected to be substantially complete worldwide in 2010. $78 million in restructuring charges recorded in 2008.
2008-12-31divestiture_reductioncompleted2,00020072008-03-31WorldwideNon-strategic businessesItem_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Eliminated 2,000 positions in connection with divestiture of non-strategic businesses, completed in early 2008.
2008-12-31restructuringannounced3002009-01-272011-12-31WorldwideManufacturingsubsequent_events
f5-10k / Qwen3.6-27B-Q8_0		Plant Network Optimization plan announced in early 2009, estimated to result in reduction of approximately 300 positions by end of 2011.
2008-09-30restructuringin_progress2,3002007-102009-12-31WorldwideMultiple (businesses, corporate functions and product franchises)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board-approved plan to eliminate approximately 2,300 positions worldwide; total pre-tax expenses expected of $425M to $450M (range, not a single value) with cash payments of $375M to $400M. Restructuring charges of $20M in Q3 2008 and $59M in first nine months of 2008; cumulative restructuring and restructuring-related costs of $304M since commitment, with cumulative cash payments of approximately $190M.
2008-09-30divestiture_reductioncompleted2,00020072008-03WorldwideAuditory, Cardiac Surgery, Vascular Surgery, Fluid Management, Venous Access and TriVascular EVAR programMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approximately 2,000 positions eliminated in connection with sales of non-strategic businesses completed January through March 2008; pre-tax proceeds of approximately $1.3 billion. Filer presents only a consolidated count, not split by business.
2008-09-30restructuringin_progress2,3002007-10-012009-12-31WorldwideCorporate and ManufacturingUSD 425 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved Oct 2007 to eliminate approx 2,300 positions. Total pre-tax expenses expected $425M-$450M. Cumulative costs incurred since inception $304M.
2008-09-30divestiture_reductioncompleted2,0002008-01-012008-03-31WorldwideAuditory, Cardiac Surgery, Vascular Surgery, Fluid Management, Venous AccessMD&A
f5-10q / Qwen3.6-27B-Q8_0		Eliminated additional 2,000 positions in connection with divestitures of non-strategic businesses completed in Q1 2008.
2008-06-30restructuringin_progress2,3002007-10-312008-12-31WorldwideMultiple — includes restructuring of businesses and product franchises, R&D project reductions, and production line transfersUSD 400 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board-approved plan eliminating approximately 2,300 positions; total pre-tax expense estimated at $400–425 million with cash payments of $350–375 million. Cumulative restructuring-related costs of $270 million incurred since October 2007; $167 million cumulative cash payments made. Announcement date reflects October 2007 Board approval; exact day not stated.
2008-06-30divestiture_reductioncompleted2,0002007-12-312008-03-31WorldwideAuditory, Cardiac Surgery, Vascular Surgery, Fluid Management, Venous Access, and TriVascular EVAR programMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approximately 2,000 positions eliminated in connection with divestitures completed in Q1 2008; pre-tax proceeds of $1.288 billion received. Announcement date approximate — sales initiated during 2007, transactions closed January–March 2008.
2008-06-30acquisition_additioncompleted2008-05-282008-05-28United StatesElectrophysiology / Cardiac Rhythm ManagementUSD 21 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of 100% of CryoCor, Inc. completed May 2008 for $21 million cash; headcount added not disclosed. Recorded $16 million pre-tax purchased R&D charge.
2008-06-30restructuringin_progress2,3002007-10-012008-12-31WorldwideVarious (R&D, SG&A, Manufacturing)USD 400 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved Oct 2007 to eliminate approx 2,300 positions. Total pre-tax expenses expected $400M-$425M. Cumulative costs incurred since inception: $270M.
2008-06-30divestiture_reductioncompleted2,0002008-01-012008-03-31WorldwideAuditory, Cardiac Surgery, Vascular Surgery, Fluid Management, Venous Access, EVARMD&A
f5-10q / Qwen3.6-27B-Q8_0		Eliminated approx 2,000 positions in connection with divestitures of non-strategic businesses completed in Q1 2008.
2008-03-31restructuringin_progress2,3002007-102008-12-31WorldwideCompany-wideUSD 425 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board-approved plan to eliminate approximately 2,300 positions; total expected pre-tax costs of $425M to $450M and cash payments of $375M to $400M. More than half of reductions completed as of 2008-03-31; $44M of costs recorded in Q1 2008 and $249M cumulative since October 2007.
2008-03-31divestiture_reductioncompleted2,000WorldwideAuditory, Cardiac Surgery, Vascular Surgery, Fluid Management, Venous Access and TriVascular businessesMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Filer states an additional 2,000 positions were eliminated in connection with the 2008 divestiture of five non-strategic businesses and the former TriVascular entity; no per-business headcount breakdown or announcement date given.
2008-03-31restructuringin_progress2,3002007-10-012008-12-31WorldwideVarious (R&D, SG&A, Manufacturing)USD 44 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Board approved plan in Oct 2007 to eliminate approx 2,300 positions. Q1 2008 incurred $44M costs. Total expected pre-tax costs $425M-$450M. More than half of headcount reductions completed as of March 31, 2008.
2008-03-31divestiture_reductioncompleted2,0002007-01-012008-03-31WorldwideAuditory, Vascular Surgery, Cardiac Surgery, Venous Access, Fluid ManagementMD&A
f5-10q / Qwen3.6-27B-Q8_0		Eliminated 2,000 positions in connection with the sale of five non-strategic businesses completed in Q1 2008.
2007-12-31restructuringin_progress2,3002007-10-012008-12-31WorldwideMultiple functionsUSD 425 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Board-approved expense and headcount reduction plan; total expected pre-tax cost $425–450M, with $205M incurred in Q4 2007. More than half of affected employees notified in Q4 2007; many did not terminate until January 2008 due to notice periods.
2007-12-31divestiture_reductionin_progress2,0002007-12-312008-02-29WorldwideAuditory, Cardiac Surgery, Vascular Surgery, Venous Access, Fluid ManagementMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Approximately 2,000 positions eliminated in connection with the sale of five non-strategic businesses; sales completed January–February 2008.
2007-12-31otherannounced24,5002008-01-31WorldwideAllItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		As of January 31, 2008, approximately 24,500 employees following employment terminations and divestitures — a reduction from 27,500 at December 31, 2007.
2007-12-31restructuringin_progress2,3002007-10-012008-12-31WorldwideMultipleUSD 425 (millions)Item_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Expense and headcount reduction plan approved in October 2007. Total costs estimated at $425-$450 million. $205 million recorded in Q4 2007. Approximately 2,300 positions to be eliminated worldwide.
2007-12-31divestiture_reductioncompleted2,0002007-01-012008-03-31WorldwideAuditory, Cardiac Surgery, Vascular Surgery, Venous Access, Fluid ManagementItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Sale of five non-strategic businesses completed in early 2008. Approximately 2,000 positions eliminated in connection with divestitures.
2007-12-31restructuringin_progress2,3002007-102008-12-31WorldwideVariousUSD 425 (millions)Item_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Expense and head count reduction plan approved in October 2007. Total costs expected $425-$450 million. More than half of impacted employees notified in Q4 2007.
2007-12-31divestiture_reductioncompleted2,00020072008-03-31WorldwideAuditory, Cardiac Surgery, Vascular Surgery, Venous Access, Fluid ManagementItem_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Approximately 2,000 positions eliminated in connection with the sale of five non-strategic businesses completed in 2008.
2007-09-30restructuringannounced2,3002007-10-312008-12-31WorldwideMultiple business units and product franchisesUSD 450 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board approved October 2007 expense and workforce reduction plan. Total pre-tax expense estimated at $450–475M, with $275–300M in Q4 2007. Approximately $400–425M expected to be cash outlays. Includes elimination, suspension, or reduction of certain R&D projects.
2007-09-30restructuringcompleted4002007-01-012007-03-31United StatesCardiac Rhythm Management (CRM) — primarily research and development, with some sales and marketingrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2007 reduction of acquired CRM workforce as part of Guidant integration exit plans. Related severance accrual of $42M for workforce reductions remained at September 30, 2007. Smaller international workforce reductions also made to eliminate duplicate facilities.
2007-09-30divestiture_reductionannounced2007-08-312008-01-31United StatesAuditory business and drug pump development program (Advanced Bionics)USD 352 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of controlling interest for $150M to entities affiliated with former Advanced Bionics shareholders. $352M loss recorded in Q3 2007, primarily goodwill writedown. Company retains 12% interest. No headcount disclosed.
2007-09-30divestiture_reductionannounced2007-11-072008-03-31WorldwideCardiac Surgery and Vascular Surgery businessessubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to sell both businesses for approximately $750M cash. Net assets approximately $750M at September 30, 2007, primarily intangible assets. No headcount disclosed.
2007-09-30restructuringin_progress4002007-03-312008-12-31GlobalCardiac Rhythm Management (CRM)USD 46 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Reduction of acquired CRM workforce by approximately 400 employees, primarily R&D. Accrual includes $46M for involuntary terminations.
2007-09-30restructuringannounced2,3002007-10-012008-12-31WorldwideMultiple business unitsUSD 463 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Board approved expense and workforce reduction plan eliminating approx. 2,300 positions. Total pre-tax expenses estimated at $450M-$475M.
2007-06-30restructuringcompleted400United StatesCardiac Rhythm Management — primarily research and development, with sales and marketing and other functions also affectedrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Reduction of the acquired CRM workforce occurred in Q1 2007; exact announcement date not disclosed. Related Guidant exit-cost accrual at 2007-06-30 was $70M total, including ~$54M for involuntary terminations, change-in-control payments, relocation and related costs; the workforce-reduction component of the accrual was $49M at 2007-06-30 after $68M of charges utilized and a $(46)M purchase-price adjustment during the period. Substantially all accrued amounts expected to be paid before 2008-12-31.
2007-06-30restructuringin_progressInternational (multiple countries)Multiple functions — duplicate facility elimination and distribution network rationalizationrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Filer describes smaller international workforce reductions as part of the same Guidant exit program; headcount not quantified. Shares the same program-level exit-cost accrual as the CRM reduction record.
2007-06-30restructuringannouncedNot specifiedCompany-wide — expense and headcount restructuring planMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan described as still in development as of the filing; no headcount, charge, or timing disclosed. Filer states such initiatives may result in significant one-time charges and initial cash expenditures.
2007-06-30restructuringin_progress4002007-03-312008-12-31United StatesCardiac Rhythm ManagementUSD 54 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Reduction of acquired CRM workforce by approximately 400 employees, primarily R&D. Accrual includes $54M for involuntary terminations, change-in-control, relocation. Substantially all amounts expected to be paid prior to Dec 31, 2008.
2007-06-30restructuringin_progress2007-03-312008-12-31InternationalMultiple Functionsrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Smaller workforce reductions internationally across multiple functions to eliminate duplicate facilities and rationalize distribution network. Specific headcount not disclosed.
2007-03-31restructuringcompleted2007-12-31United StatesCardiac Rhythm Management (primarily research and development; also sales and marketing and other functions)USD 95 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Exit plans formulated as of the April 21, 2006 Guidant acquisition date; reduction executed in Q1 2007. Filing gives a range of approximately 500 to 600 employees affected. $95M is the remaining severance/workforce-reduction accrual balance at 2007-03-31 (after a $46M purchase-price adjustment and $22M of charges utilized in the quarter); accrued amounts expected to be paid before 2007-12-31. Announcement date not stated.
2007-03-31restructuringcompleted2007-12-31International (multiple countries)Multiple functions (facility consolidation and distribution network rationalization)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Filing describes smaller workforce reductions internationally to eliminate duplicate facilities and rationalize distribution; no employee count or separate charge disclosed. Related relocation accrual was $7M and contractual commitments $10M at 2007-03-31.
2007-03-31acquisition_additioncompleted2007-01-31United StatesNeurovascular / carotid artery disease technologybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		January 2007 acquisition of EndoTex Interventional Systems (100% of fully diluted equity) for approximately $102M including about five million shares valued at approximately $91M and $11M cash; headcount added not disclosed. Exact announcement day not stated.
2007-03-31restructuringin_progress5502007-01-012007-12-31United StatesCardiac Rhythm ManagementUSD 102 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Reduction of acquired CRM workforce by approximately 500 to 600 employees, primarily R&D. Accrual includes involuntary terminations, change-in-control payments, relocation.
2007-03-31restructuringin_progress2007-01-012007-12-31InternationalMultiple functionsrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Smaller workforce reductions internationally across multiple functions to eliminate duplicate facilities and rationalize distribution network.
2006-12-31acquisition_additioncompleted2006-04-212006-04-21GlobalCardiac Rhythm Management; Cardiac Surgerybusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Guidant Corporation acquired 2006-04-21 for $28.4 billion; acquired headcount not disclosed.
2006-12-31divestiture_reductioncompleted2006-04-212006-04-21GlobalVascular intervention and endovascular solutionsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Abbott acquired these Guidant businesses immediately before the Boston Scientific-Guidant closing; affected headcount not disclosed.
2006-12-31plant_closurecompleted3002006-09-30Santa Rosa, California, United StatesVascular surgery — TriVascular AAA stent-graft programUSD 10 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Program cancelled in Q2 2006 (exact date not disclosed); approximately 300 employees displaced. Charge is severance recorded to R&D expense; a separate $20 million fixed-asset write-down and a $23 million intangible write-off were also recorded. Shutdown substantially completed in Q3 2006.
2006-12-31restructuringcompletedInternationalMultiple functions — duplicate facilities and distribution rationalizationrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Smaller international workforce reductions across multiple functions to eliminate duplicate facilities and rationalize distribution in certain countries; headcount not quantified. Part of the Guidant exit-cost accrual.
2006-12-31reduction_in_forcecompleted2007-03-31GlobalCardiac Rhythm Management — research and development, sales and marketing and other functionsUSD 190 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Announced January 2007 (exact date not disclosed); plan to reduce CRM workforce by approximately 500 to 600 employees during Q1 2007. Filer does not state a single affected count, so employees_affected_count left null. Associated charge is the workforce-reductions portion of the $235 million Guidant exit accrual recorded as a purchase-price adjustment; $27 million was utilized during 2006, leaving a $163 million balance at 2006-12-31.
2006-12-31restructuringannounced5502006-12-312007-03-31GlobalCardiac Rhythm Management (CRM)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		In January 2007, the company announced a plan to reallocate CRM resources, resulting in a reduction of 500 to 600 employees during Q1 2007. This is a subsequent event relative to the fiscal year end.
2006-12-31restructuringcompleted3002006-06-302006-09-30United StatesVascular SurgeryUSD 30 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Cancellation of TriVascular AAA program resulted in shutdown of Santa Rosa facility and displacement of approx 300 employees. Charges included $20M R&D write-downs and $10M severance.
2006-12-31restructuringcompleted3002006-06-302006-09-30Santa Rosa, CaliforniaTriVascular AAA ProgramUSD 30 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Cancellation of TriVascular AAA stent-graft program resulted in shutdown of facility and displacement of approximately 300 employees. Charges included $20M fixed asset write-downs and $10M severance.
2006-12-31restructuringannounced5502007-01-012007-03-31GlobalCardiac Rhythm Management (CRM)subsequent_events
f5-10k / Qwen3.6-27B-Q8_0		Plan announced in January 2007 to reallocate CRM resources, resulting in reduction of 500 to 600 employees during Q1 2007. Average of range used for count.
2006-09-30plant_closurecompleted3002006-06-302006-09-30United States (Santa Rosa, California)AAA stent-graft program (TriVascular)USD 10 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program cancellation in Q2 2006; facility shutdown and displacement of approximately 300 employees, with shut-down activities substantially completed during Q3 2006. Related charges: ~$20M fixed asset writedowns and ~$10M severance, both to R&D expense.
2006-09-30acquisition_additioncompleted2006-04-212006-04-21GlobalCardiac Rhythm Management and Cardiac Surgery divisionsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Guidant Corporation closed 2006-04-21; headcount added not disclosed in this filing. Guidant operating results consolidated from acquisition date.
2006-09-30divestiture_reductioncompleted2006-04-212006-04-21GlobalGuidant vascular intervention and endovascular solutions businesses (sold to Abbott)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Abbott acquired Guidant's vascular intervention and endovascular businesses prior to BSC's acquisition of Guidant; associated headcount not disclosed.
2006-09-30plant_closurecompleted3002006-06-302006-09-30Santa Rosa, CaliforniaResearch and DevelopmentUSD 30 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Cancellation of abdominal aortic aneurysm (AAA) stent-graft program obtained from TriVascular acquisition. Charge includes $20M fixed asset writedowns and $10M severance/related costs. Shut down activities substantially completed in Q3 2006.
2006-09-30acquisition_additioncompleted2006-04-212006-04-21GlobalCardiac Rhythm Managementbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Guidant Corporation. Headcount not explicitly quantified in filing, but integration costs and retention programs noted in MD&A.
2006-06-30plant_closurein_progress3002006-06-302006-09-30United States — Santa Rosa, CaliforniaAAA stent-graft program (TriVascular)USD 10 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program cancelled in Q2 2006 due to forecasted cost and time increases; facility shutdown expected substantially complete in Q3 2006. Approximately 300 employees displaced. Additional charges: ~$20M fixed asset writedowns, $23M amortization charge, $67M credit to purchased R&D.
2006-06-30acquisition_additioncompleted2006-04-212006-04-21GlobalCardiac Rhythm Management, Cardiac Surgerybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Guidant Corporation closed April 21, 2006; Guidant headcount added to consolidated workforce. Specific employee count not disclosed in this filing.
2006-06-30restructuringin_progress3002006-06-302006-09-30Santa Rosa, CaliforniaResearch and DevelopmentUSD 10 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Cancellation of abdominal aortic aneurysm (AAA) stent-graft program obtained from TriVascular acquisition. Includes $10M severance and $20M fixed asset writedowns.
2006-06-30acquisition_additioncompleted2006-04-212006-04-21GlobalAll Segmentsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Guidant Corporation. Headcount not explicitly quantified in this filing, but integration and retention costs of $32M were recorded in SG&A.
2006-03-31acquisition_additioncompleted2006-04-212006-04-21GlobalCardiac Rhythm Management (Guidant Corporation)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition closed April 21, 2006 for ~$27.5B (~577M shares + ~$14.5B cash). No employee headcount added disclosed. Company notes integration and restructuring costs will be incurred but provides no quantification.
2006-03-31divestiture_reductioncompleted2006-04-212006-04-21GlobalGuidant vascular intervention and endovascular businesses (sold to Abbott)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Abbott purchased Guidant's vascular and endovascular businesses for $4.1B initial cash plus up to $500M in milestones. Abbott assumed related liabilities. No headcount transferred disclosed.
2006-03-31restructuringannounced2006-04-21GlobalCorporate / Integrationsubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Company expects to incur integration and restructuring costs as it integrates certain operations of Guidant. No specific headcount or charge amounts disclosed in this filing.
2006-03-31othercompleted2004-08-01Minneapolis AreaGuidant (Acquired)other
f5-10q / Qwen3.6-27B-Q8_0		Approximately 70 former Guidant employees filed EEOC charges alleging age discrimination related to a reduction in force in August 2004. EEOC has not yet rendered a decision.
2005-12-31restructuringin_progressUnited States; InternationalHuman resources function; international divisionsUSD 40 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2005 exit-activity charges of approximately $40 million, primarily employee terminations and outsourcing within HR and international divisions; includes a $10 million Enteryx intangible write-off. Employee counts not disclosed.
2005-12-31acquisition_additioncompletedUnited StatesCardiovascular; Endosurgerybusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2005 acquisitions of Advanced Stent Technologies, TriVascular, CryoVascular and Rubicon Medical; headcount added not disclosed.
2005-12-31acquisition_additionannounced2006-01-252006-04-07United StatesCardiac rhythm management; cardiac surgerysubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire Guidant Corporation for approximately $27 billion; expected to close during the week of April 3, 2006. Guidant headcount not disclosed.
2005-12-31divestiture_reductionannounced2006-01-082006-04-07United StatesGuidant vascular intervention and endovascular businessessubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Abbott to acquire Guidant's vascular and endovascular businesses contingent on Boston Scientific's Guidant acquisition; associated workforce transfer not quantified.
2005-12-31restructuringcompleted2005-01-012005-12-31GlobalHuman Resources and International DivisionsUSD 40 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Approximately $40 million in charges recorded in 2005 for exit activities, primarily employee terminations and outsourcing costs within HR and international divisions. Specific headcount not disclosed.
2005-12-31restructuringcompleted2005GlobalHuman Resources and International DivisionsUSD 24 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		$24 million of asset write-downs and employee-related costs resulting from certain business optimization initiatives.
2005-12-31restructuringcompleted2005GlobalHuman Resources and International DivisionsUSD 40 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Approximately $40 million in charges associated with exit activities, including employee terminations and outsourcing costs.
2005-09-30acquisition_additioncompleted2005-03United StatesCardiovascularUSD 73 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired 100% of Advanced Stent Technologies for ~3.6 million shares (~$120M); $73M purchased R&D charge. Headcount added not disclosed.
2005-09-30acquisition_additioncompleted2005-04United StatesCardiovascularUSD 130 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired 100% of TriVascular for ~$65M plus prior investments/notes of ~$45M; $130M purchased R&D charge. Headcount added not disclosed.
2005-09-30acquisition_additioncompleted2005-04United StatesCardiovascularUSD 3 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired 100% of CryoVascular Systems for ~$50M plus prior investments of ~$10M; $3M purchased R&D charge. Headcount added not disclosed.
2005-09-30acquisition_additioncompleted2005-06United StatesCardiovascularUSD 45 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Completed acquisition of 100% of Rubicon Medical for ~$70M plus prior investments of ~$20M; $45M purchased R&D charge. Headcount added not disclosed.
2005-09-30restructuringin_progressUnited StatesHuman Resources / corporate functionsUSD 28 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Business optimization initiatives recorded $28M pre-tax charge in Q3 2005 for asset write-downs and employee-related costs, including ~$11M of employee-related costs from optimization within the Human Resources function. No employee counts, announcement date, or completion timing disclosed.
2005-09-30restructuringcompletedHuman ResourcesUSD 11 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Employee-related costs primarily as a result of optimization initiatives within the Human Resources function.
2005-09-30restructuringcompletedUSD 18 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Asset write-downs and employee-related costs that resulted from certain business optimization initiatives.
2005-06-30plant_closureannouncedUnited States (southern California)ManufacturingMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		No employee count, closure date, or charge amount disclosed; closure referenced only as a driver of first-half 2005 gross margin
2005-06-30restructuringin_progressInternationalInternational operationsMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Narrative-only disclosure; no headcount, severance accrual, or completion timeline provided. Mentioned in both SG&A discussion and Outlook; captured once
2005-06-30acquisition_additioncompleted2005-04-01United StatesInterventional Cardiology / VascularUSD 65 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of TriVascular, Inc. for approx $65M plus previous investments. Headcount not disclosed.
2005-06-30acquisition_additioncompleted2005-04-01United StatesPeripheral VascularUSD 50 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of CryoVascular Systems, Inc. for approx $50M plus previous investments. Headcount not disclosed.
2005-06-30acquisition_additioncompleted2005-06-01United StatesInterventional CardiologyUSD 70 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Rubicon Medical Corporation for approx $70M plus previous investments. Headcount not disclosed.
2005-06-30restructuringin_progress2005-06-30United StatesManufacturingMD&A
f5-10q / Qwen3.6-27B-Q8_0		Planned closure of a manufacturing facility in southern California. Specific headcount or charges not quantified in this filing.
2005-03-31acquisition_additioncompleted2005-03-31United StatesCardiovascularUSD 73 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		March 2005 acquisition of Advanced Stent Technologies for ~3.6 million shares (~$120 million); $73 million purchased R&D recorded. No employee count disclosed.
2005-03-31plant_closureannouncedUnited States (southern California)ManufacturingUSD 15 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Planned closure of a southern California manufacturing facility; part of ~$15 million of other gross-profit expenses in Q1 2005. No headcount or closure date disclosed.
2005-03-31acquisition_additionannounced2005-04-30United StatesCardiovascularUSD 65 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		April 2005 exercise of exclusive option to acquire TriVascular; ~$65 million paid plus contingent milestones. No employee count disclosed.
2005-03-31acquisition_additionannounced2005-04-30United StatesCardiovascularUSD 50 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		April 2005 exercise of exclusive option to acquire CryoVascular Systems; ~$50 million paid plus contingent milestones. No employee count disclosed.
2005-03-31acquisition_additionannounced2005-04-30United StatesCardiovascularUSD 70 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		April 2005 announced acquisition of Rubicon Medical; ~$70 million to be paid plus contingent milestones. Related Delaware class action filed 2005-04-14 seeking to enjoin the deal. No employee count disclosed.
2004-12-31acquisition_additioncompleted2004-06-012004-06-01United StatesNeuromodulationUSD 740 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Advanced Bionics Corporation for approximately $740 million initial cash payment plus earn-out payments; headcount added not disclosed. Established new Neuromodulation division.
2004-12-31acquisition_additioncompleted2004-04-022004-04-02United StatesCardiovascularUSD 75 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Precision Vascular Systems, Inc. for approximately $75 million initial cash payment plus earn-out payments; headcount added not disclosed.
2004-12-31acquisition_additionannounced2005-03-012005-03-01United StatesCardiovascularUSD 120 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Subsequent-event acquisition of Advanced Stent Technologies, Inc. in March 2005; approximately $120 million payable in common stock plus contingent milestone consideration; headcount added not disclosed.
2004-09-30acquisition_additioncompleted2004-06-01United StatesNeuromodulationbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Advanced Bionics Corporation completed; no employee headcount disclosed.
2004-09-30acquisition_additioncompleted2004-04-02United StatesNeurovascularbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of remaining shares of Precision Vascular Systems, Inc. completed; no employee headcount disclosed.
2004-09-30acquisition_additioncompleted2004-06-01GlobalNeuromodulationUSD 740 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Advanced Bionics Corporation completed June 1, 2004. Initial payment of $740 million plus earnouts. Employee count not disclosed.
2004-09-30acquisition_additioncompleted2004-04-02GlobalVascular AccessUSD 75 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of remaining shares of Precision Vascular Systems, Inc. (PVS) completed April 2, 2004. Initial payment of $75 million plus earnouts. Employee count not disclosed.
2003-12-31restructuringcompleted2502003-04-012003-12-31GlobalManufacturing, Manufacturing Support, and ManagementUSD 6 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Workforce reduction plan approved in Q2 2003 (second quarter) impacting approximately 250 employees. Substantially completed in Q4 2003. Pre-tax charge of $6 million recorded to cost of sales.
2003-03-31acquisition_additioncompleted2003-02-12United StatesCardiovascularUSD 13 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of InFlow Dynamics Inc. for ~$13M cash plus contingent payments; no employee headcount disclosed.
2003-03-31acquisition_additioncompleted2003-02-12USD 13 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of InFlow Dynamics Inc. completed Feb 12, 2003 for approx $13M cash plus contingent payments. Headcount not disclosed.
2002-12-31restructuringcompleted2502002-06-30United StatesManufacturing, manufacturing support and managementUSD 6 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance charge recorded in Q2 2002 as part of the global operations plan; plant optimization initiative substantially completed in Q2 2002. Cumulative program displaced approximately 1,950 employees since inception (2000).
2002-12-31plant_closurecompleted2002-06-30United StatesManufacturingItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Discontinuation of manufacturing activities at three U.S. facilities as part of the global operations plan; substantially completed in Q2 2002. Cumulative program planned displacement of approximately 1,950 employees since inception.
2002-12-31acquisition_additioncompleted2002-06-132002-06-13United StatesEndosurgerybusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Enteric Medical Technologies, Inc. (EMT); headcount added not separately disclosed.
2002-12-31acquisition_additioncompleted2002-06-272002-06-27United StatesEndosurgerybusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of BEI Medical Systems Company, Inc.; headcount added not separately disclosed.
2002-12-31acquisition_additioncompleted2002-12-032002-12-03United StatesCardiovascular (Target division)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Smart Therapeutics, Inc.; headcount added not separately disclosed.
2002-12-31restructuringcompleted2502002-04-012002-12-31GlobalManufacturing, Manufacturing Support, and ManagementUSD 6 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		During the second quarter of 2002, the Company recorded a $6 million pre-tax charge for severance and related costs associated with its global operations strategy. The approximately 250 affected employees included manufacturing, manufacturing support and management employees. The reductions resulted from the Company's continued achievement of operational efficiencies within its plant network and its continued effort to manage costs.
2002-12-31restructuringcompleted2502002-04-012002-12-31GlobalManufacturing, Manufacturing Support, ManagementUSD 6 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Second quarter 2002 charge for severance and related costs associated with global operations strategy. Affected employees included manufacturing, manufacturing support and management.
2002-12-31restructuringcompleted1,7002000-01-012002-12-31United StatesManufacturing, Manufacturing Support, ManagementUSD 58 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Displacement of approximately 1,700 employees under the global operations plan initiated in 2000. The plan included discontinuation of manufacturing activities at three US facilities. Total planned displacement was approximately 1,950 employees.
2002-09-30restructuringin_progress1,7002003-12-31United StatesManufacturing, manufacturing support and managementUSD 55 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plant optimization initiative substantially completed in Q2 2002; involved discontinuing manufacturing at three U.S. facilities. Approximately $9M severance accrual remaining at quarter-end, expected paid by end of 2003. Total cash outlays of ~$155M since program inception.
2002-09-30restructuringcompleted2502002-04-012002-06-30United StatesManufacturing, manufacturing support and managementUSD 6 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 2002 severance charge of $6M pre-tax to cost of sales for approximately 250 employees; part of the broader global operations strategy.
2002-09-30restructuringin_progress2502002-04-012003-12-31GlobalManufacturing, manufacturing support and managementUSD 6 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Second quarter 2002 charge for severance and related costs. Accrued costs expected to be paid by end of 2003.
2002-09-30restructuringcompleted1,7002000-01-012002-06-30GlobalManufacturing, manufacturing support and managementUSD 55 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plant optimization initiative substantially completed in Q2 2002. Cumulative charges against restructuring accrual since inception.
2002-06-30restructuringcompleted1,7002002-06-30United StatesManufacturingUSD 6 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Global operations plan approved in 2000; plant optimization substantially completed in Q2 2002. Program targets ~1,700 total displacements across manufacturing, support and management roles; discontinuation of manufacturing at three US facilities. Q2-specific severance charge of $6M for ~250 employees. $19M accrued severance at 2002-06-30; $45M cumulative charged against restructuring accrual. $23M in H1 2002 pre-tax transition costs and abnormal production variances also recorded.
2002-06-30acquisition_additioncompleted2002-06-132002-06-13EndosurgeryUSD 45 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of remaining 93% of Enteric Medical Technologies (EMT) for ~$50M initial payment plus contingent earn-outs; $45M purchased R&D charge for in-process Enteryx GERD technology. No headcount disclosed.
2002-06-30acquisition_additioncompleted2002-06-272002-06-27EndosurgeryUSD 95 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Tender offer acquisition of BEI Medical Systems for ~$95M cash; women's health / gynecology business. No headcount disclosed.
2002-06-30restructuringin_progress1,700GlobalManufacturing, manufacturing support and managementrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plant optimization initiative substantially completed in Q2 2002. Includes discontinuation of manufacturing at three U.S. facilities. $19 million accrued severance at June 30, 2002.
2002-06-30restructuringcompleted250GlobalManufacturing, manufacturing support and managementUSD 6 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Pre-tax charge recorded in Q2 2002 for severance and related costs associated with global operations strategy.
2002-03-31restructuringin_progress1,40020002002-06-30United StatesManufacturingUSD 38 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plant optimization initiative: ~1,400 of a planned ~1,700 employees terminated as of 2002-03-31; $38M cumulative charged against restructuring accrual, $20M severance accrued at quarter-end; includes discontinuing manufacturing at three U.S. facilities, with production shifting to Miami, Ireland and contract manufacturing; $10M pre-tax expense ($7M after tax) recorded in Q1 2002; ~$30M additional cash outlays expected during remainder of 2002
2002-03-31acquisition_additionannounced2002-05-142002-06-30United StatesEndosurgerysubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire BEI Medical Systems for ~$95 million ($6.84 per share), all cash; expected to close Q2 2002; no headcount disclosed
2002-03-31restructuringin_progress1,7002000-01-012002-06-30United StatesManufacturing, manufacturing support and managementUSD 20 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2000 plant optimization initiative. ~1,700 employees planned displacement. ~1,400 terminated as of March 31, 2002 with $38M charged against accrual. $20M accrued severance remaining. Discontinuation of manufacturing at three U.S. facilities.
2001-12-31restructuringin_progress1,0002000-01-012002-06-30United StatesManufacturingUSD 62 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Global operations plan / plant optimization initiative approved in 2000; cumulative ~1,000 employees terminated through FY2001 year-end; planned total displacement ~1,800 employees; $62M pre-tax expenses recorded in 2001 as cost of sales; $58M pre-tax special charge recorded in 2000; plan includes discontinuation of manufacturing at three US facilities; expected substantially complete first half of 2002
2001-12-31restructuringin_progress602001-01-012001-12-31United StatesAcquired companies — executive management and other employeesUSD 9 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance accrual for ~60 employees from 2001 acquisitions (EPI, CI, Quanam, IVT, CPC, RTC); majority terminated as of Dec 31, 2001; $9M accrual capitalized as part of purchase prices; $4M charged to accrual as of Dec 31, 2001
2001-12-31restructuringin_progress2001-01-01United StatesAcquired companies — contractual commitments (primarily distributors)USD 18 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Accrual for costs to cancel contractual commitments, primarily with distributors, in conjunction with 2001 acquisitions; $18M capitalized as part of purchase prices; $2M charged to accrual as of Dec 31, 2001; no employee count disclosed
2001-12-31restructuringin_progress1,80020002002-06-30United StatesManufacturing, Manufacturing Support, and ManagementUSD 58 (millions)Item 1. Business - Manufacturing; Raw Materials
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Plan includes discontinuation of manufacturing activities at three U.S. facilities. Approximately 1,800 employees planned for displacement. Pre-tax special charge of $58 million recorded in 2000. As of Dec 31, 2001, approx $23 million charged against accrual for approx 1,000 employees terminated. Expected completion in first half of 2002.
2001-12-31acquisition_additioncompleted2001GlobalVariousItem 1. Business - Significant 2001 Events
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Company completed acquisitions of Cardiac Pathways, Catheter Innovations, Embolic Protection, Interventional Technologies, Quanam Medical, and RadioTherapeutics. Specific headcount additions not disclosed.
2001-12-31restructuringin_progress1,8002000-01-012002-06-30United StatesManufacturing, Manufacturing Support, and ManagementUSD 58 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Global operations plan approved in 2000 includes displacement of approximately 1,800 employees. As of Dec 31, 2001, approx 1,000 terminated. Expected completion first half of 2002.
2001-12-31restructuringcompleted602001-01-012001-12-31GlobalAcquired CompaniesUSD 9 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance and related costs associated with 2001 acquisitions. Majority of 60 affected employees terminated as of Dec 31, 2001.
2001-09-30restructuringin_progress2,0002000-01-012002-03-31United StatesManufacturing, manufacturing support and managementUSD 55 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program plans displacement of ~2,000 employees; ~500 terminated as of 2001-09-30 with $8M charged against accrual. $55M total accrued severance. Includes discontinuation of manufacturing at three U.S. facilities, shifting production to Miami, Ireland, and contract manufacturing.
2001-09-30acquisition_additioncompleted2001-08-092001-08-09Electrophysiologybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Cardiac Pathways Corporation (CPC) for ~$115M cash; no headcount disclosed.
2001-09-30acquisition_additioncompleted2001-06-302001-06-30Electrophysiology / Interventionalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Four acquisitions completed in first half of 2001 (EPI, CI, Quanam, IVT) totaling ~$470M; no headcount disclosed.
2001-09-30restructuringin_progress2,0002000-01-012002-03-31United StatesManufacturing, manufacturing support and managementUSD 55 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Accrued severance and related costs of $55 million as of Sept 30, 2001. Plan includes discontinuation of manufacturing at three U.S. facilities. Approximately 500 employees terminated to date with $8 million charged against accrual.
2001-09-30acquisition_additioncompleted2001-08-092001-08-09ElectrophysiologyUSD 115 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Cardiac Pathways Corporation (CPC) completed Aug 9, 2001 for approx $115 million cash. Headcount not disclosed.
2001-09-30acquisition_additioncompleted2001-06-302001-06-30ElectrophysiologyUSD 470 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisitions of Embolic Protection Inc, Catheter Innovations Inc, Quanam Medical Corp, and Interventional Technologies Inc completed in first half of 2001. Total cost approx $470 million. Headcount not disclosed.
2001-06-30restructuringin_progress2,0002000-12-312001-12-31United StatesManufacturing, manufacturing support and managementUSD 61 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approximately 90 employees terminated as of 2001-06-30; plan expected substantially complete within six months. $61M accrued severance and related costs at quarter-end. Includes discontinuation of manufacturing at three U.S. facilities.
2001-06-30acquisition_additioncompleted2001-04-022001-04-02United StatesInterventional cardiologyUSD 345 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Interventional Technologies, Inc. (IVT) for $345M cash; headcount added not disclosed.
2001-06-30acquisition_additioncompleted2001-03-302001-03-30United StatesMedical devicesUSD 104 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Combined acquisitions of Embolic Protection, Inc., Catheter Innovations, Inc., and Quanam Medical Corporation for approximately $104M; headcount added not disclosed.
2001-06-30acquisition_additionannounced2001-06-292001-08-09United StatesElectrophysiologyUSD 115 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Cardiac Pathways Corporation announced 2001-06-29; consummated 2001-08-09. Headcount added not disclosed.
2001-06-30restructuringin_progress2,0002000-01-012001-12-31United StatesManufacturing, manufacturing support and managementUSD 61 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2000 plant optimization initiative. Accrued severance of $61 million at June 30, 2001. Plan includes discontinuation of manufacturing at three U.S. facilities. Approximately 90 employees terminated as of June 30, 2001. Expected to be substantially completed over the next six months from filing date.
2001-06-30acquisition_additioncompleted2001-04-022001-04-02GlobalInterventional cardiologyUSD 345 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Interventional Technologies, Inc. (IVT) for $345 million in cash. Headcount not explicitly disclosed.
2001-06-30acquisition_additioncompleted2001-03-312001-03-31GlobalMedical devicesUSD 104 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisitions of Embolic Protection, Inc. (EPI), Catheter Innovations, Inc. (CI), and Quanam Medical Corporation (Quanam) for approx. $104 million. Headcount not explicitly disclosed.
2001-06-30acquisition_additionannounced2001-06-292001-08-09GlobalElectrophysiologyUSD 115 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Agreement to acquire Cardiac Pathways Corporation (CPC) for approx. $115 million. Transaction consummated on August 9, 2001. Headcount not explicitly disclosed.
2001-03-31restructuringin_progress2,0002000-12-312001-12-31United StatesManufacturing, manufacturing support and managementUSD 58 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plant optimization initiative approved during 2000; planned displacement of approximately 2,000 employees across three U.S. facilities. Approximately $58 million of accrued severance and related costs at 2001-03-31; plan expected substantially complete within nine months of quarter-end.
2001-03-31restructuringin_progress402000-12-312001-12-31United StatesManufacturing, manufacturing support and managementrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approximately 40 employees terminated pursuant to the plant optimization plan as of 2001-03-31; less than $1 million charged against the restructuring accrual for these terminations. Sub-component of the ~2,000-employee program.
2001-03-31acquisition_additioncompleted2001-02-272001-02-27United StatesEmbolic protection devicesUSD 79 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Embolic Protection, Inc. (EPI) completed 2001-02-27. Headcount added not disclosed. Combined $79 million purchased R&D charge covers EPI, Catheter Innovations and Quanam acquisitions; EPI in-process projects represent over 78% of that value.
2001-03-31acquisition_additioncompleted2001-03-052001-03-05United StatesVenous access productsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Catheter Innovations, Inc. (CI) completed 2001-03-05. Headcount added not disclosed.
2001-03-31acquisition_additioncompleted2001-03-302001-03-30not disclosedDrug-delivery stent systemsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Quanam Medical Corporation completed 2001-03-30. Headcount added not disclosed. Subsequently, on 2001-04-20 the Company discontinued further enrollment in Quanam's suspended clinical trial.
2001-03-31acquisition_additioncompleted2001-04-022001-04-02United StatesInterventional cardiology (Cutting Balloon catheter)USD 345 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter acquisition of Interventional Technologies, Inc. (IVT) completed 2001-04-02 for approximately $345 million in cash plus contingent milestone payments. Headcount added not disclosed.
2001-03-31restructuringin_progress2,0002000-01-012001-12-31United StatesManufacturing, manufacturing support and managementUSD 58 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plant optimization initiative; approx. $58M accrued severance at Mar 31, 2001. Less than $1M charged for approx. 40 terminated employees. Plan expected substantially completed over next nine months.
2001-03-31acquisition_additioncompleted2001-02-272001-02-27business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Embolic Protection, Inc. (EPI). Headcount not disclosed.
2001-03-31acquisition_additioncompleted2001-03-052001-03-05business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Catheter Innovations, Inc. (CI). Headcount not disclosed.
2001-03-31acquisition_additioncompleted2001-03-302001-03-30business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Quanam Medical Corporation. Headcount not disclosed.
2001-03-31acquisition_additionannounced2001-04-02USD 345 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Interventional Technologies, Inc. (IVT) completed April 2, 2001. Obligated to pay approx. $345M cash plus contingent amounts. Headcount not disclosed.
2000-12-31restructuringin_progress1,9502000-09-302001-12-31United StatesManufacturing, manufacturing support and managementUSD 58 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Global operations plan / plant optimization initiative approved and committed during Q3 2000; $58M pre-tax special charge for severance and outplacement for approximately 1,950 employees expected to be affected over the next twelve months; plan includes discontinuing manufacturing at two U.S. facilities and closing a third; less than $1M charged against accrual for ~10 employees terminated as of year-end; total cash outlays estimated at ~$115M net of asset sale proceeds
2000-12-31acquisition_additionannounced2001-02-152001-06-30United StatesInterventional cardiologyUSD 345 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Interventional Therapeutics, Inc. (IVT) for ~$345M cash plus contingent milestone payments; headcount not disclosed
2000-12-31acquisition_additioncompleted2001-02-272001-02-27United StatesEmbolic protection devicesUSD 75 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired Embolic Protection, Inc. for ~$75M cash plus assumed restricted stock and options plus contingent milestone payments; headcount not disclosed
2000-12-31acquisition_additioncompleted2001-02-282001-02-28United StatesDrug delivery systemssubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired Quanam Medical Corporation for immaterial stock consideration plus contingent milestone payments; headcount not disclosed
2000-12-31acquisition_additioncompleted2001-03-052001-03-05United StatesVascular access productssubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired Catheter Innovations, Inc. for immaterial initial consideration plus contingent milestone payments; headcount not disclosed
2000-12-31restructuringin_progress1,9502000-09-302001-12-31United StatesManufacturing, Manufacturing Support and ManagementUSD 58 (millions)Item_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Global operations plan initiated in 2000. Discontinuation of manufacturing at three US facilities. Charge relates to severance and outplacement costs. Less than $1 million charged against accrual as of Dec 31, 2000 for ~10 employees terminated.
2000-12-31restructuringin_progress1,9502000-09-302001-12-31United StatesManufacturing, Manufacturing Support, and ManagementUSD 58 (millions)Item_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Global operations plan initiated in 2000. Discontinuation of manufacturing at three US facilities. Charge relates to severance and outplacement costs. Less than $1 million charged against accrual for ~10 employees terminated as of Dec 31, 2000.
2000-09-30restructuringin_progress1,2002000-072001-10United StatesManufacturingUSD 23 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Global operations plan announced July 2000; plant optimization involves discontinuing manufacturing at two U.S. facilities and closing a third, substantially complete over fifteen months. Charge covers severance and outplacement for ~1,200 manufacturing employees. Additional Q4 2000 charge of ~$34M severance and ~$11M transition/accelerated depreciation estimated; ~$50M further pre-tax expenses estimated for 2001.
2000-09-30restructuringin_progress1,2002000-07-012001-10-31GlobalManufacturingUSD 23 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Global operations plan announced in July 2000 includes plant optimization initiative. Charge relates to severance and outplacement costs for approximately 1,200 manufacturing employees expected to be affected over the next twelve months. Plan includes discontinuation of manufacturing at two U.S. facilities and closure of a third.
2000-06-30restructuringannounced2000-07GlobalManufacturing, supply chain and research & developmentUSD 70 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pre-tax charge of approximately $70M ($45M after-tax) in 2000, split $50M special charges and $20M cost of sales; consolidates production into Miami, Ireland and contract manufacturing. No employee count disclosed; significant actions targeted for completion within 18 months.
2000-06-30restructuringin_progress2000-07-01GlobalManufacturing and R&DUSD 70 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Announced global operations plan including plant optimization initiative. Pre-tax charges of approx $70M expected in 2000. Employee count not specified.
2000-06-30restructuringin_progressGlobalVariousUSD 21 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Accrual balance at June 30, 2000 for prior restructuring initiatives (1995-1998). Includes workforce reductions, facilities, and asset write-downs. Specific employee counts for current period activity not disclosed.
2000-03-31restructuringin_progress2000-12-31USD 9 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Accrual of $27M at 2000-03-31 covering Schneider integration, manufacturing streamlining, and legacy 1996-and-prior merger initiatives; $9M of the accrual was utilized during Q1 2000. No employee counts disclosed; company expects substantially all payments during 2000.
2000-03-31restructuringin_progress2000-12-31GlobalManufacturing, Integration, FacilitiesUSD 27 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Accrual includes $11M severance for Schneider integration and manufacturing streamlining, $6M contract cancellations, and $10M from prior mergers. Substantially all payments expected in 2000.
1999-12-31restructuringcompleted1,8001998-12-311999-12-31GlobalMultiple — primarily manufacturing and operationsrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Schneider rationalization plan; 1,800 positions eliminated in 1999, resulting in termination of approximately 1,500 employees. Original 1998 plan targeted ~2,000 positions. Included closure of five Schneider facilities. $10M reversal of prior charges recorded in Q3 1999; $6M additional purchase price adjustments recorded in 1999.
1999-12-31plant_closurecompleted1998-12-311999-12-31GlobalSchneider — manufacturingrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Closure of five Schneider facilities as part of rationalization plan; workforce impact included within the 1,800 positions eliminated above. Manufacturing transition for selected product lines to different sites.
1999-12-31restructuringcompleted1,5001998-12-311999-12-31GlobalManufacturing and OperationsUSD 26 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Rationalization plan initiated in Q4 1998 following Schneider acquisition. Approximately 1,800 positions eliminated, resulting in termination of approximately 1,500 employees. $26 million charged to operations in 1998; plan substantially completed in 1999.
1999-09-30restructuringin_progress1998-10-012000-06-30GlobalVariousUSD 10 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Reversal of $10 million in charges no longer deemed necessary, primarily related to 1998 initiatives. Includes reclassification of assets from held for disposal to held for use and reduced severance estimates due to attrition.
1999-09-30restructuringin_progress1998-09-012000-06-30GlobalSchneider IntegrationUSD 26 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Accrued severance and related costs of $26 million primarily associated with integrating Schneider (acquired Sept 1998) and streamlining manufacturing operations. Substantially all cash outlays expected in first half of 2000.
1999-06-30restructuringin_progress1999-12-31GlobalManufacturing / Schneider integrationUSD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Schneider purchase price adjustments for workforce reductions: $4M charged in 1999, $11M utilized, $20M balance at 6/30/99. Employee counts not disclosed. MD&A attributes to Schneider integration and manufacturing streamlining.
1999-06-30restructuringin_progress1999-12-31GlobalOperationsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		1998 restructuring workforce reductions: $4M utilized in 1999, $9M balance at 6/30/99. Employee counts not disclosed.
1999-06-30restructuringin_progress1999-12-31GlobalOperationsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		1995/1996 restructuring workforce reductions: $4M balance at 6/30/99 with no 1999 activity. Employee counts not disclosed.
1999-06-30restructuringin_progress1999-06-302000-06-30GlobalManufacturing and IntegrationUSD 39 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Accrued severance and related costs primarily associated with integrating Schneider and streamlining manufacturing operations. Substantially all actions expected to be completed by end of 1999, with payments extending into first half of 2000.
1999-06-30restructuringin_progress1999-06-302000-06-30GlobalContractual CommitmentsUSD 10 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Cost of canceling contractual commitments recorded in connection with the Schneider acquisition.
1999-06-30restructuringin_progress1999-06-302000-06-30GlobalPrior MergersUSD 15 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Accruals remaining from 1997 and prior mergers, primarily costs associated with rationalized facilities and statutory benefits subject to litigation.
1999-03-31restructuringin_progress1999-12-31GlobalManufacturing operations and corporateUSD 80 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Accrual of $80M at 1999-03-31 includes $43M severance for Schneider integration and manufacturing streamlining, $15M for canceling Schneider contractual commitments, and $22M remaining from 1997 and prior mergers. No employee headcount affected is disclosed. Substantially all expected paid during 1999 except $4M of 1997 facility costs subject to litigation.
1999-03-31acquisition_additioncompleted1998-09-10GlobalAll segmentsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Schneider Worldwide acquisition completed 1998-09-10; no headcount added through the acquisition is disclosed in this filing. Integration expected to complete by end of 1999.
1999-03-31restructuringin_progress1999-12-31GlobalManufacturing and IntegrationUSD 43 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Accrued severance and related costs primarily associated with integrating Schneider and streamlining manufacturing operations. Substantially all restructuring charges expected to be paid during 1999.
1999-03-31restructuringin_progress1999-12-31GlobalFacilities and ContractualUSD 37 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Includes $15 million for canceling contractual commitments related to Schneider acquisition and $22 million remaining from 1997 and prior mergers (rationalized facilities and statutory benefits).
1998-12-31restructuringin_progress2,0001998-10-011999-12-31GlobalPrimarily manufacturing (over half); remainder across operationsUSD 26 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Schneider rationalization plan; $62M total estimated cost of which $36M capitalized in purchase price and $26M charged to operations; actions approved in Q4 1998, displacement to occur during 1999
1998-12-31restructuringin_progress1,0001998-10-011999-12-31GlobalOperations / manufacturing transitionrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Approximately 1,000 positions expected to be added in 1999 as part of Schneider transition plan; net displacement of ~1,000 positions
1998-12-31plant_closurein_progress1998-10-011999-12-31GlobalSchneider manufacturing facilitiesrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Five Schneider facilities to be closed as part of rationalization plan; headcount per facility not disclosed
1998-12-31acquisition_additioncompleted1998-09-101998-09-10GlobalVascular / interventional cardiologybusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Schneider Worldwide acquired for $2.1B cash; headcount added not disclosed
1998-12-31acquisition_additioncompleted1998-06-301998-06-30United StatesGene therapy / R&Dbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		CardioGene Therapeutics, Inc. acquired (development stage company); headcount added not disclosed
1998-12-31restructuringannounced2,0001998-12-311999-12-31GlobalManufacturing and otherUSD 26 (millions)Item_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Rationalization plan following Schneider acquisition. Actions approved in Q4 1998 result in displacement of approx. 2,000 positions in 1999 (over half manufacturing). Total costs approx. $62 million; $36 million capitalized, $26 million charged to operations.
1998-12-31restructuringannounced2,0001998-12-311999-12-31GlobalManufacturing and OperationsUSD 26 (millions)Item_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Rationalization plan established after acquiring Schneider. Actions approved and committed to in Q4 1998 will result in displacement of approx. 2,000 current positions in 1999, over half manufacturing. Total estimated costs approx. $62 million, of which $26 million charged to operations in 1998. Approx. 1,000 positions expected to be added in 1999.
1998-12-31restructuringin_progress2,0001999-12-31Global (five Schneider facilities; specific locations not disclosed)Manufacturing and operations; over half of displaced positions are manufacturingUSD 26 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Schneider rationalization plan approved and committed in Q4 1998; displacements occur during 1999. Total program cost estimated at approximately $62 million, of which about $36 million was capitalized in the Schneider purchase price and $26 million ($17 million net of tax) charged to operations. Program includes closing five Schneider facilities and transitioning selected Boston Scientific product lines to different sites. Announcement date not specified beyond 'fourth quarter of 1998'.
1998-12-31otherin_progress1,0001999-12-31GlobalManufacturing (transition of product lines to alternate sites)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Approximately 1,000 positions expected to be added in 1999 as a result of the manufacturing transition plan accompanying the Schneider rationalization; transition costs expected to be less than $10 million and recognized as incurred.
1998-12-31acquisition_additioncompleted1998-09-101998-09-10GlobalCardiovascular and vascular device operations (Schneider Worldwide)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Schneider Worldwide (formerly part of Pfizer's Medical Technology Group) for $2.1 billion in cash consummated 1998-09-10; headcount added through the acquisition is not disclosed. Related rationalization plan is captured separately above.
1998-12-31restructuringin_progress2,0001998-10-011999-12-31GlobalPredominantly manufacturing (over half of positions); Schneider operations and selected Boston Scientific product linesUSD 26 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Schneider rationalization plan approved and committed in Q4 1998 (exact date not disclosed); displacements occur in 1999. Total estimated cost ~$62M, of which ~$36M capitalized in the Schneider purchase price and $26M ($17M net of tax) charged to operations. Same program also adds approximately 1,000 positions in 1999 via the transition plan.
1998-12-31plant_closurein_progress1998-10-011999-12-31GlobalSchneider manufacturing facilitiesrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Five Schneider facilities to be closed plus transition of selected Boston Scientific product lines to different sites; part of the same rationalization program as the 2,000-position displacement. Facility-specific headcount not separately disclosed; manufacturing transition costs expected to be less than $10M and recognized as incurred.
1998-12-31otherin_progress1,0001998-10-011999-12-31GlobalManufacturing and operations (positions added through transition plan)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Approximately 1,000 positions expected to be added in 1999 as a result of the manufacturing transition plan; net headcount addition within the same rationalization program.
1998-12-31acquisition_additioncompleted1998-09-101998-09-10GlobalVascular and nonvascular medical devices (Schneider Worldwide)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Schneider Worldwide for $2.1 billion in cash consummated 1998-09-10; headcount added through the acquisition is not quantified in the filing.
1998-12-31restructuringcompleted40United States (California facilities); Germany, Japan, United Kingdom sales officesTarget Therapeutics integration into vascular divisionrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cumulative through fiscal year-end for the 1997 Target program: approximately 40 employees actually displaced versus an original plan of 500, of whom approximately 35 were terminated in 1997 and the remainder subsequent to 1997. In 1998 the Company reversed its decision to integrate Target into the vascular division and reversed $20M ($13M net of tax) of 1997 merger-related charges.
1998-12-31restructuringcompletedGlobalEP Technologies, Inc. (EPT) integrationrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cumulative through fiscal year-end for the 1996 EPT program: fewer than 10 employees terminated; plan was substantially complete in 1997. Count not stated as an exact figure.
1998-09-30acquisition_additioncompleted1998-09-101998-09-10GlobalMedical devices (coronary/interventional)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Schneider Worldwide acquired for $2.1B cash; headcount added not disclosed. Integration plans expected finalized by Q3 1999.
1998-09-30restructuringin_progress1999-12-31GlobalMultiple (facilities, workforce reductions, contractual commitments)USD 40 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Workforce-reduction accrual balance of $40.4M at 9/30/98; employee count not disclosed. Part of $222.3M total merger/special charges accrual.
1998-09-30restructuringin_progress1999-12-31JapanJapanese subsidiary operationsUSD 79 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		$79M charge for net unrealizable assets from improper revenue recognition at Japanese subsidiary; investigation ongoing, no headcount impact quantified.
1998-09-30restructuringin_progress1998-09-101999-12-31GlobalAll functionsUSD 222 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Accrual for merger-related and special charges of $222 million as of Sept 30, 1998. Includes rationalization of facilities, workforce reductions, unwinding of contractual commitments, asset write-downs, and integration costs related to the Schneider acquisition. Schneider workforce initiatives involve substantially all employee groups. Integration plans expected to be completed by end of 1999.
1998-09-30restructuringcompleted1998-04-011998-06-30GlobalAll functionsUSD -20 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Reversal of approximately $20 million in accruals for merger-related and special charges no longer required, identified in Q2 1998. Related primarily to severance, contractual commitments, and facilities closure charges accrued in Q2 1997.
1998-06-30restructuringin_progress1998-12-31GlobalMultipleUSD 48 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing merger integration program includes workforce reductions, facility rationalization, and contractual unwinding; no employee count disclosed. Most plans expected complete by end of 1998.
1998-06-30acquisition_additionannounced1998-06-16GlobalMedical devices (catheter-based technologies)USD 2,100 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Schneider Worldwide from Pfizer for approximately $2.1 billion in cash; expected to close later in 1998. No headcount disclosed.
1998-06-30restructuringin_progress1998-12-31USD 20,314 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Reversal of merger-related charges previously accrued, primarily from Q2 1997. Workforce-related initiatives involved substantially all employee groups. Most plans expected to be completed by end of 1998.
1998-06-30acquisition_additioncompleted1998-06-30business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired 100% of CardioGene Therapeutics, Inc. on June 30, 1998. Headcount not disclosed.
1998-06-30acquisition_additionannounced1998-06-161998-12-31USD 2,100,000 (thousands)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Announced definitive agreement to acquire Schneider Worldwide for approx $2.1 billion. Transaction expected to be consummated later in 1998. Headcount not disclosed.
1998-03-31restructuringin_progress1998-12-31Substantially all employee groupsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Workforce-reduction component of merger/acquisition integration accrual: $23,489 thousand balance at 1998-03-31 (opened at $25,242 thousand, $1,753 thousand utilized in Q1). No employee count disclosed; total accrual for merger-related and special charges was $94 million. Most plans expected complete by end of 1998.
1998-03-31restructuringin_progress1998-12-31GlobalVariousUSD 8 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Workforce-related initiatives involve substantially all employee groups. Most plans expected to be completed by end of 1998. Cash outlays estimated at $54 million.
1997-12-31acquisition_additioncompleted1997-04-08United StatesNeuro-endovascular therapyUSD 96 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Target Therapeutics merger completed April 8, 1997; $96M estimated integration costs including workforce reductions; headcount added not disclosed
1997-12-31restructuringin_progress1998-12-31GlobalMultipleUSD 25 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Workforce reduction charges of $24.7M in FY1997 as part of multi-year merger integration program; employee count not disclosed; most plans expected complete by end of 1998
1997-12-31plant_closurecompletedDenmark, France, Massachusetts (United States)ManufacturingItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Manufacturing facilities closed in Denmark, France and Massachusetts during 1997 as part of consolidation; headcount affected not disclosed
1997-12-31restructuringin_progress1998-12-31GlobalAll segmentsUSD 175 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Includes costs for rationalization of facilities, workforce reductions, unwinding of contractual commitments, asset write-downs, and integration costs related to acquisitions (including Target). Estimated cash payments for 1998 are $51 million.
1997-12-31restructuringin_progress1998-12-31GlobalVariousUSD 175 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Company recorded merger-related charges of $175 million in 1997 related to rationalization of facilities, workforce reductions, unwinding of contractual commitments, asset write-downs and integration costs. Most plans expected to be completed by end of 1998.
1997-09-30acquisition_additioncompleted1997-04-081997-04-08United StatesNeurovascular / interventional (Target Therapeutics business)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Stock-for-stock merger with Target Therapeutics accounted for as a pooling-of-interests; approximately 16.5 million shares issued. No employee headcount added disclosed.
1997-09-30restructuringin_progress1998-12-31GlobalSubstantially all employee groups; includes facilities rationalizationUSD 24 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Workforce-reduction component of special-charge accrual: $26M opening balance, $24M charged, $19M utilized, $31M closing balance for nine months ended 1997-09-30; no employee counts disclosed. Total special charges of $158M recorded in Q2 1997; most plans expected complete by end of 1998 with ~$80M remaining cash outlays.
1997-09-30restructuringin_progress1997-04-081998-12-31GlobalAll employee groupsUSD 158 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Merger with Target Therapeutics; charges include $96M for integration costs such as workforce reductions and facility rationalization. Most plans expected to be completed by end of 1998.
1997-06-30restructuringin_progress1997-04-081998-12-31GlobalMultiple — includes facilities rationalization, workforce reductions, contractual commitments, asset writedownsUSD 158 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Special charges of $158M ($117M net-of-tax) recorded in Q2 1997 for Target Therapeutics merger integration. Workforce reductions accrual: $26M balance at Dec 31 1996, $14M charged, $14M utilized, $26M at Jun 30 1997. No employee headcount disclosed. Plans expected complete by end of 1998; remaining cash outlays estimated at ~$118M.
1997-06-30acquisition_additioncompleted1997-04-081997-04-08United StatesTarget Therapeutics, Inc. — neurovascular/interventional devicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Stock-for-stock merger completed April 8, 1997, accounted for as pooling-of-interests. Approximately 16.5 million shares issued at 1.07 exchange ratio. No employee headcount for Target disclosed in this filing.
1997-06-30restructuringin_progress1997-04-081998-12-31GlobalAll functionsUSD 158 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Merger with Target Therapeutics Inc. resulted in $158 million special charges including $96 million for integration costs such as workforce reductions and facility rationalization. Employee count not disclosed.
1997-03-31restructuringin_progress1997-12-31GlobalMultipleUSD 20 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Workforce reductions, facilities rationalization, and integration costs for 1995–1996 acquisitions; $19.7M utilized in Q1 1997, $45.8M accrual remaining at quarter-end. No employee count disclosed.
1997-03-31acquisition_additionannounced1997-04-081997-04-08United StatesNeurovascular devicessubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Merger with Target Therapeutics completed April 8, 1997; ~16.5 million shares issued. No headcount added disclosed. Non-recurring charges expected in Q2 1997.
1997-03-31restructuringin_progress1997-12-31GlobalAll employee groupsUSD 20 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges incurred in Q1 1997 related to 1995/1996 business combinations. Includes workforce reductions, facility rationalization, and contract unwinding. Plans expected substantially completed by end of 1997.
1996-12-31restructuringin_progress1997-12-31GlobalMultipleUSD 4 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Workforce reduction charges of $3.655M in 1996 as part of special charges program; employee count not disclosed. Plans expected substantially complete by end of 1997.
1996-12-31acquisition_additioncompleted1996-01-221996-01-22United StatesElectrophysiologybusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		EP Technologies acquired via stock-for-stock pooling transaction; headcount added not disclosed
1996-12-31acquisition_additioncompleted1996-03-141996-03-14United StatesEndoscopyUSD 153 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Symbiosis Corporation acquired for $153M cash; headcount added not disclosed
1996-12-31acquisition_additioncompleted1996-05-031996-05-03United StatesEndovascular SurgeryUSD 72 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Endotech/MinTec assets acquired for $72M cash; headcount added not disclosed
1996-12-31restructuringin_progress1995-01-011997-12-31GlobalAll segmentsUSD 128 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Charges recorded in 1996 related to mergers with EPT and acquisitions of Symbiosis and Endotech/MinTec. Includes workforce reductions, facility rationalization, and integration costs. Cash payments for 1996 were approx $60 million; estimated 1997 payments $47 million. Specific headcount not disclosed.
1996-12-31restructuringin_progress1995-01-011997-12-31GlobalAll segmentsUSD 237 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Charges recorded in 1995 related to acquisitions of SCIMED, CVIS, Vesica, Meadox, and Heart. Includes workforce reductions and facility rationalization. Specific headcount not disclosed.
1996-12-31restructuringin_progress1996-12-311997-12-31GlobalVariousUSD 128 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Special charges of $128 million recorded in 1996 related to mergers with EPT and acquisitions of Symbiosis and Endotech/MinTec. Includes workforce reductions, facility rationalization, and contract unwinding. Employee count not explicitly disclosed in aggregate for 1996 actions.
1996-09-30restructuringin_progress1996-01-221997-12-31Not specifiedEPT business and Company subsidiariesUSD 128 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Special charges of $128.3M ($113.7M net of tax) for the nine months ended 1996-09-30, including $12.2M of estimated integration costs covering facility rationalization, workforce reductions, contract unwinding and asset write-downs. No employee counts disclosed. Integration expected substantially complete by end of 1997; remaining cash outflows estimated at $22.0M in Q4 1996 and $32.0M thereafter.
1996-09-30acquisition_additioncompleted1996-01-221996-01-22Not specifiedEP Technologies, Inc. (EPT)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Stock-for-stock merger accounted for as pooling-of-interests; 0.297 Company shares per EPT share, approximately 3.4 million shares issued. No headcount added disclosed.
1996-09-30acquisition_additioncompleted1996-03-141996-03-14Not specifiedSymbiosis Corporation (specialty medical devices)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cash purchase of approximately $153 million, purchase-method accounting; approximately $146 million of intangible assets and $38.7 million of purchased R&D. No headcount added disclosed.
1996-09-30acquisition_additioncompleted1996-05-031996-05-03Not specifiedEndotech/MinTec (stent graft technology)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Asset purchase of approximately $72 million, purchase-method accounting; approximately $14 million of intangible assets and $57.3 million of purchased R&D. Company assumed control of related Cook Inc. patent litigation. No headcount added disclosed.
1996-09-30restructuringin_progressUSD 12 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Estimated costs to merge EPT business, including workforce reductions and facility rationalization. Employee count not disclosed.
1996-09-30restructuringin_progressUSD 16 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Change in estimates for prior year merger-related charges, primarily unwinding contractual obligations and facility rationalization. Employee count not disclosed.
1996-06-30restructuringin_progress1997-12-31GlobalMultiple (EPT, Symbiosis, Endotech/MinTec integration)USD 128 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Special charges of $128.3M ($113.7M net-of-tax) for H1 1996 covering EPT merger and Symbiosis/Endotech acquisitions. Includes $96.0M purchased R&D, $4.6M transaction costs, $12.2M integration costs (workforce reductions, facility rationalization, contract unwinding). No employee count disclosed. Integration expected substantially complete by end of 1997.
1996-06-30acquisition_additioncompleted1996-01-221996-01-22United StatesEP Technologies (electrophysiology)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Stock-for-stock merger of EP Technologies completed 1996-01-22; pooling-of-interests accounting. No headcount added disclosed.
1996-06-30acquisition_additioncompleted1996-03-141996-03-14United StatesSymbiosis Corporation (specialty medical devices)USD 153 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cash acquisition of Symbiosis for ~$153M; purchase method. No headcount added disclosed.
1996-06-30acquisition_additioncompleted1996-05-031996-05-03United StatesEndotech/MinTec (stent graft technology)USD 72 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cash asset acquisition for ~$72M; purchase method. No headcount added disclosed.
1996-06-30restructuringin_progress1996-01-221997-12-31GlobalAll functionsUSD 12 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Estimated costs for merging EPT operations, including workforce reductions and facility rationalization. Integration plans expected to be substantially completed by end of 1997.
1996-06-30restructuringin_progress1995-01-011997-12-31GlobalAll functionsUSD 16 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Change in estimates for prior year merger-related charges, primarily unwinding contractual obligations and facility rationalization.
1996-03-31acquisition_additioncompleted1996-01-221996-01-22United StatesCardiology / Electrophysiologybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Stock-for-stock pooling-of-interests merger; approximately 3.4 million shares issued. No employee count disclosed.
1996-03-31acquisition_additioncompleted1996-03-141996-03-14United StatesSpecialty medical devicesUSD 153 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cash purchase for approximately $153 million; $100 million seller-financed. No employee count disclosed.
1996-03-31restructuringin_progress1996-01-221997-12-31United StatesEnterprise-wide integrationUSD 12 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Estimated integration costs for EPT merger include workforce reductions, facility rationalization, and contract unwinding. No specific employee count disclosed. Integration expected substantially complete by end of 1997.
1996-03-31acquisition_additionannounced1996-05-03United StatesStent graft technologyUSD 70 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Announced May 3, 1996, after quarter end. Cash purchase for approximately $70 million. Special charge for purchased R&D expected in Q2 1996. No employee count disclosed.
1996-03-31restructuringin_progress1996-01-22USD 12 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Estimated costs to merge EPT operations, including workforce reductions and facility rationalization.
1996-03-31restructuringin_progress1995-12-31USD 13 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Change in estimates for prior year merger-related charges, primarily unwinding contractual obligations and facility rationalization.